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Abstract
Neural tube defects (NTD) are congenital malformations caused by abnormalities in the 
developmental process of neurulation. Folate metabolism appears to be a determinant of 
risk of NTD since periconceptional supplementation with folic acid has been shown to 
reduce the frequency of NTD in humans while sub-optimal folate levels are a risk 
factor. The mechanisms underlying prevention of NTD by folic acid or susceptibility 
owing to reduced levels are not known. The aims of this thesis were to understand the 
role of the folate and, the closely linked, methylation cycle in the cause and prevention 
of NTD.
The effect of methylation cycle intermediates, homocysteine and methionine, on cranial 
neural tube closure were investigated in cultured mouse embryos. Homocysteine 
exposure was embryotoxic but did not increase the incidence of NTD, which suggests 
that increased levels of homocysteine are not a direct cause of cranial NTD. Embryos 
cultured with high levels of methionine or methylation cycle inhibitors specifically 
developed cranial NTD in the absence of other developmental defects. These results 
suggest that the integrity of the methylation cycle is essential for cranial neural tube 
closure to occur.
Mouse embryos that are homozygous for the Splotch211 mutation exhibit NTD that are 
preventable by folic acid. In Splotch mice, increased apoptosis has been suggested to be 
responsible for the production of NTD in homozygous embryos. However, in this study 
immunohistochemical measurement of apoptosis and proliferation in the
3
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neuroepithelium in the cranial region of neurulation-stage embryos suggest that the
i  r_r
Splotch mutation does not result in increased apoptosis.
Finally, in order to test whether there is an underlying defect in folate metabolism in 
human NTD fetuses, a series of human embryonic cell lines were analysed. The 
deoxyuridine monophosphate (dUMP) suppression test was modified for use with 
mammalian fibroblast cell lines and the efficiency and sensitivity of the modified test 
were analysed by the use of inhibitors of one-carbon metabolism. The test was then 
applied to human NTD and control cell lines and the results indicate that a subset of the 
NTD cases have a diminished response, suggestive of an abnormality of folate 
metabolism.
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CHAPTER 1; Introduction
1.1 NEURULATION
In vertebrates, formation of the primordium of the central nervous system, the neural 
tube, occurs by a process referred to as neurulation. This process begins with the 
induction of a subset of ectodermal cells along the dorsal midline of the embryo, which 
subsequently segregate and thicken to form the neural plate. The neural plate then 
undergoes a number of morphological changes that result in the formation of the neural 
tube. Impairment of this process results in a group of anomalies termed neural tube 
defects (NTD).
The molecular mechanisms underlying neurulation are not yet completely understood, 
however, the morphological process has been described in detail in both chick and 
mouse (Schoenwolf and Smith, 1990;Shum and Copp, 1996;Morriss-Kay et al., 1994). 
There are two phases of neurulation in the developing vertebrate embryo, termed 
primary and secondary neurulation. Primary neurulation results in the formation of the 
neural tube in the cranial and upper spinal regions of the embryo. The lateral edges of 
the neural plate elevate to form neural folds. This elevation continues until the apical 
tips of the neural folds are apposed when they then fuse along the dorsal midline to form 
a tube. Secondary neurulation occurs later in development after primary neurulation is 
complete; condensation of mesenchymal cells in the tailbud of the embryo is followed 
by cavitation that results in the creation of the neural tube at the low sacral and 
coccygeal levels (Schoenwolf, 1984). Although the mechanisms of neural tube 
formation differ between the two phases, the transition between primary and secondary 
neurulation results in a continuous tube along the body axis of the embryo. All cranial 
NTD and open spina bifida arise from defects during primary neurulation in both mouse
24
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and humans (Copp and Brook, 1989;Mtiller and O'Rahilly, 1987). Therefore, this study 
concentrates on the period of development in which primary neurulation occurs.
1.1.1 Primary neurulation
In mouse embryos, primary neurulation is a discontinuous process with closure of the 
neural tube starting at a number of de novo initiation sites along the neural tube (Sakai, 
1989). The first initiation site, termed closure 1, is at the level of the second and third 
somites of embryos with 4-6 somites. Closure then continues in a 'zippering’ action in 
both cranial and caudal directions. After closure 1, two further sites of initiation, termed 
closure 2 and closure 3, occur when embryos typically have 11 and 12 somites 
respectively. Fusion from the site of closure 2 at the forebrain/midbrain boundary, 
continues in both caudal and rostral directions. Closure 3 is situated at the extreme 
rostral end of the neural tube and further closure occurs in a caudal direction. (Figure 
l.i).
The areas of neural folds that remain open after fusion at the initiation sites are termed 
neuropores. These neuropores gradually shorten and close as neurulation proceeds, 
resulting in an intact closed tube. The anterior neuropore (ANP), formed in the forebrain 
region between closures 2 and 3, closes at around the 15/16-somite stage of 
development. Closure of the hindbrain neuropore (HNP), formed between closures 1 
and 2, is completed at the 16/17-somite stage of development. The final neuropore 
located at the posterior end of the embryo, referred to as the posterior neuropore (PNP), 
closes when the embryo has approximately 29 somites (Copp et al., 1990) (Figure 1.1). 
The exact timing and duration of these events can vary between mouse strains
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(MacDonald et al., 1989;Golden and Chemoff, 1993), and the timing given here is 
therefore for an ‘average’ mouse strain (Copp et al., 1990).
Exencephaly
HNPClosure 2
ANP
Closure 1
Closure 3
Craniorachischisis
PNP
Spina bifida
Figure 1.1 The three sites of initiation of neural tube closure in mouse
Diagram to illustrate the three sites o f initiation o f neural tube closure (black text), the 
direction closure proceeds in (black arrows) and the three neuropores formed during 
primary neurulation (red text). The main subtypes o f NTD, which result from a failure 
o f closure initiation or failure to complete closure o f a neuropore, are shown in blue 
(Copp and Bemfield, 1994). Abbreviations: ANP, anterior neuropore; HNP, hindbrain 
neuropore; PNP, posterior neuropore.
Neurulation has been described as a multi-step process, with initiation of closure 
occurring at a number o f de novo sites in many other vertebrates including rabbit 
(Peeters et al., 1998b), chick (Van Straaten et al., 1996) and pig (Van Straaten et al., 
2000). Analysis o f human NTD has suggested that neural tube closure in humans
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involves de novo initiation at multiple sites in a similar manner to that seen in mouse 
neurulation (Van Allen et al., 1993; Martinez-Frias et al., 1996). Most studies to date 
have investigated the positions of NTD in regard to the multi-site closure theories 
described for mouse and other vertebrates. The specific details of human neurulation, 
particularly in the cranial region, remain somewhat controversial.
Thus, based on analysis of NTD, Van Allen and colleagues (1993) suggested the 
presence of 5 initiation sites in human embryos. The proposed closure sites 1-3 
correspond to closure sites 1-3 described in mice. An additional initiation site in the 
cranial region, closure 4, is described to lie over the hindbrain with closure continuing 
in a rostral direction. The fifth closure site is proposed to be situated at the caudal 
extremity of the embryo closing in a rostral direction. This multi-site closure theory was 
supported by Martinez-Frias and colleagues (1996) after the investigation of 744 live- 
born infants with NTD. A further study of cranial NTD (Golden and Chemoff, 1995) 
supported Van Allen’s model of multi-site closure. However, analysis of ‘normal’ 
neurulation in early human embryos (Carnegie stages 10-12) provided evidence to 
support a 3 site closure model (Nakatsu et al., 2000). In this model the sites of closure 
initiation correspond to the three closure sites described in mouse neurulation except 
closure 2 is in a more caudal position at the midbrain-hindbrain border. The authors also 
related this model to the various types of NTD exhibited in human embryos. A more 
recent study, again using ‘normal’ human embryos at the time of neural tube closure has 
suggested a 2 site closure model, corresponding to mouse closure sites 1 and 3 
(O'Rahilly and Muller, 2002). The authors also describe the presence of accessory loci 
of fusion, that is small, variable points of fusion observed in a small number of embryos
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usually in the hindbrain region. These could represent the closure 2 site classified by the 
Nakatsu study, however, whether these fusion points are consistent in occurrence or 
position remains contentious and they were not classified as initiation sites by O’Rahilly 
and Muller.
Although there are discrepancies in the exact position and number of fusion sites during 
neural tube closure in human embryos, there is a large body of evidence to support a 
model of multi-site closure of the human neural tube. Perhaps definite patterns will 
become apparent as more early embryo samples are examined.
1.2 MECHANISMS OF PRIMARY NEURULATION
Different mechanisms are involved in the closure of the neural folds along the cranio- 
caudal axis of the mouse embryo and, in particular, there are differences between 
cranial and spinal neural tube closure.
1.2.1 Cranial neurulation
The presumptive brain region of the neural plate is wider than the presumptive spinal 
region in vertebrate embryos, and this is more pronounced in mammalian embryos. 
Different mechanisms may be needed in the presumptive brain region to allow closure 
to occur from a wider starting position and to overcome cranial flexure, ventral bending 
of the cranial region that occurs throughout cranial neurulation in mammals (Kaufman, 
1979;Morriss-Kay et al., 1994). Neurulation in the cranial region of mammals has been 
described as a two-stage process. The first stage appears to be unique to the cranial
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region of mammalian embryos, whereas the second stage is similar to the neurulation 
process in more caudal regions of the neural tube (Morriss and Solursh, 1978b;Copp et 
al., 2003b). The first stage involves the formation of bihemispherical neural folds. 
During cranial neurulation the neural folds enlarge and initially bend outwards with the 
cranial flexure (Kaufman, 1979) resulting in a biconvex morphology. During the first 
stage of cranial neurulation the neural folds ‘flip around’ from the biconvex morphology 
to become biconcave (Figure 1.2).
Phase 1
NE
SE
NE
$E
biconvex
morphology biconcavemorphology
Phase 2
DLHP
Figure 1.2 The two phases of cranial neurulation in mammals
The first phase of cranial neurulation in mammalian development (A) is unique and 
involves the formation of bihemispherical neural folds, first showing a biconvex 
morphology followed by a biconcave morphology. The second phase (B) is similar to 
the neurulation process seen in the spinal region. Abbreviations: DLHP, dorsolateral 
hinge points; M, mesenchyme; NE, neural epithelium; SE, surface ectoderm.
2 9
CHAPTER 1; Introduction
The forebrain neuroepithelium expands greatly during cranial neurulation through 
internal cell division and cell migration from the presumptive midbrain and hindbrain 
regions (Tuckett and Morriss-Kay, 1985). The midbrain and hindbrain neural epithelium 
cell number stays constant throughout neurulation. Although cell division occurs, the 
mitotic spindles are oriented parallel to the anterior-posterior axis of the embryo 
resulting in longitudinal growth (Morriss-Kay, 1981;Tuckett et al., 1985). Changes in 
cell arrangement in both the neural epithelium and the underlying mesenchyme occur 
while the neural folds are in the initial biconvex morphology, these changes lead to the 
flipping of the neural folds to the biconcave morphology. The organisation of the 
neuroepithelium changes from columnar to a pseudostratified appearance, which 
subsequently thickens (Morris-Wiman and Brinkley, 1990). The mesenchyme 
undergoes a large expansion that includes both an increase in cell number and 
intercellular space (Morriss et al., 1978b). Changes in cell orientation in the cranial 
mesenchyme also occur, from a random distribution to an arrangement where the cells 
lie parallel to the neuroepithelial basal lamina (Morris-Wiman et al., 1990). In addition, 
a hyaluronate-rich extracellular matrix accumulates around the mesenchymal cells 
during this stage of cranial neurulation (Morriss and Solursh, 1978a). The second stage 
of cranial neurulation involves the medial convergence, apposition and fusion of the tips 
of the neural folds to form a closed neural tube. During the ‘flipping’ process, bending 
regions of lateral neuroepithelium, dorsolateral hinge points, are formed which then, as 
the folds elevate, allow the lateral edges of the neural folds to move medially and 
subsequently allow apposition and fusion to occur (Morris-Wiman et al., 1990) (Figure 
1.2).
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During cranial neurulation, as neural tube closure continues from closure initiation site 
1 into the hindbrain region, the apposition and fusion of the neural folds at the 
forebrain-midbrain boundary (closure 2) and fusion of the folds at the rostral extremity 
(closure 3) also occur (Section 1.1.1). The exact position of closure 2 varies in different 
mouse strains (Juriloff et a l, 1991) and this can affect the susceptibility of the strain to 
developing exencephaly. A more rostral position of closure 2 confers greater 
susceptibility to the development of cranial NTD (Fleming and Copp, 2000). It has been 
suggested that closure 2 is not present at all in one mouse strain (SELH/Bc), leaving the 
embryos highly susceptible to developing exencephaly with a spontaneous cranial NTD 
incidence of 10-20% (Gunn et al., 1995).
1.2.2 Spinal neurulation
Closure of the neural tube in the spinal region occurs in a similar manner to the second 
phase of cranial neurulation, that is the neural folds elevate, appose and fuse along the 
midline. However, the neuroepithelial morphology in spinal neural tube closure differs 
along the longitudinal axis of the mouse embryo (Shum et al., 1996) suggesting 
different mechanisms of closure are involved as translocation of the posterior neuropore 
(PNP) proceeds in a cranio-caudal direction. There are three modes of closure that differ 
in the number and location of specific bending sites seen in the neuroepithelium, and 
vary with the position of the PNP along the axis of the embryo.
In mode 1 the neuroepithelium bends only in the region above the notochord, forming a 
median hinge point. Mode 1 neurulation can be seen at the PNP of embryos at the 8-15 
somite stages and results in a slit-like lumen of the neural tube. Mode 2 occurs at the 16-
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23 somite stages o f development and, in addition to a median hinge point, the 
neuroepithelium also bends at paired lateral sites, referred to as dorso-lateral hinge 
points, resulting in a diamond shaped lumen. From the 24 somite stage onwards, mode 3 
closure is observed at the PNP. In mode 3, specific bending of the neuroepithelium only 
occurs at the dorso-lateral hinge points resulting in a round lumen (Figure 1.3) (Shum et 
al., 1996).
Upper spinal 
closure
Mode 1
Lower spinal 
closure
Mode 2 Mode 3
Median hinge point ^  Dorso-lateral hinge point 
°  notochord
Figure 1.3 Morphological modes of neural closure in the PNP
Diagram to illustrate the three modes o f closure o f the neural tube at the PNP, at 
different axis levels in primary neurulation of mouse. (Adapted from (Ybot-Gonzalez et 
al., 2002)).
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1.3 NEURAL TUBE DEFECTS
NTD are among the most common congenital malformations in humans with an 
incidence of approximately 0.5-3 in every 1000 births although there is considerable 
variation in incidence world-wide (Copp et al., 1994). The term NTD covers a range of 
anomalies that can result from a failure of one or a number of initial closure events or a 
failure to complete closure of a neuropore. There are three main subcategories of NTD 
which occur at different axial levels of the embryo. Failure of initiation at closures 2 or 
3 and incomplete closure of the anterior or hindbrain neuropores result in an open neural 
tube in the cranial region referred to as exencephaly (Figure 1.4 D). As development 
proceeds the exposed neural folds degenerate, finally resulting in anencephaly where the 
exposed brain tissue degenerates and the skull vault is absent (Figure 1.4 A). Since 
anencephaly is incompatible with life, the foetus will usually die before or at birth. The 
neural tube defect caused by failure of initiation at the site of closure 1 is known as 
craniorachischisis, which results in an open neural tube in the hindbrain and throughout 
the entire spinal region (Figure 1.4 C, E). Craniorachischisis is the most severe NTD 
and is a lethal congenital malformation. Finally, failure to close the PNP results in spina 
bifida (Figure 1.4 B, D). The severity of symptoms affecting individuals with spina 
bifida is dependent on the type and position of the lesion but generally affect the 
musculoskeletal, gastrointestinal and urinary systems (Harding and Copp, 2002).
1.4 CAUSES OF NTD IN HUMANS
The cause of most NTD in humans is believed to be multifactorial involving both 
environmental and genetic influences. Changes in the prevalence of NTD in different
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Figure 1.4 Neural tube defects in humans and mice
Human newborns illustrate the appearance of anencephaly (A dorsal view figure 
adapted from Volpe (1995)), spina bifida (B dorsal view courtesy of Prof. A.J.Copp) 
and craniorachischisis (C lateral view courtesy of Prof A.J.Copp). In craniorachischisis, 
the region of open neural tube extends from the forebrain to the lower spine (C black 
arrows). Mouse foetuses at El 5.5 also illustrate the various types of NTD. A curly tail 
mutant with open regions of neural tube in the cranial region, exencephaly (D, flanked 
by white arrows) and caudal region, spina bifida (D, flanked by white arrowheads). 
Craniorachischisis is shown in a Celsrl mutant (E), where the neural tube is open from 
the midbrain to the lower spinal region (E, white arrows). Asterisks in D and E 
highlight curly tails in both mutants. D and E are adapted from Copp et al. (2003b).
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populations indicate that there is heterogeneity in the aetiology of NTD. For example, 
the incidence ranges from 1.0 in 1000 births, in Paris (EUROCAT Working Group, 
1991), to 10.6 in 1000, in Shanxi Province in the north of China (Xiao et al., 1990) over 
a similar period in time. The causes of NTD which occur as isolated defects are likely to 
differ from the causes of NTD that occur with other malformations or as part of a 
syndrome. Up to 24% of NTD that occur in association with other congenital 
malformations are associated with a cytogenetic abnormality (Lynch, 2005). 
Chromosome anomalies including aneuplody, duplications and deletions have been 
identified in individuals suffering from syndromes which include an NTD (Lynch, 
2005). The underlying genetic predisposition in most cases of NTD is unknown and 
may involve a combination of various polymorphisms which can then be influenced by 
external environmental factors. Thus, some cases of NTD may occur as a result of the 
summation and/or interaction of several predisposing factors which individually are 
insufficient to cause NTD.
1.4.1 Genetic predisposition
Varying prevalence rates for different populations world-wide could be attributed to 
differences in environmental influences on those populations. However, evidence for a 
genetic role in the incidence of NTD has been found by studying the movement of 
populations and through investigating familial cases (Detrait et a l, 2005). For example, 
the high incidence of NTD found in North-Indian Sikhs compared to non-Sikh North 
Indians (Verma, 1978) is believed to be due to genetic factors, as this elevated 
prevalence continues in Sikh communities that have migrated to a different area of the 
world (British Columbia, Canada) (Hall et al., 1988;Baird, 1983). In addition, a study of
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the prevalence of NTD in a number of ethnic groups in Boston, Massachusetts showed 
higher prevalence rates in those with Irish ancestry than the Jewish population reflecting 
the higher prevalence rates in Ireland compared to Israel (Naggan and MacMahon, 
1967).
Investigations into familial cases have shown that there is an increased risk of an NTD 
affected pregnancy following a previous affected pregnancy, referred to as the 
recurrence risk. The recurrence risk for siblings varies between different populations 
and is related to the occurrence risk (Carter and Evans, 1973;Carter et al., 1968). 
Populations with a relatively high occurrence risk, Britain and Ireland, have a sibling 
recurrence risk of up to 5% (Elwood and Elwood, 1980) whereas populations with a low 
occurrence risk, white infants in North America, have a lower recurrence risk of 1.7% 
(Holmes et al., 1976). In addition, a study in a low incidence population in New York 
State (data collected between 1950-1974) showed that the recurrence risk is higher in 
concordant twins (6.8%) than full siblings (1.8%) which have a higher risk than half­
siblings (0.8%), that share one parent, suggesting that NTD follow a polygenic mode of 
inheritance (Janerich and Piper, 1978). Moreover, the occurrence of NTD among first-, 
second-, and third-degree relatives of probands in the USA were 3.2%, 0.5%, and 
0.17% respectively (Toriello and Higgins, 1983), all of which were elevated compared 
to the general population occurrence rate of 0.12%, again suggesting genetic influences 
are involved in the aetiology of NTD.
Further evidence for a genetic influence on the aetiology of NTD is the higher 
prevalence rate in females compared to males. This observation has been made in many
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different populations (Xiao et al., 1990;Naggan et al., 1967;Sever, 1982;Carter et al., 
1968;Carter et al., 1973;Snyder et al., 1991). When NTD were categorised according to 
the axial level of the lesion there was a preponderance among females at all levels 
except in low spinal regions where there was a male excess (Seller, 1987). The reasons 
behind an increased predisposition for females to develop NTD more often than males 
are not known. One theory suggested a difference in growth rates between the sexes in 
which neurulation occurred over a longer time period in females, rendering them more 
susceptible to neurulation problems (Seller, 1987). However, a subsequent study in mice 
showed that although males are more advanced than their female littermates, the 
duration of neurulation was similar in both sexes (Brook et al., 1994).
1.4.2 Environmental influences
In addition to genetic susceptibility a number of environmental factors are believed to 
affect the prevalence rates of NTD. These include seasonal trends, variations in 
geographic area, social class, maternal age and reproductive history, maternal illness, 
exposure to toxins and maternal nutrition. Obviously, several of these factors are inter­
related and it should also be noted that there are likely to be differences in accuracy of 
diagnosis and reporting between studies.
The different prevalence rates throughout the world could be due to differences in local 
environmental influences. One trend that may be due to the effect of environmental 
factors on the aetiology of NTD is the declining prevalence rate of NTD detected over 
the last century in Britain and the USA. In Britain, the prevalence fluctuated from 2 per 
1,000 births in 1936-7 to a peak of 2.8 per 1,000 in 1940. This was followed by a drop
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to 1.54 per 1,000 births in 1948 and then another peak in 1956 of 2.8 per 1,000 births. 
(Leek, 1966). Records for the prevalence of NTD in America also show fluctuations 
with a peak in NTD incidence in 1932 of 5 per 1,000 births rising from a steady rate of 
2 per 1,000 between 1890-1920 (MacMahon and Yen, 1971). The prevalence of NTD 
has continued to decline in both these populations (Janerich, 1973;Stone, 1987;Snyder 
et a l, 1991), and a number of possible explanations have been suggested. The screening 
and termination of NTD affected pregnancies has often been believed to account for 
declining rates of NTD births. However, the decline in NTD prevalence in North 
America began before screening was available (Yen et al., 1992). In addition, a decline 
of 52% in the rate of perinatal mortality from anencephaly was recorded in the Republic 
of Ireland between 1974-82 even though screening and termination of affected foetuses 
was not available (Kirke and Elwood, 1984). Moreover, a decline in total prevalence 
rate (including terminations, still-births and live-births) was detected in the UK between 
1984-96, indicating a decrease in NTD prevalence that is unrelated to prenatal diagnosis 
and termination (Rankin et al., 2000). The exact reason for the decline in NTD 
prevalence has not been established but may be due to changes in maternal nutrition or 
other environmental factors.
The socio-economic status of the proband’s family, usually determined by father’s 
occupation, has been associated with NTD. For example, an increased NTD prevalence 
was associated with lower socio-economic status in Boston, USA, in a number of 
different ethnic groups (Naggan et a l, 1967). Seasonal variation in the prevalence of 
NTD has also been reported in some studies. Within each country in the UK, seasonal 
peaks for the development of anencephaly were observed in May-June and spina bifida
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in July over a number of years (Maclean and MacLeod, 1984). Another study described 
a higher prevalence of NTD for conceptions in February to April in Greater London 
(Carter et al., 1973), although, seasonal variation in NTD prevalence has not been 
detected in all studies (Sever, 1982).
In some ethnic groups, the prevalence of NTD in the descendants of migrants changes 
to the prevalence of the adoptive countries rather than their ancestral home which 
suggests environmental factors in either country may have an effect on the NTD 
prevalence rate. For example, the prevalence among Bostonians of Irish ancestry is 
lower than that of Irish-born mothers in Boston (Naggan et al., 1967).
Reproductive history and birth order have also been suggested to play a role in the 
prevalence rate of NTD. In a number of studies carried out in Britain, a ‘U’-shaped risk 
pattern of maternal age was found, with a higher risk factor in the youngest and oldest 
mothers (Carter et al., 1968;Carter et al., 1973). A U-shaped curve was also described 
for birth order risk in many different ethnic groups in Boston, USA (Naggan et al., 
1967). In particular, there appears to be an elevated risk of NTD in the first pregnancy 
(Carter etal., 1968;Carter etal., 1973;Janerich etal., 1978).
Maternal illness during the period of neurulation has been associated with an increased 
risk of the embryo developing an NTD. Embryos of diabetic mothers are up to 21 times 
more likely to develop an NTD than control embryos (Zacharias et al., 1984). Several 
factors may contribute to the occurrence of diabetes-associated NTD, including elevated 
levels of glucose and free radicals (Loeken, 2005). In addition, a retrospective study
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discovered a two- to four-fold increase in risk for NTD-affected offspring in mothers 
who had a fever or febrile illness within the first trimester of pregnancy, suggesting that 
hyperthermia can increase the risk of NTD (Suarez et a l , 2004). Maternal exposure to 
toxins has also been suggested to induce NTD. Consumption of blighted potatoes or 
fumonisin-contaminated maize have both been associated with temporal periods and 
geographical areas of high NTD prevalence (Renwick, 1972;Marasas et al., 2004).
A number of the environmental factors that are believed to play a role in the aetiology 
of NTD in humans could be related to maternal nutrition. The peaks of prevalence in the 
US (1930s) and Britain (early 1940s, mid 1950s) could be due to poor maternal 
nutrition during the Great Depression (US) (MacMahon et a l , 1971) or as children 
during the World Wars (Britain) (Stone, 1987). Improvements in maternal nutrition 
during the last five decades may account for the continued decline in NTD prevalence 
observed in both US and British populations (Yen et a l , 1992). Variation in maternal 
intake of nutrients could also relate to seasonal variations and the impact of socio­
economic status on the risk of NTD. Smithells et al. (1977) found lower intakes of all 
nutrients in mothers of lower social classes. Particular nutrients that have been studied 
with regard to the aetiology of NTD include folic acid and vitamin B n (Section 1.9).
In considering a multifactorial aetiology for NTD, in which both genetic and 
environmental factors play a role, the initial prevalence rate of each population may 
need to be taken into account. For example, it has been hypothesised that in low 
prevalence populations environmental influences are less important than in high 
prevalence areas (Janerich et a l , 1978). For example, in an area of low prevalence of
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NTD there were no detectable associations between NTD-affected births and seasonal 
or annual variation, maternal age or parity and fathers occupation (socio-economic 
status) (Sever, 1982). In this population, differences in sex ratios, a high concordant rate 
in twins and differences between racial groups were detected, illustrating clearly that 
genetic influences are involved in the aetiology of NTD. In areas of high prevalence the 
influence of genetic factors are not as apparent, possibly due to the effect of 
environmental factors on the incidence of NTD (Carter et a l, 1968). In addition, greater 
fluctuations in the prevalence rate from year to year have been detected in high 
prevalence populations compared to low prevalence populations over the same time 
period (EUROCAT Working Group, 1991) possibly indicating the greater influence of 
environmental factors.
1.5 THE MOUSE AS AN EXPERIMENTAL MODEL FOR NTD
A large number of genetic mutant mouse strains exhibit NTD. These include models 
that arose spontaneously and models that were generated experimentally (Copp et a l, 
2003b).
1.5.1 The full spectrum of NTD is represented in mouse
Mouse models are available that exhibit the different subsets of NTD resulting from 
failure of different neurulation events. The majority of NTD mouse models exhibit 
exencephaly either alone, as observed in Cited-2 null mutants (Martinez-Barbera et a l, 
2002) or together with caudal NTD as seen in splotch (Sp) mice (Auerbach, 1954). The 
looptail (Lp) mouse has a mutation in the Vangl2 gene that results in the most severe
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type of neural tube defect, craniorachischisis (Murdoch et al., 2001;Kibar et al., 2001) 
arising from the failure of initiation at the site of closure 1. Spina bifida can be exhibited 
either alone, as observed in Vacuolated lens (v/) mice (Wilson and Wyatt, 1988) or with 
exencephaly (as in splotch (Sp) mice).
1.5.2 Genetic and environmental influences affect the incidence 
of NTD in mouse models
Causes of NTD in humans are thought to be multifactorial. This is reflected in mouse 
models such as curly tail (ct) (Seller and Adinolfi, 1981), in which the incidence of 
NTD is affected by genetic and environmental factors. In this strain the penetrance of 
spinal NTD varies considerably depending on the genetic background (Gruneberg, 
1954;Neumann et al., 1994) and is influenced by exogenous agents such as retinoic acid 
(Chen et al., 1994) or inositol (Greene and Copp, 1997;Cogram et al., 2004).
In addition to genetic mouse models, a number of teratogen-induced NTD mouse 
models may also be useful to study the process of neurulation or the development of 
NTD. Post-conceptional exposure to valproic acid (VPA), an anti-convulsant agent, 
induces NTD in mouse embryos (Kao et al., 1981), mirroring the effect of VPA 
administration on human embryos (Robert and Guidbaud, 1982). NTD can also be 
induced in mice by environmental influences such as brief maternal hyperthermia 
(Shiota, 1988). Moreover, genetic background can affect responses to environmental 
factors as may be the case in human NTD. For example, the ability of maternal 
hyperthermia to induce cranial NTD varies in different strains of mice. In one study, 
identical treatment of different mouse strains resulted in exencephaly incidences ranging
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from 44% (SWV) to 0% (DBA/2J) (Finnell et al., 1986). Reciprocal crosses between 
sensitive and insensitive strains showed that it was the embryo genotype, not the 
maternal genotype, that influenced the susceptibility to heat-induced NTD. Differences 
in the rate of teratogen-induced cranial NTD between mouse strains may be related to 
strain differences in the position of closure 2 (Section 1.2.1) (Fleming et a l, 2000).
With a plethora of mutant mouse models available, the mouse is an excellent system to 
investigate the molecular mechanisms of mammalian neural tube closure and defects. 
Another advantage of mice as an experimental model is the ability to manipulate 
environmental factors that may affect neural tube closure, especially through the 
technique of whole embryo culture. This technique permits investigations into the direct 
effect of environmental/nutritional factors on neural tube closure in the embryo, without 
the added complexity of maternal metabolism.
1.6 GENETIC AND CELLULAR MECHANISMS IN NORMAL 
NEURULATION
Studies in mouse models have highlighted some genetic pathways and mechanisms 
required for neurulation to occur (Table 1.1).
1.6.1 Different mechanisms are involved in neural tube closure 
along the cranial-caudal axis of the embryo
Genetic analysis of NTD in mice provides evidence to support the theory that different 
mechanisms of neural tube closure are involved at different axial levels of the embryo,
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both in terms of the molecular requirements and the morphological events. Different 
mutations give rise to cranial and/or caudal NTD (Section 1.5.1) suggesting that specific 
gene products are required for neural tube closure at different levels along the body 
axis. In addition, disruption of neurulation by teratogens may also show different effects 
on cranial versus spinal neural tube closure (Section 3.1). This is perhaps not surprising, 
as de novo initiation most likely involves different processes to continuation or 
completion of closure at the neuropores. Moreover, the embryo continues to develop 
while neurulation progresses, such that the extrinsic factors affecting the neural tube 
may differ throughout neurulation.
1.6.2 Factors involved in cranial neurulation -  evidence from 
mouse models
1.6.2.1 Cranial mesenchyme
The first phase of cranial neurulation in mammalian embryos involves the expansion of 
the mesenchyme underlying the neural folds. This expansion is believed to have a 
mechanical role in supporting the neural folds in preparation for apposition and fusion 
and is driven by an increase in both mesenchymal cell number and extracellular matrix 
volume (Morriss et al., 1978b). Exposure of neurulation stage rat embryos to excess 
Vitamin-A results in reduced numbers of mesenchyme cells and ‘floppy’ neural folds 
that fail to appose and fuse resulting in exencephaly (Morriss and Steele, 1974). 
Exencephaly also occurs in association with a reduction of the number of mesenchymal 
cells in genetic mouse models (Table 1.1) such as Twist and Cartl deficient mice (Chen 
and Behringer, 1995;Zhao et al., 1996). In addition to the number of mesenchymal cells
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Mutant name Type
of
NTD
Gene
mutated
Mutation Protein function Possible mechanism References
Dysregulated
apoptosis
AP2a Ex AP2cc Null Transcription factor Increased apoptosis in 
cranial mesenchyme, and 
HB and MB NE
(Schorle etal., 1996)
Apafl and fog Ex
and/or
SB
Apafl Apafl -null 
fog -  aberrant 
mRNA processing, 
greatly reduced 
mRNA, protein and 
activity
Apoptosis activating 
factor
Reduced apoptosis and 
increased cell 
proliferation
(Harris etal., 
1997;Yoshida et al., 
1998;Honarpour et 
a l, 2001)
Apolipoprotein
B
Ex Apob Truncated protein -  
50% reduction in 
circulating 
cholesterol
Plasma lipoprotein Increased apoptosis in 
HB NE
(Homanics et al., 
1995)
Bel 10 Ex Bel 10 Null Regulator of NF-kB 
activation
Increased apoptosis in 
HB NE
(Ruland et al., 2001)
Bmp5/Bmp7 Ex Bmp5,
Bmp7
Null
Null
Signalling proteins Reduced apoptosis (Solloway and 
Robertson, 1999)
Brcal Ex
and
SB
Brcal Null Transcription factor Increased apoptosis in 
HB NE and increased 
proliferation in luminal 
NE
(Gowen et al., 1996)
Caspase 9 Ex Casp9 Null Cysteine-containing,
aspartate-specific
protease
Reduced apoptosis (Kuida et al., 1998)
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Cited2 Ex Cited2 Null Transcriptional
coactivator
Increased apoptosis in 
MB region
(Bamforth et al 
2001;Martinez- 
Barbera et a l , 2002)
IKK1/IKK2 Ex Chuk,
Ikbkb
Null
Null
Kinases activating 
NF-kB transcription 
factors
Increased apoptosis (Li et al., 2000)
Jnkl/Jnk2 Ex Mapk8,
Mapk9
Null
Null
c-Jun-N-terminal
kinases
Increased apoptosis in 
HB NE and reduced 
apoptosis in FB NE
(Kuan et al., 1999)
Mdm4 Ex Mdm4 Null p53-dependant cell 
cycle regulation
Increased apoptosis (Migliorini et al., 
2002)
MEKK4 Ex
and/or
SB/C
T
MEKK4 Null Mitogen-activated 
protein kinase kinase 
kinase
Increased apoptosis in 
NE
(Chi et al., 2005)
Ski Ex ski Null Transcription factor Increased apoptosis in 
cranial NE and cranial 
mesenchyme
(Berk etal., 1997)
Telomerase
RNA
Ex
and
SB
Terc Null Component of the 
telomerase reverse 
transcriptase 
complex
Increased apoptosis (Herrera et al., 1999)
Treacle Ex Tcofl Heterozygous; loss 
of a single allele
Nucleolar
phosphoprotein
Excessive apoptosis in 
the neural tube and 
cranial region
(Dixon et a l, 2000)
Tubby-like 
protein 3
Ex
and
SB
Tulp3 Unknown; C- 
terminal deletion
Unknown Increased apoptosis in 
ventral region of HB NE 
and caudal neural tube
(Ikeda et al., 2001)
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Aberrant
proliferation
Curly tail Ex
and
SB
Grhl-3? Unknown; 30% 
reduction of Grhl-3 
expression in ct/ct
Transcription factor Defective ventral cell 
proliferation
(Van Straaten and 
Copp, 2001;Ting et 
al., 2003)
n-cofilin CRN n-cof Null F-actin
depolymerising
factor
Reduced cell 
proliferation in NE
(Gumiak et al., 
2005)
Disrupted
cytoskeleton
Abl/Arg Ex Abll,
Abl2
Null
Null
Non-receptor 
tyrosine kinases
Disrupted apical 
neuroepithelial actin 
distribution
(Koleske et al., 
1998)
MARCKS Ex Macs Null cytoskeleton-related
protein
Disrupted cytoskeletal 
function
(Stumpo e f«/., 1995)
MARCKS- 
related protein
Ex 
with/ 
witho 
ut SB
Mlp Null cytoskeleton-related
protein
Disrupted cytoskeletal 
function
(Wu etal., 1996)
Mena/profilinl Ex Enah,
Pfnl
Null for Mena, 
heterozygous for 
profilin 1
Regulation of actin 
polymerisation
Disrupted cytoskeletal 
function
(Lanier et al, 1999)
RhoGAP P I90 Ex Grlfl Truncated protein; 
loss-of-function
Glucocorticoid- 
receptor DNA- 
binding factor
Disrupted neuroepithelial 
actin distribution
(Brouns et al., 2000)
Shroom Ex
and
SB
shrm Null F-actin binding 
cytoskeletal protein
Disturbed F-actin 
localisation
(Hildebrand and 
Soriano, 1999)
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Vinculin Ex Vcl Null Cytoskeletal protein Disrupted cytoskeletal 
function; cell migration 
and adherence
(Xu etal., 1998)
Abnormal cranial 
mesenchyme
Cartl Ex Cartl Null Transcription factor Reduced cranial 
mesenchyme
(Zhao et al., 1996)
Twist Ex Twist Null Transcription factor Reduced cranial 
mesenchyme
(Chen et al.9 1995)
Defective planar cell 
polarity pathway
Circle tail CRN Scrbl Frameshift mutation; 
unknown result
Cytoplasmic protein 
with a role in apico- 
basal polarity
Defective planar cell 
polarity
(Murdoch et al., 
2003)
Crash CRN Celsrl Point mutation; 
disrupted function
T ransmembrane
non-classical
cadherin
Defective planar cell 
polarity
(Curtin et al., 2003)
Dishevelled 1 
and 2
CRN Dvll
Dvl2
Null
Null
Cytoplasmic proteins Defective planar cell 
polarity
(Hamblet et al., 
2002)
Loop-tail CRN Vangl2 Null T ransmembrane 
protein
Defective planar cell 
polarity
(Murdoch et a l, 
2001)
Other suggested 
mechanisms
Eph-A7 Ex Epha7 Null Receptor tyrosine 
kinase
Defective neural fold 
fusion
(Holmberg et al., 
2000)
Ephrin-A5 Ex Efna5 Null Receptor tyrosine 
kinase
Defective neural fold 
fusion
(Holmberg et a l, 
2000)
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Folate-binding 
protein 1
Ex Folbpl Null folate transport Reduced folate 
availability
(Piedrahita et al., 
1999)
Hairy Ex Hesl Null Transcription factor Premature neuronal 
differentiation in FB
(Ishibashi et al., 
1995)
Numb Ex Numb Null Membrane-bound 
protein involved in 
asymmetric cell 
division
Premature neuronal 
differentiation in FB
(Zhong et al., 2000)
Table 1.1 Mouse genetic models of NTD with suggested underlying mechanisms
Abbreviations: CRN, craniorachischisis; CT, curly tail; Ex, exencephaly; FB, forebrain; HB, hindbrain; MB, midbrain; NE, 
neuroepithelium; SB, spina bifida.
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present in the cranial region, the integrity of extracellular matrix surrounding the cranial 
mesenchyme may also play an important role in cranial neurulation (Morriss-Kay and 
Crutch, 1982).
1.6.2.2 Actin cytoskeleton
Cranial neurulation requires a functional actin cytoskeleton. Targeting of genes that 
encode proteins involved in cytoskeletal function results in cranial NTD. For example, 
knockout mouse models of shroom (an actin-binding protein) and vinculin (a 
cytoskeletal protein) result in a 100% incidence of exencephaly in homozygous 
embryos (Hildebrand et al., 1999;Xu et al., 1998). Similarly, deficiency of MARCKS 
(an actin binding protein) also results in cranial neural tube defects in a significant 
number of homozygous embryos (25%) (Stumpo et al., 1995). The actin cytoskeleton 
appears to be particularly involved in the closure of the cranial neural folds as the 
majority of neural tube defects exhibited by these mouse models affect the cranial 
region (Table 1.1). In addition, disruption of the actin cytoskeleton by cytochalasin D 
treatment also resulted in isolated cranial neural tube defects with caudal closure 
unaffected (Ybot-Gonzalez and Copp, 1999). The exact role of the actin cytoskeleton in 
neurulation is unclear. However, evidence from mouse and other animal studies, points 
to possible roles in medial convergence of the neural folds through the formation of 
DLHP (Morriss-Kay and Tuckett, 1985;Schoenwolf et al., 1988) and in providing 
stability for the lateral neural folds (Morriss-Kay et al., 1985;Ybot-Gonzalez et al., 
1999).
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1.6.2.3 Apoptosis
Correct regulation of apoptosis in the neuroepithelium and the underlying cranial 
mesenchyme appears to be necessary for cranial neurulation to occur normally. Both 
increases and decreases in the rate of apoptosis have been associated with the 
development of exencephaly (Table 1.1). Mouse mutant models that develop cranial 
neural tube defects in association with increased levels of apoptosis include the Mdm4 
knockout (Migliorini et al., 2002) and mice lacking the ski oncogene (Berk et al., 1997). 
In addition, some mouse models exhibit exencephaly in association with reduced levels 
of apoptosis including the Bmp5/Bmp7 double knockout (Solloway et al., 1999) and 
mice deficient for caspase 9 (Kuida et al., 1998). Moreover, the importance of 
regulation of apoptosis in cranial neurulation is evident from exposure of neurulation 
stage embryos to various teratogens. For example, lithium-induced cell death in the 
neuroepithelium of mouse embryos has been suggested to lead to the subsequent cranial 
neural tube defects (Giles and Bannigan, 1997), although the possibility that apoptosis 
is secondary to another effect of lithium cannot be excluded.
1.6.3 Factors involved in spinal neurulation -  evidence from 
mouse models
1.6.3.1 Planar cell polarity pathway
In mice, the development of craniorachischisis has been linked to a non-canonical Wnt 
signalling pathway called the planar cell polarity pathway. Disruption of genes involved 
in this pathway lead to the development of craniorachischisis in mice (Table 1.1) 
(Murdoch et al., 2001;Kibar et al., 2001;Curtin et al., 2003). The phenotypes are
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believed to be caused by the inhibition of convergent extension, a morphogenetic 
process of cell movement in which a field of cells lengthens along one axis and narrows 
in a perpendicular axis (Wallingford et al., 2002). Suppression of convergent extension 
leads to an abnormally wide floorplate, and excessively wide spacing of the neural 
folds, which cannot converge in the midline resulting in failure of neural tube closure at 
initiation site closure 1 (Ueno and Greene, 2003;Copp et al., 2003a).
1.6.3.2 Axial curvature
Axial curvature has been suggested to have an important influence on spinal neural tube 
closure. The rate of neural tube closure has been shown to correlate with the degree of 
axial curvature in a number of vertebrates (Peeters et al., 1998a). In the mouse, axial 
curvature decreases at the PNP region as neurulation proceeds along the cranio-caudal 
axis, correlating with an increase in the rate of PNP closure throughout neurulation 
(Peeters et al., 1998a). In addition, studies in the curly tail mouse indicate that an 
increase in axial curvature caused by reduced proliferation in the ventral hindgut, slows 
down PNP closure. The consequent delay or failure of closure of the PNP, results in a 
curly tail phenotype or spina bifida, respectively (Copp et al., 1988a). Correction of the 
increased ventral curvature mechanically or by hyperthermia-induced growth 
retardation has been shown to reduce the incidence of caudal NTD in curly tail mice 
(Copp et al., 1988b;Brook et al., 1991). These studies show that both correct axial 
curvature and co-ordinated proliferation are required for PNP closure.
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1.7 FOLATE PREVENTS NTD IN HUMANS
Periconceptional vitamin supplementation was initially implicated as a potential 
approach for the prevention of NTD following the observation that supplementation 
reduced the risk of recurrence of an NTD-affected pregnancy in humans (Smithells et 
al., 1981). Further evidence has indicated that supplementation with folic acid alone 
reduces the risk of an NTD-affected pregnancy. A randomised double-blind clinical trial 
conducted at 33 centres across 7 countries showed that NTD recurrence was reduced by 
up to 70 % following periconceptional supplementation with 4 mg/day folic acid (Wald 
et al., 1991). This result has been confirmed by a number of smaller studies using 
supplements of folic acid alone or in combination with other vitamins (Mulinare et al., 
1988;Milunsky et al., 1989). In addition, maternal supplementation with multi-vitamins 
containing folic acid reduced the incidence of a first occurrence of NTD (Czeizel and 
Dudas, 1992). A more recent study has investigated the prevention of NTD in high and 
low risk areas in China by periconceptional supplementation with 400 pg/day folic acid. 
Both populations showed a significant reduction in the rate of NTD after folic acid 
supplementation. Moreover, in a subgroup of women with high compliance (those who 
took the supplementation more than 80 % of the time) similar rates of NTD were 
observed in both supplemented populations, with a reduced risk for an NTD-affected 
pregnancy of 85 % in the high prevalence area (Berry et al., 1999).
As a result of these studies, women of childbearing age are advised to take 400 pg/day 
folic acid prior to, and for three months following conception, to reduce the risk of an 
NTD-affected pregnancy. On 1st January 1998, the addition of folic acid to enriched 
cereal grain products became mandatory in the USA. The addition of 140 pg folic acid
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per 100 g cereal grain product was introduced with the aim of increasing the daily 
intake of folic acid of women of childbearing age (Mills and Signore, 2004). 
Subsequently, a number of other countries (including Canada (150 pg per 100 g of 
flour) (Mills et al., 2004) and Chile (220 pg per lOOg of flour) (Hertrampf et a l, 2003)) 
have established fortification programmes. The current levels of fortification are 
relatively conservative, and it is estimated that the resultant additional folic acid intake 
in the USA and Canada is 100 pg/day (Liu et al., 2004). Preliminary studies indicate 
that this level of fortification has reduced the prevalence of NTD to various degrees, by 
31 % in the USA (Williams et al., 2002) to 78 % in a high risk area of Newfoundland, 
Canada (Liu et al., 2004). Continued surveillance is required to clearly distinguish the 
effects of folic acid fortification from the declining trend in NTD prevalence observed 
in these populations over the last few decades (Section 1.4.2) (Williams et a l, 2002). 
Nevertheless, the current level of fortification has succeeded in increasing folate status, 
as indicated by increased serum folate, red blood cell folate levels and reduced 
homocysteine levels, in the overall US population (Rader, 2002) and in women of 
childbearing age (19-44 years) and seniors (65 years or over) in Canada (Liu et al., 
2004). In response to the limited reductions in NTD risk in some populations, there have 
been suggestions that the level of fortification is not currently high enough, and 
increased levels would prevent further cases of NTD (Wald et al., 2001). However, 
there are concerns over the effects of long term exposure to high levels of folic acid on 
specific subgroups in the population (Campbell, 1996;Reynolds, 2002;Rader and 
Yetley, 2002;Kim, 2004). The possibility of detrimental effects on non-targeted 
members of the population has led to several countries rejecting the implementation of
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fortification strategies in favour of public education campaigns to increase folic acid 
supplementation among women of childbearing age (Bailey et al., 2003).
1.8 ONE CARBON METABOLISM
1.8.1 Folate metabolism
Folate metabolism is essential for a number of important cellular processes, including 
the synthesis of purines, thymidylate and methionine. Eukaryotes are unable to 
synthesise folate and, therefore, rely on dietary sources to provide sufficient amounts. In
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Figure l.S A representation of the molecular structure of folic acid
The molecular structure of folic acid and its components. R2 denotes the site of y- 
carboxyl peptide bond links to glutamic acid moieties in polyglutamate folates (Adapted 
from (Van der Put et al., 2001)).
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the circulation, folate is present in monoglutamated form and following cellular uptake 
polyglutamated by the action of folylpolyglutamate synthase (Lucock, 2000). The 
polyglutamate moieties ensure folate is retained in the cell, maintaining cellular folate 
pools, and increase the affinity of folate for folate-dependant enzymes.
The circulating form of folate, 5-methyltetrahydrofolate (5-methyl THF), is a co­
substrate for the remethylation of homocysteine to methionine which is mediated by 
methionine synthase (MS). This reaction, which is vitamin Bn-dependent, connects the 
folate and methylation cycles (Figure 1.6). The folate-derived product of the MS- 
mediated reaction, tetrahydrofolate (THF), can be converted to 5,10- 
methylenetetrahydrofolate (5,10-methylene THF) by a reversible reaction catalysed by 
serine hydroxymethyltransferase (SH); this reaction also mediates the interconversion of 
serine and glycine (Figure 1.6). 5,10-methylene THF is the substrate for three different 
reactions, all of which are involved in important pathways in the cell:
(i). Reduction of 5,10-methylene THF by methylenetetrahdrofolate reductase (MTHFR) 
replenishes 5-methyl THF levels (Figure 1.6). This is the only reaction capable of 
producing 5-methyl THF and polymorphisms in MHTFR have been associated with 
increased NTD risk (Section 1.9).
(ii). The conversion of 5,10-methylene THF back to THF via the trifunctional enzyme, 
methylenetetrahydrofolate dehydrogenase /methenyltetrahydrofolate cyclohydrolase 
/formyltetrahydrofolate synthetase (MTHFD1), results in the intermediates, 5,10- 
methenyl tetrahydrofolate (5,10-methenyl THF) and 10-formyltetrahydrofolate (10- 
formyl THF). 10-formyl THF donates a one-carbon unit in synthesis of the purine ring 
(Figure 1.6).
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Figure 1.6 The folate cycle
A simplified diagram of the folate cycle. Folate and methylation cycle intermediates are in black text and the enzymes involved in the cycle 
are shown in blue. Biosynthetic pathways are boxed.
Abbreviations: DHF, dihydrofolate; DHFR, dihydrofolate reductase (EC 1.5.1.3); dUMP, deoxyuridine monophosphate; dTMP, 
deoxythymidine monophosphate; MS, methionine synthase (EC 2.1.1.13); MTHFD1, methylenetetrahydrofolate dehydrogenase (EC 
1.5.1.5) /methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9) /formyltetrahydrofolate synthetase (EC 6.3.4.3); MTHFR, 
methylenetetrahydrofolate reductase (EC 1.5.1.20); SH, serine hydroxymethyltransferase (EC 2.1.2.1); TS, thymidylate synthase (EC 
2.1.1.45).
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(iii). In the de novo pathway of pyrimidine biosynthesis, the thymidylate synthase (TS) 
mediated reaction converts 5,10-methylene THF to dihydrofolate (DHF) during the 
production of deoxythymidine monophosphate (dTMP) from deoxyuridine 
monophosphate (dUMP) (Figure 1.6). DHF is subsequently reduced to THF by 
dihydrofolate reductase (DHFR) completing the cycle (Figure 1.6) (Carmel and 
Jacobsen, 2001).
1.8.2 The methylation cycle
The methylation cycle is essential for the production of S-adenosylmethionine (SAM), 
the universal substrate for methyltransferase reactions. In all mammalian cells a ‘core’ 
methylation cycle occurs, that generates SAM and involves the folate-dependant 
remethylation of homocysteine to methionine The methylation and folate cycles are 
connected through this methionine synthase (MS) mediated reaction (Figure 1.7). 
Methionine is converted to SAM by methionine adenosyltransferase (MAT). SAM is 
the methyl donor in the methylation of a large number of substrates including nucleic 
acids, proteins and lipids (Chiang et al., 1996). The resultant product of these reactions 
(in addition to the methylated substrate) is S-adenosylhomocysteine (SAH) (Figure 1.7). 
SAH undergoes hydrolysis in a reversible reaction mediated by SAH hydrolase, 
producing homocysteine and adenosine. The equilibrium of this reaction favours the 
synthesis of SAH, such that rapid removal of the products is required to maintain flux 
through the methylation cycle (Finkelstein, 1998).
SAH and SAM levels have a regulatory role in both methylation and folate cycles. 
When cellular levels of SAH are elevated, SAH acts as a product inhibitor of
60
Figure 1.7 The methylation cycle
A simplified diagram of the methylation cycle. Methylation and folate cycle intermediates are in black text and the enzymes involved in the 
cycle are shown in blue. Additional pathways are boxed and cell specific reactions are indicated by dotted lines.
Abbreviations: BHMT, betaine-homocysteine methyltransferase (EC 2.1.1.5); MAT, methionine adenosyltransferase (EC 2.5.1.6); MS, 
methionine synthase (EC 2.1.1.13); SAH, S-adenosylhomocysteine; SAH hydrolase, S-adenosylhomocysteine hydrolase (EC 3.3.1.1); 
SAM, S-adenosylmethionine; SAMDC, S-adenosylmethionine decarboxylase (EC 4.1.1.50); THF, tetrahydrofolate.
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methyltransferase reactions (Carmel et al., 2001). The ratio of SAM:SAH levels in the 
cell also has an important role in regulating the activity of MTHFR, a decrease in the 
ratio resulting in increased enzyme activity (Matthews et al., 1998). Increased MTHFR 
activity drives the production of 5-methyl THF, the co-substrate for the remethylation of 
homocysteine to methionine (Figure 1.7).
SAM is also required for the biosynthesis of polyamines (Figure 1.7). The propylamine 
moiety from decarboxylated SAM can be transferred to either putrescine or spermidine 
to produce either spermidine or spermine (Finkelstein, 1990).
In addition to the MS-mediated remethylation of homocysteine, two other pathways for 
the metabolism of homocysteine are present in specific cell types. Remethylation of 
homocysteine to methionine by a second methyltransferase, betaine-homocysteine 
methyltransferase (BHMT), which employs betaine as the methyl donor, occurs in 
mammalian liver and kidneys (McKeever et al., 1991). The transulphuration pathway, 
results in conversion of methionine to cysteine and is the only route of homocysteine 
removal from the methylation cycle. The enzymes cystathionine p-synthase and 
cystathionase convert homocysteine to cysteine and a-ketobutyrate via the intermediate 
cystathione. In mammals, the complete pathway has only been reported in liver, 
pancreas, kidney and intestine (Finkelstein, 1990). Other tissues including neurulation- 
stage embryos, are not thought to have a functioning transulphuration pathway 
(VanAerts et al., 1995;Finkelstein, 1998). Therefore, during neurulation, the only 
functional pathway for the removal of homocysteine in the embryo is likely to be the 
folate-dependant MS mediated reaction.
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1.9 FOLATE-RELATED RISK FACTORS FOR THE 
DEVELOPMENT OF NTD IN HUMANS
A number of environmental and genetic factors have been associated with the aetiology 
of NTD-affected pregnancies (Section 1.4). Due to the complex aetiology of NTD, the 
identification of individual factors that are directly involved in determining the 
susceptibility to NTD (risk factors) is difficult. Some risk factors have been identified 
through studying associations between NTD-affected pregnancies and maternal 
nutritional status.
Sub-optimal maternal folate levels have been associated with increased risk of an NTD- 
pregnancy in a number of studies (Smithells et al., 1976;Kirke et al., 1993). It is 
interesting to note that red cell folate levels detected in these studies were within the 
‘normal’ range and therefore the mothers were not classified as folate deficient. Vitamin 
B12 insufficiency has also been suggested as a risk factor for NTD-affected pregnancies. 
Reduced levels of vitamin B 12 have been detected in amniotic fluid and maternal plasma 
samples of NTD-affected pregnancies compared to control samples (Kirke et al., 
1993;Steen et al., 1998;Ray and Blom, 2003;Felix et al., 2004). Several studies have 
also shown that women carrying embryos with NTD (Mills et al., 1995) and women 
who have had children affected with NTD (Steegers-Theunissen et al., 1994) have 
significantly elevated levels of plasma homocysteine. In addition, elevated levels of 
total homocysteine have also been detected in spina bifida patients and their parents 
(Van der Put et al., 1997a) suggesting elevated homocysteine levels may be a risk factor 
for NTD.
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Not all populations exhibit these risk factors, for example, several studies have not 
identified NTD associations with maternal folate status (Economides et al., 1992;Mills 
et al., 1992;Van der Put et al., 1997a), folate levels in amniotic fluid (Economides et al., 
1992;Steen et al., 1998) or maternal vitamin Bn status (Economides et al., 1992;Mills 
et al., 1992). As discussed previously, different populations are likely to be affected by 
genetic and environmental factors in different ways with respect to NTD (Section 1.4). 
For example, areas with a high prevalence of NTD tend to have greater response to 
folate supplementation than areas of low prevalence (Section 1.7). This correlation may 
also be evident in the association of NTD risk in certain populations with folate-related 
nutritional status (Mills et al., 1992).
In many studies, investigation of potential genetic risk factors has been based on the 
known prevention of NTD by folic acid supplementation. The possibility that 
supplementation may be overcoming a defect in folate metabolism has led to the 
analysis of many folate-related genes. In addition, the association of elevated 
homocysteine, reduced vitamin B 12 and sub-optimal folate levels with risk for NTD, led 
to the analysis of enzymes directly involved in maintaining cellular levels of these 
nutrients.
The first folate-related genetic risk factor to be identified was a polymorphism in the 
MTHFR gene (Whitehead et al., 1995;Van der Put et al., 1995). A point mutation, 
677C>T, causing an alanine-valine amino acid substitution produces a thermolabile 
variant of the enzyme that has reduced activity (Frosst et al., 1995). Homozygous 
individuals for the 677T allele have significantly elevated plasma homocysteine levels
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(Frosst et al., 1995;Van der Put et al., 1996;Friso et al., 2002) and hypomethylated 
DNA when they also have low serum folate values (Friso et al., 2002;Castro et al., 
2004). A number of studies have shown that the frequency of the 677T allele is 
increased in NTD-affected patients (Shields et al., 1999;Whitehead et al., 1995;Van der 
Put et al., 1995;Wenstrom et al., 2000;De Marco et al., 2002;Rampersaud et al., 2003). 
However, other studies carried out in different population groups have not identified an 
increased risk of NTD in association with the MTHFR 677T allele (Papapetrou et al., 
1996;Koch et al., 1998;Perez et al., 2003;Felix et al., 2004). In addition, elevated 
homocysteine levels have been observed in patients with NTD, independent of their 
MTHFR 677 genotype (Wenstrom et al., 2000;Perez et al., 2003), suggesting that other 
risk factors which affect folate metabolism may be involved in the aetiology of some 
NTD.
A second single nucleotide polymorphism (SNP) (1298A>C) has been identified in the 
MTHFR gene which causes a glutamate-alanine substitution resulting in decreased 
MTHFR activity. This mutation does not result in a thermolabile enzyme and the 
reduction in activity is not as pronounced as for the 677C>T mutation. In addition, 
homozygotes for the 1298CC allele do not show elevated homocysteine levels or 
reduced plasma folate levels (Van der Put et al., 1998). At present there are no studies 
supporting an independent role for the presence of the 1298C allele in the aetiology of 
NTD (Parle-McDermott et al., 2003;Felix et al., 2004). However, it has been suggested 
to have an exacerbating effect on the risk of NTD in patients when present in combined 
heterozygosity with the MTHFR 667T allele (Van der Put et al., 1998).
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The methionine synthase mediated reaction, in which homocysteine is remethylated to 
methionine, has also been investigated in respect to NTD risk. Analysis of 
polymorphisms in the methionine synthase gene (MTR; 2756A>G) and methionine 
synthase reductase gene (MTRR; 66A>G) have been carried out in many populations. 
The MTR 2756A>G polymorphism results in an aspartic acid to glycine amino acid 
change in the activation domain of the enzyme (Leclerc et al., 1996). Methionine 
synthase reductase reactivates methionine synthase (MS) that has lost activity due to the 
oxidation of its co-factor cob(I)alamin to cob(II)alamin, and therefore, is required to 
maintain MS activity. The MTRR 66A>G polymorphism is thought to affect the 
binding affinity for MS and reduce the reductive activities of the enzyme(01teanu et al., 
2004). Both variants, MTR 2756A>G and MTRR 66A>G, have been identified as 
individual maternal (Doolin et al., 2002) and infant (Zhu et al., 2003) risk factors for 
spina bifida. The presence of G alleles at both loci has been suggested to result in a 
greater risk for NTD than either alone (Zhu et al., 2003). However, other studies have 
not identified associations of variants in either gene with NTD risk (Morrison et al., 
1997;Van der Put et al., 1997b;Christensen et al., 1999;De Marco et al., 2002;0'Leary 
et a l, 2005).
A number of other potential genetic risk factors have been identified in folate-related 
genes in some populations. These include maternal homozygosity for the R653Q 
polymorphism in the MTHFD1 gene (Brody et al., 2002), maternal homozygosity for a 
DHFR allele with a 19bp deletion in intron 1 (Johnson et al., 2004) or maternal 
homozygosity for the 776C>G polymorphism in the gene encoding the vitamin B12 
binding protein, transcobalamin II (TCII) (Pietrzyk and Bik-Multanowski, 2003).
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Polymorphisms in the promoter enhancer region and 3’UTR of the TS gene have been 
associated with elevated risk of spina bifida in non-Hispanic whites (Volcik et a l, 
2003). A significant association has also been detected between NTD risk and the 
presence of a polymorphism in the reduced folate carrier gene (RFC1), 80A>G (Pei et 
al., 2005). Microconversion events in the FRa gene have also been suggested to act as 
genetic risk factors for NTD (De Marco et al., 2000). Thus, a range of studies have 
implicated polymorphisms in several folate-related proteins in mildly elevated risks of 
NTD.
However, several studies have failed to detect associations between polymorphisms in 
these genes and NTD (Barber et al., 1998;Wilding et al., 2004;Swanson et a l, 2005). In 
addition, studies in other folate-related genes; cSHMT/mSHMT (Heil et a l, 2001), 
BHMT/BHMT2 (Zhu et a l, 2005), FRp (O'Leary et al., 2003) and CBS (Afinan et al., 
2003b), have so far failed to identify any genetic variants that are significantly 
associated with NTD.
Currently the known genetic risk factors are not sufficient to explain the susceptibility 
to NTD for all cases. For example, in populations with a positive association between 
MTHFR genotype and NTD occurrence, the frequency of the 677T allele cannot 
account for all the folate-preventable NTD (Shields et a l, 1999). As discussed 
previously (Section 1.4), susceptibility to NTD probably follows a polygenic mode of 
inheritance in addition to being influenced by environmental factors. A number of 
studies have analysed the impact of combinations of potential risk factors on the 
aetiology of NTD. Combined genetic and/or environmental risk factors could result in a
68
CHAPTER 1; Introduction
greater risk for NTD than either factor alone. For example, homozygosity for MTHFR 
677T allele and low RBC folate in cases and mothers were independent risk factors that 
showed possible synergistic effects, resulting in increased NTD risk in a Canadian study 
(Christensen et al., 1999). In another study, a MTRR 66GG maternal genotype 
increased NTD risk when vitamin B 12 was low (valued within the lowest quartile of the 
control range) or in the presence of a MTHFR 677TT genotype (Wilson et al., 1999). 
These studies indicate that gene-nutrient and gene-gene interactions may be involved in 
determining the susceptibility to NTD. In support of these findings, another study 
observed an increase in NTD risk in individuals carrying both the MTRR 66G and 
MTHFR 677T variants (Relton et al., 2004). Further studies have indicated that the 
possession of more than one polymorphism at folate-related loci can elevate risk of 
NTD (Van der Put et al., 1998;Gueant-Rodriguez et al., 2003;Zhu et al., 2003). In order 
to understand the complex aetiology and potential contributions of possible risk factors 
to the susceptibility for NTD, more sophisticated studies are required that account for 
summation and interaction of multiple risk factors. Such studies could possibly 
elucidate some of the biological mechanisms underlying NTD.
1.10 PREVENTION OF NTD IN MOUSE MODELS
In humans, clinical trials have demonstrated that folic acid supplementation can prevent 
the recurrence of up to 70 % of NTD (Wald et al., 1991). Therefore, 30 % of 
pregnancies developed NTD despite folate supplementation, suggesting that some NTD 
are resistant to folic acid administration. This observation is mirrored among the mouse 
models. Several models respond to folic acid or folate-related metabolites (Table 1.2),
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showing a decrease in the incidence of NTD, while others do not (Copp and Greene, 
2000).
One example of an apparently folate-insensitive NTD mouse model is curly tail (ct) in 
which supplementation with folic acid, folinic acid or methionine do not affect the 
frequency of NTD among homozygous ct/ct embryos (Seller, 1994;Van Straaten et al., 
1995). However, maternal administration of myo-inositol significantly reduces the 
incidence of spinal NTD in homozygous ct/ct embryos. The preventative effect of myo­
inositol of NTD in these mice is mediated by the activation of protein kinase C (PKC) 
(Greene et al., 1997;Cogram et al., 2004). This mechanism of NTD prevention is 
thought to be unrelated to folate metabolism, suggesting that alternative preventative 
approaches to folate supplementation need to be investigated. However, a better 
understanding of the mechanism underlying folate-responsive NTD may enable 
improvement of current prevention strategies.
A number of mouse NTD models have been tested for sensitivity to folic acid and/or 
folate-related metabolites. Identification of strains that are responsive to 
supplementation with folic acid (Carter et al., 1999;Martinez-Barbera et al., 2002) or 
folate-related metabolites, such as methionine (Essien, 1992;Greene and Copp, 2005) 
(Table 1.2) confirm the ability of folic acid treatment to prevent some NTD. In addition, 
some teratogen-induced NTD can also be prevented by folate treatment (Shin and 
Shiota, 1999;Trotz et a l, 1987;Sadler et a l, 2002) (Table 1.2).
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Mouse Model Type of 
NTD
Preventative treatment Reference
Genetic models
Axial defects 
(Axd)
SB Methionine
Maternal i.p. administration 
On E8 and E9
(Essien, 1992)
Cartilage 
homeoprotein 1 
(Cartl)
Ex Folic acid
Maternal i.p. administration 
Throughout pregnancy
(Zhao et al., 1996)
Cited2 Ex Folic acid
Maternal i.p. administration 
Throughout pregnancy
(Martinez-Barbera 
et al., 2002)
Crooked tail 
(Cd)
Ex Folic acid
Dietary maternal administration 
Prior to conception and 
throughout pregnancy
(Carter et al., 1999)
Folate binding 
protein 1 
(Folbpl)
Ex Folinic acid 
Maternal intubation 
Prior to conception and 
throughout pregnancy
(Piedrahita et al., 
1999)
Splotch (SpJti) Ex
and/or
SB
Folic acid and thymidine 
Maternal i.p. administration 
On E8.5 and E9.5 
Whole embryo culture 
E8.5 to E10.5
(Fleming and 
Copp, 1998)
Teratogen
models
Fumonisins Ex Folinic acid 
Whole embryo culture 
E9 to E10
(Sadler et a l, 
2002)
Hyperthermia Ex Folic acid 
Maternal intubation 
E0.5 to E9.5
(Shine/ al., 1999)
Valproic acid SB and 
Ex
Folinic acid
Maternal i.p administration 
On E8 only or thrice daily from 
E5 toElO
(Trotz et al.,
1987;Padmanabhan 
and Shafiullah, 
2003)
Table 1.2 Mouse models in which NTD are preventable by folate-related 
treatments
Abbreviations: Ex, exencephaly; i.p. intraperitoneal injection; SB, spina bifida.
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These folate-responsive mouse models may be useful tools in the investigation of the 
mechanisms of prevention of NTD by folic acid, and one such model, splotch, is used in 
this project.
1.10.1 Splotch mice
There are six variants of the splotch allele that all encode mutant forms of the Pax3 gene 
(Table 1.3). Pax3 is a transcription factor that contains paired-box and homeobox DNA 
binding motifs. It is expressed in the dorsal neural tube, dermomyotome and neural crest 
cells of neurulation stage embryos (Goulding et al., 1991). The splotch phenotype 
includes NTD (comprising exencephaly and/or spina bifida), limb muscle defects and 
defects in neural crest cell derivatives. The severity of the abnormalities seen in splotch 
homozygotes differ between the allelic variants (Table 1.3). However, all heterozygotes 
are characterised by a white patch on the abdomen due to impaired migration of 
melanocytes, which are derived from the neural crest (Auerbach, 1954). The splotch 
allele utilised in this study is Sp2H. This mutation was induced by X-ray irradiation, 
resulting in a 32bp deletion in the paired box region of the Pax3 gene that causes 
premature termination of the protein, which is predicted to result in a functionally null
•  7 f - fallele (Epstein et al., 1991). In Sp mice, treatment with folic acid or thymidine reduces 
the incidence of cranial and caudal NTD, both in whole embryo culture and through 
maternal intraperitoneal injections (Fleming et al., 1998).
Abnormal folate metabolism in Sp2H/Sp2H embryos was detected using the deoxyuridine 
monophosphate (dUMP) suppression test in whole embryo culture. The ability of 
exogenous dUMP to suppress the incorporation of exogenous [3H] thymidine into DNA
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Splotch
allele
Mutation in 
Pax3
Effect on Pax3 
protein
Mode of 
mutation
Homozygous phenotype References
Splotch
(Sp)
Mutation in 
splice acceptor 
site in intron 3
Four aberrantly 
spliced transcripts 
-  none expected to 
result in functional 
Pax3 proteins
Spontaneous Exencephaly and/or spina bifida, 
Defects in neural crest derivatives*. 
Lethal between E l3-16
(Russell,
1947; Auerbach, 
1954;Epstein et al., 
1993)
Splotch-
delayed
(Sp*)
Point mutation Non-conservative 
amino acid 
substitution within 
the paired box
Spontaneous Spina bifida,
Reduced size and number of spinal 
ganglia
Perinatally lethal
(Dickie, 1964;Moase 
and Trasler, 
1989;Vogan et al., 
1993)
Splotch- 
retarded 
(Spr)
Large
chromosomal 
deletion including 
entire Pax3 gene
Null mutation X-ray
induced
Preimplantation lethal (Beechey and Searle, 
1986)
Splotch111
(Sp1H)
Unknown Unknown X-ray
induced
Exencephaly and/or spina bifida, 
Defects in neural crest derivatives* 
Lethal between El 3-16
(Beechey et al., 1986)
Splotch211
(Sp2H)
32bp deletion Truncated protein X-ray
induced
Exencephaly and/or spina bifida, 
Defects in neural crest derivatives* 
Lethal between E l3 and birth
(Beechey et al., 
1986;Epstein et al., 
1991)
Splotch411
(Sp4H)
Entire Pax3 gene 
deleted
Null mutation X-ray
induced
Lethal before E7 (Goulding et al.,
1993 ;Fleming et al., 
1996)
Table 1.3 Splotch allele phenotypes and mutations in Pax3
* includes absent or abnormal spinal ganglia, enteric ganglia, limb muscles and melanocytes, and cardiac defects (Auerbach, 1954;Moase 
et al., 1989;Franz, 1989;Machado et al., 2001).
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relies on the integrity of the folate cycle. An intermediate of the folate cycle, 5,10- 
methylene tetrahydrofolate, is the co-substrate, with dUMP, for thymidylate synthase in
1  J T
the de novo pathway of pyrimidine synthesis. In homozygous Sp embryos, the extent 
of suppression of [ H]-thymidine incorporation by exogenous dUMP is significantly 
reduced compared to heterozygotes and wild type littermates (Fleming et al., 1998). 
This could indicate a restricted supply of 5,10-methylene tetrahydrofolate resulting from
9 f - fimpairment in the folate cycle. These results indicate that the prevention of NTD in Sp 
embryos by folic acid supplementation may be mediated through the correction of an 
abnormality in folate metabolism. Another possible explanation is that Sp2H/Sp2H 
embryos have an increased requirement for dTMP. The exact abnormality affecting
7 bffolate metabolism in Sp homozygotes has yet to be discovered.
1.10.2 Possible mechanisms of folate prevention of NTD
As stated earlier, the mechanism of folate prevention of NTD is not known. Folate 
treatment does not appear to prevent a specific subtype of NTD suggesting that folic 
acid protection may act through a general effect on neurulation (Seller, 1995).
1.10.2.1 Correction of maternal folate deficiency
A number of potential mechanisms have been suggested, including the possibility that 
folate supplementation simply corrects a maternal deficiency. This is unlikely as 
maternal folate levels during NTD-affected pregnancies are normal or only mildly 
deficient (Scott et al., 1994). In addition, dietary folate deficiency in mice results in
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reduced litter sizes and embryonic growth retardation but does not induce NTD (Heid et 
al., 1992;Burgoon et a l , 2002).
1.10.2.2 Overcoming abnormalities in folate metabolism
Folate supplementation could act to overcome a metabolic block within the folate cycle. 
Inborn errors in folate metabolism or transport could leave embryos requiring an 
increased supply of folic acid and render them susceptible to NTD. Murine studies 
involving the disruption of a number of enzymes in the folate cycle by chemical 
inhibitors and the production of null mutants of folate-related genes have allowed 
investigation of the role of specific enzymes in the development of NTD (Juriloff and 
Harris, 2000). A number of the enzymes involved in folate metabolism are essential for 
the viability of embryos, but to date no single genetic mutation of a folate-related gene 
in mice has been identified that mirrors NTD in humans. Alternatively, folate protection 
against NTD could be achieved through stimulation of proliferation, with folic acid 
driving the production of purines and pyrimidines for DNA synthesis (Section 1.8.1). 
Cells are dividing rapidly during the process of neurulation resulting in a high demand 
for nucleotides, a possible limiting factor for embryos susceptible to NTD.
1.10.2.3 Overcoming abnormalities in the methylation cycle
Another possible mechanism for the folate prevention of NTD may be through 
overcoming defects within the methylation cycle. It has been hypothesised that defects 
in the methylation cycle may be involved in the production of NTD, either through 
changes in cellular methylation or through causing an increase in the concentration of
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homocysteine. Folic acid supplementation could increase the supply of 5-methyl THF, 
thereby facilitating the remethylation of homocysteine to methionine (Section 1.8). This 
could increase the flux through the methylation cycle, ensuring the production of SAM 
and reducing cellular homocysteine levels.
Conversion of methionine to SAM provides the universal substrate for 
methyltransferase reactions. Methylation of DNA, proteins and phospholipids, all utilise 
SAM as the methyl donor (Chiang et a l , 1996). Changes in cellular methylation 
processes could affect protein function and gene expression (Carmel et al., 2001), which 
could potentially result in the production of NTD in the developing embryo.
As discussed earlier, elevated levels of homocysteine have been identified as a risk 
factor for NTD in some human populations (Section 1.9). However, it is unclear 
whether increased homocysteine levels are directly involved in the production of NTD. 
Moreover, the effect of elevated levels of homocysteine on neural tube closure in 
various animal models has given conflicting results, ranging from NTD-induction and 
non-specific embryotoxicity, to no detrimental effects on embryo development 
(VanAerts et al., 1994;Rosenquist et al., 1996;Hansen et al., 2001). Therefore the role 
of elevated homocysteine in the induction of NTD is still unclear.
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1.11 INVESTIGATING FOLATE METABOLISM IN THE CLOSURE 
OF THE MAMMALIAN NEURAL TUBE
The aim of this study is to investigate the role of folate and methylation cycle 
intermediates in neural tube closure. The project can be separated into three areas of 
investigation:
(i) Examination of the effect of methylation cycle intermediates on neural tube 
closure in non-mutant mice (Chapter 3 and 4).
(ii) Investigation into the mechanisms of NTD production in a folate-responsive 
mouse model (Chapter 5).
(iii) The analysis of folate metabolism in fibroblastic cell lines derived from 
human NTD-affected fetuses (Chapter 6).
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2.1 MOUSE STRAINS AND GENERATION OF EXPERIMENTAL 
LITTERS
In the experiments reported in this thesis two different mouse strains have been studied; 
one non-mutant strain, CD1, and one mutant strain, splotch (Sp2H). The CD1 mice 
(purchased from Charles River) were used as non-mutant controls in all the 
experiments. The Sp2H mice were maintained as a randomly bred colony. Heterozygous 
animals were selected by the presence of a white belly spot and mated to produce 
experimental litters.
Mice were maintained under light/dark conditions with a 24 hour cycle consisting of 12 
light hours from 7 am to 7 pm and then 12 dark hours. Adult mice were paired overnight 
and females were checked for copulation plugs the following morning. The day of 
finding a copulation plug was designated embryonic day 0.5 (E0.5) at midday. Pregnant 
females were killed by cervical dislocation on the desired day of gestation. The uterus 
was removed and placed in Dulbecco’s modified Eagles medium (DMEM, Gibco) 
containing 10% fetal calf serum (FCS, Sigma) for further dissection.
2.2 DISSECTION OF EMBRYOS
Dissection was carried out in DMEM with 10% FCS under a stereo-microscope (Zeiss, 
Stemi SV6) using fine forceps (Weiss, No. 5). The individual decidual swellings (Figure 
2.1A,B) containing the embryos were removed from the uterus and transferred to a fresh 
petri dish (Greiner) containing DMEM with 10% FCS (Figure 2.1C). The decidual layer 
was then removed to reveal the trophoblast (Figure 2.ID) when the conceptus was again
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transferred to a petri dish containing fresh DMEM/10% FCS (Figure 2.IE). The 
decidual layer was removed from each conceptus in turn before further dissection took 
place. Immediately beneath the trophoblast layer is a very thin ‘elastic’ layer called 
Reichert’s membrane which was then carefully removed along with the trophoblast 
layer (Figure 2.IF). The embryo, with yolk sac and ectoplacental cone intact, was then 
ready for whole embryo culture (Figure 2.2A).
Embryos not used for whole embryo culture needed further dissection. The yolk sac, 
ectoplacental cone and amnion were removed. Where necessary the yolk sac was rinsed 
in IX phosphate-buffered saline (PBS, Sigma) and stored at -20 °C for genotyping. 
Care was taken to ensure that no maternal tissue was transferred with the yolk sac as 
contamination could lead to incorrect genotyping.
2.3 WHOLE EMBRYO CULTURE
2.3.1 Preparation of rat serum
Following the method described by Cockroft (1990), blood was collected from the 
dorsal aorta of diethyl ether anaesthetised male Wistar rats. The rats were culled by 
cutting the diaphragm after exsanguination. The blood was immediately centrifuged at 
4,000 rpm for 5 minutes to pellet the red blood cells. The serum was expelled from the 
fibrin clot by gently squeezing the clot with a pair of forceps. Centrifugation was 
repeated and the serum supernatant was transferred to a clean tube; at this point the 
serum from several rats was pooled together. Centrifugation was again used to pellet 
any remaining red blood cells and the supernatant was pipetted into a
80
CHAPTER 2;Materials and Methods
Figure 2.1. Dissection steps for whole embryo culture
The decidual swellings (white arrows in A) were dissected from the uterus (B) and 
transferred to fresh medium (C). The decidua (De) was opened revealing the trophoblast 
(* in D) which was dissected free from decidual tissue and transferred to fresh medium 
(E) The trophoblast layer and underlying Reichert’s membrane were then removed 
(white arrowhead in F) to reveal the embryo within the yolk sac (white arrow in F). 
Scale bars represent 1 mm.
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fresh tube. The serum was then heat-inactivated at 56 °C for 30 minutes with the lids 
loosely secured to the tubes to allow maximum evaporation of dissolved ether. Once the 
serum had cooled to room temperature it was pooled and then pipetted into 5 ml, 3 ml 
and 2 ml aliquots and stored at -20 °C.
2.3.2 Whole embryo culture
Before use, rat serum was thawed, filtered through a 0.45 pm filter (Millipore) and 
warmed to 38 °C in a rolling tube incubator. Vacuum grease (Glisseal, Borer Chemie) 
was applied to the rim of each culture tube (NUNC) to form a gas-tight seal. The tubes 
were gassed with an 02, CO2, and N2 gas mixture (Cryoservice) according to the age of 
the embryos (Table 2.1) and then incubated for at least 15 minutes at 38 °C. Embryos 
with an intact yolk sac and ectoplacental cone were rinsed in PBS and transferred into 
the pre-warmed, pre-gassed rat serum (1 embryo/ml) with a maximum of 3 embryos per 
tube. The culture tubes were placed in the rolling tube incubator at 38 °C. After 30 
minutes, treatment or control solutions were added to the serum and the tubes were
Age of embryo Gas mixture
E8.5-E9.5 5% 0 2, 5% C02, 90% N2
E9.5-E10.5 20% 0 2, 5% C02, 75% N2
El 0.5 onwards 40% 0 2, 5% C02, 55% N2
Table 2.1 Gas mixtures required for whole embryo culture of embryos at different 
developmental ages.
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returned to the rolling incubator for the duration of the culture period. The tubes were 
re-gassed every time they were opened and at least every 16 hours during the culture 
period with the appropriate gas mixture (Table 2.1) for the age of the embryo at that 
time.
2.3.3 Solutions for whole embryo culture
All reagents used in whole embryo culture were of cell culture grade and were obtained 
from Sigma Chemicals unless otherwise stated. The reagent stock solutions were made 
up in distilled water or PBS and added as 1-4% (v/v) additions to the culture medium 
(10-40 pl/ml). The equivalent volume of vehicle alone was added to control groups.
2.3.4 Measurements after whole embryo culture
Embryos were assessed for developmental progress and viability at the end of the 
culture period. The yolk sac circulation (Figure 2.2B) was described on a scale of 0 to 3 
with 0 indicating no circulation and 3 being full and complete circulation throughout the 
whole yolk sac. The yolk sac, ectoplacental cone and amnion were then dissected away 
from the embryo (Figure 2.2D) and where necessary yolk sacs were kept for 
genotyping. Progression of cranial neural tube closure and axial rotation were recorded, 
the number of somites were counted and the crown-rump length (Figure 2.2D) was 
measured with an eyepiece graticule for each embryo. Any morphological abnormalities 
were also recorded. The embryos were washed in PBS and fixed overnight in 4% 
paraformaldehyde (PFA) in diethyl pyrocarbonate treated PBS (DEPC-PBS) or 
immediately frozen on dry ice.
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Figure 2.2. Embryo morphology and measurements before and after whole 
embryo culture
An E8.5 embryo ready for whole embryo culture (A), with yolk sac (YS) and 
ectoplacental cone (EC) intact. After embryo culture (B shows an embryo after 24 hours 
in culture from E8.5 to E9.5) the YS circulation (white arrows in B) was scored as an 
indication of the health of the embryos during the culture period. Embryos dissected 
clear of the YS, EC and amnion (AM) at E8.5 (C) and E9.5 (D). The crown-rump length 
was measured for E9.5 embryos (between dotted lines in D) as an indication of growth 
and the number of somites was counted as an indicator of developmental progression. 
Scale bar(s) in C represents 200 pm, A and D represent 500 pm, and B represents 1 
mm. Abbreviations; AM, amnion; EC, ectoplacental cone; FB, forebrain; HB, 
hindbrain; H, heart; HF, head folds; MB, midbrain; OC, optic cup; OV, otic vesicle; 
PNP, posterior neuropore; S, somites.
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2.4 PROCESSING OF EMBRYOS
For embryos not undergoing whole embryo culture, progression of cranial neural tube 
closure, axial rotation, somite number and crown-rump length were noted for each 
embryo. Embryos were rinsed in PBS and fixed overnight in 4% PFA in DEPC-PBS or 
frozen immediately on dry ice.
Embryos that were frozen after dissection or whole embryo culture were stored at 
-80 °C until needed. Embryos that underwent fixation and were needed for histological 
analysis were dehydrated through a series of ethanols (30%, 50%, 60%) diluted with 
distilled water to 70 % and stored at 4 °C until needed. After fixation embryos 
undergoing whole mount in situ hybridisation or whole mount TUNEL were dehydrated 
through a methanol series (25%, 50%, 75% diluted with DEPC-PBS) to 100% and 
stored at -20 °C until needed.
2.5 GENOTYPING OF MUTANT EMBRYOS BY POLYMERASE 
CHAIN REACTION (PCR)
2.5.1 Extraction of DNA from yolk sac samples
Yolk sacs, previously dissected from the embryos, were digested with 10 pg/ml 
proteinase K (Invitrogen) in 50 pi PBS at 56 °C for 3 hours. Proteinase K was heat- 
inactivated at 105 °C for 10 minutes followed by centrifugation at 14,000 rpm for 5 
minutes to pellet the cell debris. A 2 pi sample of the supernatant was used as the 
template for the PCR reaction.
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2.5.2 PCR protocol
A reaction mixture was prepared that contained IX NH4 -PCR buffer (Bioline), 1.5 mM 
MgCh, 0.25 mM of each deoxynucleoside triphosphate (dNTP), and 0.8 mM of both 
reverse and forward primers (Table 2.2). The reaction mixture was kept on ice and just 
before use 1 unit of Taq polymerase (Bioline) per reaction was added followed by 
distilled deionised water (ddtbO) to give a final volume of 23 pi for each reaction. The
Forward Primer sequence 5’ CCTCGGTAAGCTTCGCCCTCTG 3’
Reverse Primer sequence 5’ C AGCGC AGG AGC AG A ACC ACCTT C 3’
PCR product size Wild type allele 122bp 
Mutant allele 90bp
I f fTable 2.2 The primer sequences and product sizes for genotyping Sp mice.
resulting solution was mixed and 23 pi was added to 2 pi of yolk sac sample containing 
20-100 ng of DNA. Controls were run with each PCR reaction; the negative control did 
not contain any DNA to ensure the reaction mixture was not contaminated and the 
positive control used previously genotyped heterozygous DNA to check the components 
of the reaction mixture. The amplification reaction was carried out on a PTC-200 DNA 
Engine (MJ Research) and involved an initial denaturation step at 94 °C for 4 minutes 
followed by amplification cycles of denaturation at 94 °C for 1 minute, annealing at 
58 °C for 1 minute with an extension step at 72 °C for 1 minute. This amplification
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cycle was repeated 30 times before a final extension step was carried out at 72 °C for 
1 0  minutes.
O f - fThe primers used to genotype Sp mice were designed to span the 32 bp deletion in the 
paired box region of the Pax3 gene, as described by Epstein and colleagues (1991), 
resulting in different sized bands for wild type and mutant alleles (Table 2.2, Figure 
2.3). The PCR products were resolved by horizontal agarose gel electrophoresis 
(Section 2.5.3).
2.5.3 Agarose gel electrophoresis
A 2% agarose in IX TAE (0.04 M Tris-acetate, 0.001 M EDTA) gel was made by 
melting the mixture in a microwave with occasional stirring. The gel was then left to 
cool, approximately 0.5 mg/ml ethidium bromide was added and the mixture was 
poured into a casting tray with combs and allowed to set at room temperature. Once the 
gel was solid and placed in a horizon gel tank (Gibco BRL) containing IX TAE, 10 pi 
of the PCR products in IX loading dye (0.25% bromophenol blue, 0.25% Xylene 
cyanol FF, 15% Ficoll in water) were loaded into the wells. A molecular weight marker 
(Hyperladder V, Bioline) was run in a lane alongside the samples on each gel to allow 
identification of the size of the products. After electrophoresis at 120 volts for 1 hour 
the PCR products were visualised under UV light and photographed using an 
alphaimager system (Alpha Innotech).
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Figure 2.3 Visualisation of Sp2H PCR products after agarose gel electrophoresis
Lane 1 contains 5 pi (960 ng DNA) of hyperladder V, and DNA bands of 100, 125 and 
200 bp have been indicated. The negative and positive controls are shown in lanes 2 and 
3 respectively. The positive control, using heterozygote DNA, illustrates both the wild 
type allele (the upper band at 122bp) and the mutant allele (the lower band at 90 bp). 
The remaining lanes show the genotyping of wild type (lane 8 ), heterozygous (lanes 4- 
6 ) and homozygous mutant (lane 7) embryos.
2.6 HISTOLOGICAL ANALYSIS
2.6.1 Embedding and sectioning
Embryos requiring wax embedding that had been stored in 70% ethanol were further 
dehydrated to 100% ethanol then washed twice for 20 minutes in HistoClear (National 
Diagnostics). Samples were successively incubated for 20-30 minutes at 60 °C in 
HistoClear, followed by a pre-warmed HistoClear: paraffin wax (56 °C melting point; 
Raymond Lamb) mixture (1:1), and three changes of fresh wax. Embryos were then 
transferred to a watchglass in fresh wax and orientated using heated needles. The wax 
was left to set at room temperature overnight. Sectioning was carried out by mounting 
wax blocks containing the embedded embryos onto wooden cubes and 7 pm sections
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were cut with a rotary microtome (HM 325, Micron). The sections were floated onto 
3-aminopropyltriethoxysilane (TESPA)-coated (Section 2.6.2) or Superfrost plus (BDH) 
slides covered with distilled water and warmed to 37 °C until fully expanded. The water 
was removed and the slides were dried overnight at 37 °C. Slides were stored at 4 °C 
until required for analysis.
After whole mount in situ hybridisation (Section 2.10), embryos requiring vibratome 
sectioning were equilibrated in a gelatin-albumin solution (27 g chicken albumin grade 
II, 18 g sucrose and 0.45 g of gelatin 300 Bloom) for a minimum of one hour. Embryos 
were orientated and embedded by addition of 2.5% (v/v) glutaraldehyde. Once 
orientated, the gelatin-albumin-glutaraldehyde mixture was left to set for one hour, after 
which the cubes were stored in PBS at 4 °C prior to sectioning. Thimerazol was added 
to prevent fungal growth (0.05% v/v). Embedded embryos were sectioned at 50 pm 
thickness with a Series 1000 vibratome (Agar Scientific). Sections were mounted on 
glass slides in a 50% glycerol-PBS solution and stored at 4 °C.
2.6.2 Preparation of TESPA-coated slides
Glass slides (Menzel-Glaser) were coated in TESPA in order to aid the binding of wax 
sections to the glass. This reagent acts to electrostatically charge the slide, making it 
‘sticky’ to molecules within the tissue sections. Racks of slides were coated by briefly 
dipping them into baked glass troughs containing the necessary solutions. Initially the 
slides were cleaned by washes in 10% HC1 in 70% ethanol, DEPC-H2O and finally 95% 
ethanol. The slides were then wrapped in foil and dried at 80 °C for 5 minutes. The
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slides were then coated by immersion in 2% TESPA in acetone for 10 seconds followed 
by two washes in acetone and two washes in distilled water (dt^O). The slides were 
covered and left to dry overnight at 37 °C. When they were completely dry individual 
racks were wrapped in foil and stored at 4 °C until needed.
2.6.3 Haematoxylin and Eosin (H&E) staining
Wax was removed from the sections by two washes with HistoClear for 10 minutes 
each. The sections were then rehydrated through an ethanol series (100%, 95%, 70%, 
50%) to distilled water. The slides were then immersed in haematoxylin (BDH), to stain 
the nuclei a dark blue/purple colour, for 1 - 2  minutes, rinsed in distilled water and briefly 
dipped in acid-alcohol (1% HC1 in 70% ethanol). After a two minute wash in water the 
slides were stained with 1% aqueous eosin (Raymond Lamb), which stains the 
cytoplasm pink, for 2 minutes. The slides were then dehydrated through the ethanol 
series to 100% with two final 5 minute washes in HistoClear. Coverslips were mounted 
onto the slides with dextropropoxyphene (DPX) mounting medium (Fisher chemicals) 
and the slides were left to dry overnight.
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2.7 IMMUNOHISTOCHEMISTRY WITH ANTI-
PHOSPHORYLATED HISTONE H3 AND ANTI-ACTIVATED 
CASPASE 3 ANTIBODIES
2.7.1 Sample preparation
Embryos were embedded and sectioned following the protocols described in section 
2.6.1. Embryos at the developmental stage of E8.5 were embedded in an orientation that 
gave transverse sections through the cranial region. E9.5 embryos were embedded to 
give sections of a coronal orientation. Embryos at E9.0 were embedded in either 
orientation. Pairs of sections were placed on alternate slides allowing both apoptosis 
(anti-activated caspase-3 staining) and proliferation (anti-phosphorylated histone H3 
staining) to be investigated in each embryo.
2.7.2 Immunohistochemistry
Both antibodies used in this thesis, anti-activated caspase 3 (Cell Signalling 
Technology) and anti-phosphorylated histone H3 (Upstate) were raised in rabbit, 
allowing the same secondary antibody (biotinylated goat anti-rabbit, DAKO) and 
blocking serum (goat serum, DAKO) to be used. The initial steps of de-waxing, 
rehydration and antigen retrieval differed for the two antibodies.
Slides with sections undergoing immunohistochemistry for activated caspase 3 were 
placed in working concentration Declere (Cell Marque) (1:20 Declere.dfUO) and heated 
in a microwave on the simmer setting for 20 minutes. After 10 minutes a fresh trough of
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working strength Declere was placed into the microwave to warm up. The slides were 
transferred into the fresh pre-warmed Declere and left to cool to room temperature.
The anti-phosphorylated histone H3 antibody did not require an antigen retrieval step. 
Slides were de-waxed by two 5 minute washes in HistoClear and the HistoClear was 
removed by two 2 minute washes in 100% ethanol. The slides were then rehydrated 
through a series of ethanol (90%, 70%, 50%, 25%) diluted with distilled water.
For both antibodies subsequent steps of the protocol were the same. The slides were 
washed in PBS (all PBS washes in this protocol involve three 2 minutes washes) and 
then placed in 3% hydrogen peroxide in methanol for 10 minutes. This step inactivates 
endogenous peroxidases giving reduced background staining. Slides were washed in 
PBS and then laid flat in a humidified chamber, containing wet tissue. The slides were 
covered with 5% goat serum in PBS and incubated at room temperature for 30 minutes, 
to block any non-specific binding of the antibody to the tissue section. In the humidified 
chamber a strip of nescofilm, cut to size, was placed on top of the solution on each slide 
to ensure even coverage and to prevent evaporation during longer incubations. The 
slides were again washed with PBS and the primary antibody was diluted to the required 
concentration (1:1,000 for anti-activated caspase 3 and 1:500 for anti-phosphorylated 
histone H3) with 1% FCS in Tris buffered saline (TBS; 50 mM Tris-HCl pH 7.6, 150 
mM NaCl). Slides were incubated with the primary antibody, in humidified chambers, 
overnight at room temperature.
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Slides were washed with PBS while the biotinylated secondary antibody was diluted 
with 1% FCS in TBS to the required concentration (1:250). Slides were incubated in 
humidified chambers with diluted secondary antibody for 60 minutes. After washes with 
PBS the sections were overlaid with ABC reagent (Vectastain Elite ABC kit, Vector 
laboratories) made according to the manufacturer’s instructions (2 drops reagent A 
[Avidin DH solution], 2 drops reagent B [Biotinylated peroxidase] in 5 ml PBS). Each 
avidin molecule within the ABC reagent has four binding sites for biotin. When reagent 
A and reagent B are mixed, a complex between avidin and the biotinylated enzyme is 
formed which still retains biotin-binding sites. The free biotin-binding sites attach to the 
secondary antibodies on the tissue sections, amplifying the signal.
After 30 minutes incubation in humidified chambers and subsequent washes with PBS, 
the slides were incubated with working strength 3,3-diaminobenzidine (DAB) solution 
(DAB substrate kit for peroxidase, Vector laboratories), according to manufacturer’s 
instructions (2 drops buffer stock, 2 drops DAB stock, 2 drops hydrogen peroxide stock 
and 2 drops nickel solution in 5 ml dP^O). The DAB solution acts as an electron donor 
for peroxidase activity. Upon oxidation, a coloured insoluble product is formed; in this 
case the presence of nickel chloride results in a grey/black product. Slides were 
incubated for 10 minutes and then washed in tap water for 5 minutes.
Sections were counterstained with nuclear fast red, which gave a pink nuclear stain that 
contrasts with the grey/black DAB staining. Slides were incubated for 1 minute in 
nuclear fast red solution (0.1% w/v nuclear fast red, 5% w/v aluminium sulfate, 1% v/v 
chloroform). The sections were washed twice in dP^O for 2 minutes and dehydrated
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through an ethanol series (25%, 50%, 70%, 90%) with two final washes in 100% 
ethanol. Slides were incubated for two 5 minute washes in HistoClear and mounted with 
DPX.
Five percent goat serum in PBS was used in place of the primary antibodies as negative 
controls and in no case was specific signal observed. The sections were photographed 
using a digital camera attached to a Zeiss Axiophot 2 microscope and images were 
imported into Adobe Photoshop v6.0 for further analysis.
2.8 WHOLE MOUNT TUNEL
TUNEL (TdT-mediated dUTP-biotin nick end labelling, (Gavrieli et al., 1992)) was 
performed on whole embryos to detect apoptotic cells, according to the method of 
Martinez-Barbera and colleagues (2002). All PBT (PBS with 0.1% 
polyoxyethylenesorbitanmonolaurate [tween 20, Sigma]) washes were repeated three 
times at room temperature for 5 minutes unless otherwise stated.
2.8.1 Sample preparation
Embryos were rehydrated through a methanol series (75%, 50%, 25% diluted with 
PBT), followed by washes with PBT. They were then incubated in PBS with 10 pg/ml 
proteinase K at room temperature for different times depending on the size of the 
embryo (E8.5 for 1 minute, E9.5 for 3 minutes and E l0.5 for 5 minutes). Digestion was 
stopped by a two minute wash in 2 mg/ml glycine in PBT, followed by two washes with 
PBT. The embryos were incubated at room temperature for 20 minutes in 4% PFA in
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PBS and then washed in PBT. The embryos were re-fixed in pre-chilled ethanol: acetic 
acid (2:1) on ice for 10 mins, and then washed with PBT.
2.8.2 Terminal transferase reaction
The terminal transferase reaction used components from the ApopTag In Situ Apoptosis 
detection kit (Intergen). The embryos were incubated for 1 hour with equilibration 
buffer. After removal of the equilibration buffer, working strength terminal 
deoxynucleotidyl transferase (TdT) enzyme (reaction buffer: TdT enzyme, 2:1 with 
0.3% (v/v) Triton X I00) was added to cover the embryos and incubated overnight at 
37 °C. The reaction was stopped by washing the embryos in working strength stop 
buffer (stop buffer diluted 1:17 in distilled water) for 3 hours at 37 °C with several 
changes, followed by three washes in PBT.
2.8.3 Detection
The embryos were blocked in a wash solution (2 mg/ml BSA [Sigma] in PBT) 
containing 5% (v/v) sheep serum (Sigma) for 1 hour then incubated with antibody 
solution (1/2,000 anti-digoxigenin-AP Fab [Roche], 1% sheep serum in wash solution) 
overnight at 4 °C. Excess antibody was removed by incubating the embryos throughout 
the day and overnight in a number of changes of wash solution at room temperature. 
The following day the embryos were equilibrated with NTMT (100 mM sodium 
chloride, 100 mM Tris.HCl pH 9.5, 50 mM magnesium chloride, 0.1% Tween-20) by 
three 10 minute washes and then incubated with 17 pl/ml nitroblue tetrazolium/5- 
bromo-4-chloro-indolyl-phosphatase (NBT/BCIP, Roche) in PBT in the dark for 15
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minutes. The reaction was stopped by washes in PBT, the embryos were then fixed with 
4% PFA in PBS for 30 minutes and washed in PBT. Embryos were stored at 4 °C, in the 
dark to prevent bleaching of the staining, in PBT with 0.05% thimerazol (Sigma) to 
prevent fungal growth. Embryos were analysed and the images captured using an 
imagemanager 1000 system (Leica).
2.9 PROBE GENERATION FOR WHOLE MOUNT IN SITU 
HYBRIDISATION
Digoxigenin-labelled RNA probes were generated from plasmids containing a cDNA 
insert of the gene of interest. All solutions used in the preparation of the riboprobes 
were treated with diethyl pyrocarbonate (DEPC), an inhibitor of ribonucleases, in order 
to avoid degradation of the newly synthesised RNA. DEPC was added to solutions at 
0.05% v/v, mixed thoroughly and left overnight at room temperature before the 
solutions were autoclaved.
2.9.1 T ransformation
To obtain large amounts of plasmid, DH5a competent cells (Promega) were 
transformed with the plasmid of interest and recombinants were selected on the basis of 
acquired antibiotic resistance to ampicillin.
A 50 pi aliquot of competent DH5a cells in a 1.5 ml eppendorf was thawed on ice for 
10 minutes, 50 ng of plasmid DNA was added and mixed gently. A negative control, 
where no plasmid DNA was added, was carried out in parallel with each step. Cells
98
CHAPTER 2; Materials and Methods
were incubated on ice for 30 minutes before heat-shocking at 42 °C for 45 seconds in a 
water bath. The cells were again placed on ice for 1-2 minutes and 1 ml of LB-broth 
(Invitrogen) containing 20 mM glucose, 2.5 mM KC1 and 10 mM MgCk was added. To 
allow expression of antibiotic resistance proteins, the bacteria were incubated at 37 °C 
with vigorous shaking for 1 hour before 100 pi was plated onto an LB-agar culture plate 
containing 50 pg/ml ampicillin. After incubation at room temperature for 15 minutes, 
the plates were inverted and incubated at 37 °C overnight.
The cDNAs of interest had been cloned into bluescript vectors (Stratagene) which 
contain the p-lactamase gene that confers resistance to ampicillin. Only bacteria 
containing a plasmid survive on the ampicillin-containing agar plates, as confirmed by 
the lack of colony growth on the negative control plates.
2.9.2 Isolation of plasmid DNA
Isolation of plasmid DNA was carried out using a HiSpeed Plasmid Midi kit (Qiagen) 
following the manufacturer’s instructions. A single colony was grown for 8  hours at 
37 °C with vigorous shaking in 5 ml LB-broth containing 50 pg/ml ampicillin. A 100 pi 
aliquot of this starter culture was then added to 50 ml fresh LB-broth (1:500 dilution) 
containing ampicillin (50 pg/ml) and incubated overnight at 37 °C with vigorous 
shaking. The cells were harvested by centrifugation at 6,000 g for 15 minutes at 4 °C. 
The bacterial pellet was resuspended in 6  ml buffer PI (50 mM Tris.HCl, pH 8.0; 
10 mM EDTA; 100 pg/ml RNase A). The cells were then lysed by addition of 6  ml 
buffer P2 (200 mM NaOH, 1% w/v SDS), followed by gentle mixing through the
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inversion of the tube a number of times and incubation for 5 minutes at room 
temperature. The lysis reaction was stopped and the cell debris was precipitated by 
addition of 6  ml of chilled buffer P3 (3 M potassium acetate, pH 5.5) followed by gentle 
inversion to ensure complete precipitation. The lysate was then poured into the barrel of 
a filtration unit (QIAfilter Cartridge) to remove the unwanted cell debris. A HiSpeed-tip 
was equilibrated during the lysate-cartridge incubation by allowing 4 ml of buffer QBT 
(750 mM NaCl; 50 mM MOPS, pH 7.0; 15% v/v isopropanol; 0.15% v/v Triton X-100) 
to drain through the tip by gravity flow. After being left at room temperature for 
1 0  minutes the lysate was pushed through the cartridge and collected in a previously 
equilibrated anion-exchange resin column (HiSpeed-tip). The cleared lysate was 
allowed to pass through the equilibrated HiSpeed-tip by gravity flow. The column was 
then washed twice with 20 ml buffer QC (1 M NaCl; 50 mM MOPS, pH 7.0; 15% v/v 
isopropanol) to remove any remaining contaminants; again gravity flow was used to 
pass the solution through the column. The DNA was eluted from the column with 5 ml 
buffer QF (1.25 M NaCl; 50 mM Tris.HCl, pH 8.5; 15% v/v isopropanol). The eluted 
DNA was precipitated by incubation with 3.5 ml of isopropanol for 5 minutes at room 
temperature. After the incubation period the solution was added to a syringe with a 
QIAprecipitator module attached to the end. The DNA was trapped in the 
QIAprecipitator when the solution was filtered through. To clean the DNA, 2 ml 70% 
ethanol was pushed through the syringe and then air was pushed through the filter to 
remove any remaining ethanol. Plasmid DNA was eluted from the QIAprecipitator with 
1 ml buffer TE (10 mM Tris.HCl, pH8.0; 1 mM EDTA). The quantity of DNA 
recovered was determined by spectrophotometry (UVminil240, Shimadzu). The
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absorption of a DNA aliquot at 260 nm was measured and used to calculate the final 
concentration.
Concentration of plasmid DNA (pg/ml) = OD260nm x dilution factor x 50 
The purity of the DNA was also assessed by measuring the absorption at 280 nm; the 
ratio OD260nm* OD280nm for good quality DNA should be approximately 1.8.
2.9.3 Linearisation of plasmid DNA
Plasmids were linearised in preparation for the in vitro transcription reaction to generate 
riboprobes. A reaction mixture was prepared containing 5 pg plasmid DNA, 20 units of 
the appropriate enzyme (Table 2.3) and a final concentration of IX of the corresponding 
reaction buffer, the volume was made up to 50 pi with DEPC-H2O. The reaction 
mixture was incubated at 37 °C for 2-4 hours. The success of the linearisation was 
checked by comparison of a sample (5 pi) of each digestion to an uncut plasmid sample 
on a 1% agarose gel. After electrophoresis, linear DNA runs at an apparently different 
molecular weight than uncut circular DNA. The linearised plasmids were recovered 
from the reaction mixture by phenol-chloroform extraction (Section 2.9.4).
Plasmid Insert size 
(bp)
Insert site Linearised
with
Transcribed
with
Source
Dll 1 1117 EcoRI Hindlll T3 (Bettenhausen et 
al., 1995)
Dll 3 2 1 0 0 EcoRI Notl T7 (Dunwoodie et 
a l ,1997)
Pax 3 519 PstI Hindlll T7 (Goulding et al., 
1991)
Table 2.3 Antisense RNA probes used for whole mount in situ hybridisation
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2.9.4 Phenol-chloroform DNA extraction
An equal volume of phenol-chloroform (International Biotechnologies Inc.) was added 
to the reaction mixture (Section 2.9.3), mixed thoroughly and then centrifuged at
12,000 g for 15 minutes. The aqueous layer was transferred to a clean tube and an equal 
volume of chloroform was added. After thorough mixing and centrifugation the aqueous 
phase was again transferred to a clean tube, three volumes of 1.3% potassium acetate in 
95% ethanol was added and incubated at -20 °C overnight or -80 °C for 30 minutes to 
precipitate the DNA. After centrifugation for 10 minutes at 4 °C the supernatant was 
discarded and the pellet washed with two and a half volumes (of the original volume) of 
70% ethanol. The pellet was collected by centrifugation for 2 minutes at 4 °C, followed 
by air drying for 10 minutes. The pellet was resuspended in 10 pi TE (10 mM Tris.HCl, 
pH 8.0; 1 mM EDTA) or distilled water and quantified by spectrophotometry.
2.9.5 Synthesis of digoxygenin (DIG)-labelled probes
Antisense and sense (control) riboprobes were synthesised and labelled using DIG RNA 
labelling mix (Roche). A transcription reaction was prepared containing 
IX transcription buffer, IX DIG RNA labelling mix, 1 pg linearised plasmid DNA, 
40 units of the appropriate RNA polymerase (Table 2.3) and the volume was made up to 
20 pi with DEPC-H2O. The reaction mixture was briefly vortexed and incubated at 
37 °C for 2 hours. Agarose gel electrophoresis was used to visualise the efficiency of 
the transcription reaction. Two bands were expected; a high molecular weight band 
corresponding to the plasmid DNA template and a low molecular weight band 
corresponding to the transcript, which after an efficient reaction should be 
approximately 10 times more intense than the template DNA band. The DIG labelled
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RNA was precipitated by addition of 0.1 volumes DEPC-treated 3M sodium acetate, 
3 volumes 100% ethanol and 1 pi tRNA and incubation at -20 °C overnight. The 
precipitate was pelleted by centrifugation at 13,000 rpm for 10 minutes at 4 °C, and then 
washed with 500 pi 70% ethanol to remove any remaining salts. After centrifugation at
13,000 rpm at 4 °C for 2 minutes the pellet was air dried and resuspended in DEPC-H2O 
to give a final concentration of 0.1 pg/pl. One pi (36 u) RNAse guard (Amersham) was 
added and the riboprobes were stored at -20 °C.
2.10 WHOLE MOUNT IN SITU HYBRIDISATION
Whole mount in situ hybridisation was performed following the method described by 
Wilkinson (1992) with some adaptations (Ybot-Gonzalez et al., 2005). Unless otherwise 
stated all washes were carried out at room temperature with rocking for 5-10 minutes, in 
5-10 ml volumes.
2.10.1 Embryo pre-treatment
Embryos previously stored in 100% methanol at -20 °C were rehydrated through a 
methanol series (75%, 50%, 25%) diluted in PBT, followed by two washes for 
10 minutes in PBT. In order to quench endogenous peroxidases, embryos were 
incubated in 6 % hydrogen peroxide in PBT for 1 hour, followed by three washes in 
PBT. Embryos were treated with 10 pg/ml proteinase K in PBT for varying times 
depending on the size of the embryo (E8.5 for 1 minute, E9.5 for 4 minutes, E l0.5 for 
8  minutes) in order to permeabilise cell walls to allow penetration by the riboprobe. The 
reaction was stopped by washing in 2 mg/ml glycine in PBT followed by two washes in
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PBT. Embryos were refixed in 4% PFA in PBS for 20 minutes, washed twice in PBT 
and then placed in 2 ml prehybridisation mixture (50% formamide, 5X SSC, 2.5 mg/ml 
yeast RNA, 1% SDS, 2.5 mg/ml heparin) at 65 °C. Once the embryos had sunk, the 
prehybridisation mix was replaced with 5 ml of fresh mix and incubated at 65 °C for 
1 hour. Embryos were stored at -20 °C in the prehybridisation mixture.
2.10.2 Hybridisation and post-hybridisation washes
Embryos were placed in 1 ml of fresh prehybridisation mix, 0.1 pg/ml of digoxigenin- 
labelled probe was added and incubated at 70 °C overnight. The following day the 
hybridisation mix (prehybridisation mix with riboprobe) was removed and stored at 
-20 °C for use in one subsequent experiment. In order to remove excess probe, embryos 
were washed three times for 30 minutes at 70 °C in solution 1 (50% formamide, 5X 
SSC pH 4.5, 1% SDS) followed by two washes at 65 °C in solution 2 (50% formamide, 
2X SSC pH 4.5, 1% SDS) for 30 minutes each. Embryos were then washed three times 
in TBST (0.14 M sodium chloride, 25 mM potassium chloride, 25 mM Tris.HCl pH 7.5, 
1% Tween-20, 2 mM levamisole) for 10 minutes then blocked in 10% sheep serum in 
TBST for 90 minutes to avoid non-specific binding of the antibody. Embryos were 
incubated overnight in the preabsorbed antibody solution (Section 2.10.3) at 4 °C.
2.10.3 Preparation of preabsorbed antibody solution
A suitable volume of preabsorbed antibody solution was prepared to give a final volume 
of 2 ml for each tube of embryos. The volumes stated in this section are suitable for 
preparing enough antibody solution for one tube of embryos. Embryo powder was
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prepared by homogenising E8.5-E14.5 embryos in a minimum volume of PBS. The 
homogenate was washed in four volumes of ice-cold acetone followed by centrifugation 
at 6,000 rpm for 10 minutes. The acetone wash was repeated and followed by 
centrifugation. The pellet was ground into a powder, spread on filter paper to air dry and 
stored at -20 °C. A 3 mg sample of embryo powder was incubated at 70 °C for 
30 minutes with 0.5 ml TBST. After cooling on ice, 5 pi of sheep serum and 1 pi anti- 
digoxygenin antibody (alkaline phosphatase-conjugated Fab fragments, Boehringer 
Mannheim) were added. The mixture was incubated for 1 hour at 4 °C to preabsorb the 
antibody and then centrifuged at 6,000 rpm for 10 minutes at 4 °C. The antibody 
solution (supernatant) was removed and diluted to 2 ml with 1% sheep serum in TBST. 
The embryo powder was stored at -20 °C for re-use.
2.10.4 Post-antibody washes and development
The antibody solution was removed and the embryos were washed in TBST three times 
for 1 0  minutes followed by a minimum of five 1 hour washes and left overnight in 
TBST. Embryos were placed in glass pots and equilibrated with three 10 minute washes 
in NTMT before incubation with 17 pl/ml NBT/BCIP in 1 ml NTMT in the dark for 
20 minutes with rocking. The incubation continued without rocking until the signal had 
developed. The reaction was stopped by two washes with PBT and embryos were stored 
at 4 °C in the dark in PBT with 0.05% thimerazol. Embryos were analysed and the 
images captured on an imagemanager 1000 system (Leica). No specific hybridisation 
signals were seen with the sense probes.
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2.11 CELL CULTURE OF HUMAN EMBRYONIC FIBROBLASTS
2.11.1 Basic cell culture procedures
Sterile conditions were used throughout the cell culture procedures to minimize the 
possibility of contamination. Procedures were carried out in a class II microbiological 
safety cabinet (Envair) and, before use, all materials were sprayed with 70% industrial 
methylated spirit (IMS). Solutions were warmed to 37 °C before use. All the reagents 
used for cell culture were obtained from Sigma unless otherwise stated. DMEM 
containing 1.5 g/1 sodium bicarbonate, 10% FCS, 2% chicken serum, 100 u penicillin 
and 1 0 0  pg/ml streptomycin was used as culture medium throughout this study and is 
referred to as “medium”. Medium was made up in 500 ml bottles when needed, 
sterilized by vacuum driven filtration through a 0.22 pm filter stericup (Millipore) and 
used or discarded within a month. Cells were cultured in a Galaxy R CO2 incubator 
(Scientific Laboratory Supplies Ltd), with 5% CO2 at 37 °C.
2.11.2 Sample collection and processing
Samples of amniotic fluid, skin, cord or cartilage were collected with ethical permission 
by fetal pathologists at University College Hospital, from fetuses aged 12-21 weeks. 
Samples were allocated to one of three groups, NTD-affected, normal control or 
affected control (fetuses affected with malformations other than NTD). The samples 
were sent to Great Ormond Street Hospital (GOSH) Cytogenetics Laboratory where 
fibroblastic cell lines were established.
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3T3 mouse fibroblast cells were obtained from the Dunn School Cell Bank (Department 
of Pathology, University of Oxford) by Dr. Andrew Stoker. A frozen aliquot was stored 
in liquid nitrogen until needed.
Human cell lines established by the GOSH Cytogenetics Laboratory were frozen down 
and stored in liquid nitrogen until required. Cells were removed from the culture flasks 
by trypsinisation. A stock solution of 10X trypsin-EDTA was diluted to IX in PBS and 
1 ml was added to the cells for 2-3 minutes until they had rounded up and begun to 
detach from the bottom of the flask. The digestion was stopped by adding 5 ml of 
medium and cells were pelleted by centrifugation for 5 minutes at 1,000 rpm and 
resuspended in 0.9 ml medium. The cell suspension was transferred to cryotubes and 
0.1 ml dimethyl sulfoxide (DMSO) was added to give a final concentration of 10%. The 
tubes were immediately placed in an isopropanol tray (Nalgene) and transferred to 
-70 °C. When placed at -70 °C this tray allows cooling to occur at -1 °C/minute 
ensuring the cells were not damaged during the freezing process. Once frozen the tubes 
were transferred to liquid nitrogen until needed.
2.11.3 Maintenance of cells in culture
The 3T3 cells and human cell samples were treated in the same manner throughout 
these experiments, although 3T3 cells did grow at a much faster rate. Cells were 
defrosted and immediately placed in 5 ml medium to dilute the DMSO, which could 
cause cellular damage. The cells were pelleted by centrifugation at 1,000 rpm for 
5 minutes. The supernatant was discarded and the cells were resuspended in 2 ml of 
medium then placed into a well of a 6 -well plate (NUNC) and incubated at 37 °C in 5%
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CO2 . Cells were grown to confluence with changes of medium when necessary; spent 
medium was removed by aspiration before fresh medium was added. The growth and 
health of cultures was checked daily using an inverted microscope (Zeiss). Once the 
cells were confluent they were passaged by trypsinisation (Section 2.11.2). After 
centrifugation the cells were resuspended in 4 ml medium and each sample was seeded 
in 2 wells (2 ml/well). Cells were again grown to confluence and subsequently passaged 
by trypsinisation. The cells were resuspended and seeded in 4 wells/sample. Once 
confluent, the cells from one of the wells were frozen down (passage 3) as described 
above (Section 2.11.2) while the other cells were seeded for the third time into two 
25 cm culture flasks. When the cells were confluent these flasks yielded enough cells 
to carry out the dU suppression test.
2.11.4 Solutions for the deoxyuridine (dU) suppression test
In initial experiments a series of deoxyuridine (dU) stocks (500 mM, 50 mM, 1 mM, 
0.1 mM) were added to the culture medium as 1-3% (v/v) additions (10-30 pl/ml) to 
give final concentrations ranging from 1 pM to 500 pM. In later experiments, 1 mM dU 
was used as a 1-2% (v/v) addition giving final concentrations of 10 pM, 15 pM or 
20 pM. In the inhibitor experiments the folate/methylation cycle inhibitors 
5-fluorouracil, aminopterin and cycloleucine were added to the relevant flasks as 
0.5-2% (v/v) additions to test the sensitivity of the experiment. Each test condition was 
carried out in duplicate within each experiment.
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2.11.5 dU suppression test
Cells were seeded (passage 5) in 6-well plates at 0.5 xlO6 cells/well for 3T3 cells and 
0.25 xlO6 cells/well for the human samples and incubated overnight to allow the cells to 
adhere. The dU and/or inhibitors were added to the appropriate wells and an equal 
volume of PBS was added to the untreated cells. After two hours of incubation the 
medium in all the wells was replaced with fresh medium containing 0.5 pCi/ml [3H]- 
thymidine (Amersham Pharmacia). The dU, PBS and/or inhibitors were then added to 
the relevant wells as before. The cells were cultured for 24 hours after which the 
medium was removed and stored for disposal in a designated radioactive waste area. 
The cells were then detached by trypsinisation, pelleted by centrifugation and 
resuspended in 200 pi PBS containing 0.3 M sodium hydroxide. Cells were lysed by 
repeated freeze/thawing (three cycles) and stored at -20 °C. Samples were taken for 
determination of protein content (Section 2.11.6) and incorporation of [ H]-thymidine 
into DNA (Section 2.11.7).
2.11.6 Determination of protein content
Duplicate 5 pi samples of homogenate were used for determination of protein content 
using the bicinchoninic acid (BCA) protein assay reagent (Pierce) following the 
manufacturer’s instructions. A fresh series of standard protein solutions were made in 
duplicate from an initial 200 pg/ml standard protein solution (bovine serum albumin) 
for each protein assay. Water was added to standards and samples to a final volume of 
50 pi. The BCA working reagent, a 50:1 mixture of reagents A and B (Pierce) was 
made fresh for each assay. BCA working reagent (1 ml) was added to each 
standard/sample tube and incubated for 30 minutes at 60 °C. The OD562nm for each
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sample and standard was read using a UVminil240 spectrophotometer (Shimadzu), a 
standard curve was plotted and protein concentrations of the samples calculated, using 
pre-installed software.
2.11.7 Measurement of [3H]-thymidine incorporation
The DNA was extracted from duplicate 40 pi samples of the homogenate by digestion 
with 10 pg/ml proteinase K at 56 °C for 3 hours followed by precipitation with three 
volumes of 1.3% potassium acetate in 95% ethanol (as described in Section 2.9.4). 
Following centrifugation, the pellet was resuspended in 60 pi ddHhO and 0.8 ml 
scintillation cocktail (universol, ICN) was added, mixed thoroughly and the cpm was 
measured on a 1450 MicroBeta (Trilux) scintillation counter.
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3.1 INTRODUCTION
Metabolism of homocysteine provides the link between the methylation cycle and folate 
metabolism. Methionine is formed by the remethylation of homocysteine by methionine 
synthase in a vitamin-B^ and folate dependent reaction. The methyl donor in this 
reaction is 5-methyl tetrahydrofolate (5-methyl THF), generated in the folate cycle 
(Figure 1.6). As discussed earlier (Section 1.9), elevated levels of homocysteine have 
been implicated in the production of NTD (Steegers-Theunissen et al., 1994;Mills et al., 
1995;Van der Put et a l, 1997a). Previous animal studies to investigate the possible 
deleterious effect of homocysteine on neural tube closure gave conflicting results. 
Treatment of chick embryos with homocysteine throughout neurulation induced NTD in 
27% of the embryos and 23% exhibited heart defects (Rosenquist et al., 1996). 
However, in vitro treatment of rat embryos with high doses of homocysteine did not 
cause NTD but was embryotoxic, causing growth retardation and somite defects 
(VanAerts et al., 1994). In contrast to both of these studies, a recent investigation of the 
effect of homocysteine on neural tube closure in mouse embryos concluded that 
homocysteine is neither embryotoxic nor causes NTD (Hansen et al., 2001). Therefore, 
I aimed to carry out a comprehensive study of the effect of homocysteine on cranial 
neural tube closure in mouse.
Cranial neural tube closure was investigated because in the initial study that identified 
homocysteine-induced neural tube defects in chick, the majority of NTD affected the 
cranial region (Rosenquist et al., 1996). A large number of studies in several different 
animal models have shown that teratogens can affect cranial and spinal neural tube 
closure to varying degrees. For example, in vitro exposure of mouse embryos to sodium
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arsenate throughout neurulation resulted in a 25% incidence of cranial NTD, with the 
caudal end of the embryo unaffected (Chaineau et a l, 1990). Maternal injection with 5- 
azacytidine produced exencephaly, but not spina bifida, in both mouse and rat embryos 
(Takeuchi and Murakami, 1978;Takeuchi and Takeuchi, 1985). In addition, rat embryos 
exposed throughout neurulation to high levels of oxygen fail to complete cranial neural 
tube closure (Morriss and New, 1979). Neural tube closure at this axial level may 
therefore be more sensitive to homocysteine treatment than more caudal regions.
Homocysteine thiolactone was used in the experiments in this chapter, because in the 
thiolactone form homocysteine is more stable within the whole embryo culture system 
(Hansen et al., 2001). Homocysteine thiolactone has also been shown to simulate the 
physiological effects of homocysteine in experimental systems, as similar effects of 
homocysteine and the equivalent level of homocysteine thiolactone have been shown in 
chick (Rosenquist et al., 1996) and rat embryos (VanAerts et a l,  1994).
Homocysteine thiolactone is synthesized naturally in the body and has been found in 
every cell type examined from bacteria to human (Carmel et a l, 2001). Some 
aminoacyl-tRNA synthetases (primarily methionyl-tRNA synthetase (Jakubowski and 
Goldman, 1993)) have an error-editing function to prevent the incorrect incorporation of 
homocysteine into protein. This error-editing function involves the misactivation of 
homocysteine and ATP, subsequently resulting in the production of the cyto-reactive 
thiolester, homocysteine thiolactone (Jakubowski and Fersht, 1981). Hydrolysis of 
homocysteine thiolactone results in its conversion back to homocysteine (Jakubowski, 
1997).
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In my study, homocysteine thiolactone exposure was observed to affect somite 
development (Table 3.2) and genetic markers of somite development {Delta-like 1 and 
Delta-like 3) were used to investigate this phenomenon. Delta-like genes are mouse 
homologues of the Drosophila gene Delta which, along with its receptor Notch, is 
involved in cell fate determination during development. In vertebrates, Notch and Delta 
signalling is involved in neurogenesis and somitogenesis (Lewis, 1998). Delta-like 1 
{Dill) and Delta-like 3 {DU3) have distinct expression patterns during somitogenesis 
and are believed to function together in the formation of somite borders and boundaries 
during segmentation (Dunwoodie et al., 1997). Dill is expressed in the paraxial 
mesoderm and in the caudal half of condensed somites (Bettenhausen et al., 1995). In 
D ill-deficient mouse embryos, somite boundaries are not maintained and there is no 
rostro-caudal polarity within the somites (De Angelis et al., 1997). Dll3 is expressed in 
the paraxial mesoderm and the rostral half of the most recently formed somite 
(Dunwoodie et al., 1997). In the Pudgy mouse a mutation in the Dll3 gene results in 
severe disruption of somite boundaries resulting in somites with irregular size and shape 
(Kusumi et al., 1998).
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3.2 RESULTS
Dose toxicity studies were carried out using non-mutant CD1 embryos cultured for 24 
hours from E8.5 (4-6 somite stage) to E9.5 in the presence of homocysteine thiolactone. 
PBS was used as a vehicle control and embryos from within litters were randomly 
selected for different treatment groups to minimise any effect of litter to litter variation. 
At the end of the culture period embryos were assessed for developmental progression, 
growth and viability. Any morphological abnormalities were recorded for each embryo.
3.2.1 Dose-dependent embryotoxicity of homocysteine 
thiolactone in CD1 mice
Exposure of embryos to homocysteine thiolactone during the period of cranial neural 
tube closure resulted in a dose-dependent occurrence of developmental defects and 
toxicity. A homocysteine thiolactone concentration of 1.5 mM was embryotoxic, with 
none of the embryos surviving to the end of the culture period as illustrated by the 
absence of yolk sac circulation (Table 3.1). These embryos did survive for part of the 
culture period, however, as the embryo somite numbers increased from 4 to 6 to an 
average of 15 to 16 before the embryos died. Some of the embryos cultured in 1 mM 
homocysteine thiolactone survived throughout the culture period but they were growth- 
retarded, as indicated by significantly lower mean somite number and mean crown- 
rump length compared to embryos treated with PBS only (vehicle control) (Table 3.1). 
There were no indications of developmental or growth retardation in embryos treated 
with 500 pM and lower concentrations of homocysteine thiolactone.
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Hey cone. 
(mM)
No.
embryos
No. viable 
embryos
Yolk Sac 
circulation
Somite
number
Crown-rump 
length (mm)
0 59 58 2.61 ± 0.09 19.17 ±0.38 2.43 ± 0.04
0.25 27 27 2.81 ±0.09 18.85 ±0.24 2.45 ± 0.05
0.5 72 71 2.44 ±0.10 18.64 ±0.27 2.40 ± 0.03
1.0 10 4 0.40 ±0.16* 16.22 ±0.81* 2.13 ±0.10*
1.5 6 0 0.00 ± 0.00* 15.67 ±0.67* 2.13 ±0.04*
Table 3.1 Growth and development of CD1 mouse embryos cultured in the 
presence of homocysteine thiolactone
Embryos were assessed for viability, yolk sac circulation score (0-3) and growth 
parameters at the end of the culture period. Values are given as mean ± SEM. * 
indicates significant variation from control embryos cultured without Hey. (p<0.001, 
tested by one-way ANOVA followed by pair-wise analysis by TUKEY test) 
Abbreviations: Hey, homocysteine thiolactone.
3.2.2 Developmental defects in homocysteine thiolactone-treated 
embryos
Whole embryo culture with 500 pM and higher concentrations of homocysteine 
thiolactone induced a number of developmental abnormalities (Table 3.2). These 
abnormalities can be divided into two groups: (i) defects that reflect the growth 
retardation of the embryo and (ii) defects that are independent of growth retardation.
The failure to complete axial rotation and cranial neural tube closure observed in 
embryos treated with 1 mM and above concentrations of homocysteine thiolactone 
(Table 3.2) are associated with growth retardation. In CD1 mouse embryos, cranial
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Hey
cone.
(mM)
No.
embryos
No.
Abnormal
embryos
Axial
rotation
failed
Cranial 
neural tube 
open
Cranial
NTD
Blisters Somite
defects
0 59 6 (10.1) 4(6.8) 4(6.8) 1 (1.8) 0 (0.0) 0 (0.0)
0.25 27 4 (14.8) 1 (3.7) 1 (3.7) 0 (0.0) 0 (0.0) 0 (0.0)
0.5 72 37 (51.4)* 4(5.5) 9(12.3) 6 (9.0) 14(19.4)* 21 (29.2)*
1.0 10 10(100)* 2 (20.0) 3 (33.3) 1 (12.5) 2 (20.0)* 6 (60.0)*
1.5 6 6 (100)* 4 (66.7)* 3 (50.0)* 0 (0.0) 3 (50.0)* 2 (33.3)*
Table 3.2 Incidence of developmental defects in mouse embryos exposed to homocysteine thiolactone
The total incidence of abnormalities includes the absence of yolk sac circulation, failure of axial rotation and embryonic malformations. 
Cranial NTD are defined as failure to complete neural tube closure in embryos that have 16 or more somites. Data are presented as number 
of embryos with percentage in each treatment group in parentheses. * indicates significant variation from control embryos cultured without 
Hey (p<0.05, tested by Z-test). Abbreviations: Hey, homocysteine thiolactone.
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neural tube closure is normally completed by the time embryos have developed to the 
16 somite stage and axial rotation is completed at an earlier developmental stage (13-14 
somites). At a concentration of 1.5 mM homocysteine thiolactone the cranial neural tube 
had not closed in half of the embryos treated. However, due to the toxic effect of 
homocysteine thiolactone none of these embryos developed to a stage at which closure 
would be expected to occur and cannot, therefore be described as exhibiting NTD. Only 
embryos which failed to complete cranial neural tube closure after they had reached the 
16 somite stage of development were described as exhibiting an NTD. At 1 mM 
homocysteine thiolactone, a large proportion of treated embryos also exhibit open 
cranial neural tubes but are severely growth retarded. A few cases of NTD, in which the 
cranial neural tube remains open in embryos with at least 16 somites, do arise in 
embryos cultured in the presence of lower doses of homocysteine thiolactone (Table 
3.2). However, there is no statistically significant difference in the incidence of NTD in 
treatment groups compared to the control group, tested by Z-test. These data suggest 
that homocysteine thiolactone treatment does not cause isolated cranial NTD in mouse 
embryos (Table 3.2).
Developmental defects observed in embryos treated with 500 pM homocysteine 
thiolactone are likely to be unrelated to growth retardation since, at this concentration, 
no significant reduction in somite number or crown-rump length after culture was 
observed. The most frequently observed abnormalities occurred in the caudal somites. 
In some cases, the most caudal two or three somites were difficult to identify 
individually, as the boundaries between somites were indistinct (Figure 3.1). In other 
cases the caudal-most somites were distinct but they were often irregular in size and
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Figure 3.1. Developmental abnormalities induced by homocysteine thiolactone 
treatment
A-D show CD1 embryos after 24 hour culture with PBS (A, C) or 500 juM 
homocysteine thiolactone (B, D). C and D are magnified images of the embryos in A 
and B respectively. Significant developmental abnormalities induced by homocysteine 
thiolactone treatment included blisters on the surface epithelium of embryos (white 
arrow in B) and defects in the caudal-most somites. In some homocysteine thiolactone- 
exposed embryos a greater length of paraxial mesoderm remains unsegmented therefore 
the last few identifiable somites were in a more rostral position than those in the PBS 
treated control embryos (compare the three white arrowheads in C and D). Subsequent 
somites were often irregular in size and shape or indistinguishable (white arrow in D). 
Scale bars represent 200 pm. Abbreviations: Hey, homocysteine thiolactone.
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shape. Exposure to 500 pM or greater concentrations of homocysteine thiolactone also 
induced the formation of blisters on the surface epithelium of a significant number of 
embryos (p<0.001) when compared to PBS-treated controls (Figure 3.1, Table 3.2). 
Blisters were mainly observed on the forebrain and hindbrain surface but were also seen 
on other areas. Less common defects induced by homocysteine thiolactone treatment 
included an uneven or crinkled appearance of the surface epithelium and a reduction in 
the size of the forebrain.
3.2.3 The effect of homocysteine thiolactone treatment on 
somitogenesis in CD1 embryos
The most frequent defect observed in homocysteine thiolactone-treated embryos 
involved abnormal formation of the caudal-most somites. I examined whether these 
defects can be detected at the level of gene expression using the Delta-like genes as 
markers of somite development. In control embryos after culture, Dill transcripts were 
expressed in the presomitic mesoderm and the caudal half of each somite. There was a 
stripe of strong Dill expression in the anterior presomitic mesoderm that appeared to 
mark the nascent somites. In mature somites lower levels of transcript were restricted to 
the posterior halves of the somites (Figure 3.2 A,D). Dill expression was also observed 
in the cranial neuroepithelium in the presumptive forebrain and midbrain (Figure 3.2 E) 
and in the spinal neural tube (Figure 3.2 D,E,F). Dll3 was expressed in the presomitic 
mesoderm and the rostral half of the nascent somite. The highest level of transcript 
accumulation was in the presomitic mesoderm with lower levels expressed in the somite 
being formed (Figure 3.2 G). These expression patterns correspond to previous reports
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of Dill and Dll3 expression in E9.5 embryos (Bettenhausen et a l, 1995;Dunwoodie et 
a l, 1997).
Expression of the Delta-like genes in the presomitic paraxial mesoderm of 
homocysteine thiolactone-treated embryos, with affected or unaffected somites, did not 
differ from control embryos (Figure 3.2 A-H). However, homocysteine thiolactone- 
treated embryos with abnormal somites showed more diffuse expression of Dill in the 
somites compared to controls or unaffected homocysteine thiolactone-treated embryos 
(Figure 3.2 C,F compared to A,D and B,E respectively) illustrating a loss of somite 
boundaries in some homocysteine thiolactone-treated embryos.
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Figure 3.2 Expression of D ill and DllS in homocysteine thiolactone-treated 
embryos
Expression of Dill (A-F) and Dll3 (G, H) in CD1 mouse embryos after 24 hours culture 
with PBS (A, D, G) or 500 pM homocysteine thiolactone (B, C, E, F, H). The embryos 
in A-C have been re-positioned in D-F respectively to provide a clearer view of the 
somites. Homocysteine thiolactone treatment caused irregular or indistinct somites in 
some embryos (black arrows in C, F), whereas the somites in other treated embryos 
were not affected (black arrows in B, E). The expression of Dill in the presomitic 
mesoderm (PS) including the stripe of strong expression indicating the nascent somite 
(black arrowheads) were comparable between treated embryos (B, C, E, F) and controls 
(A, D). Dill expression in the somites of affected homocysteine thiolactone treated 
embryos (black arrows in C, F) was more diffuse than that of unaffected homocysteine 
thiolactone treated (black arrows in B, E) and control (black arrows in A, D) embryos. 
Dill transcripts were also detected in the forebrain and midbrain neuroepithelium (A) 
and the closed spinal neural tube (white arrowheads) in control (D) and treated (E, F) 
embryos. The expression of D113 in the presomitic mesoderm (PS) and rostral half of the 
nascent somite (black arrowheads) were comparable between control (G) and treated 
(H) embryos. Scale bars represent 500 pm. Abbreviations: Hey, homocysteine 
thiolactone; PS, presomitic mesoderm; FB, forebrain; MB, midbrain; S, somites
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3.3 DISCUSSION
Exposure of non-mutant mouse embryos to homocysteine thiolactone during the period 
of cranial neural tube closure (24 hours from E8.5) resulted in dose-dependent toxicity, 
growth retardation and developmental abnormalities. Some of these abnormalities such 
as failure to turn appear secondary to the growth retardation. Many embryos exposed to 
high concentrations of homocysteine thiolactone failed to reach the developmental stage 
at which the cranial neural tube should have closed (16 somites). However, there was no 
increase in the incidence of NTD observed in homocysteine thiolactone-treated embryos 
that had reached the 16 somite stage compared to control embryos. Moreover, it is 
unlikely that a longer culture period with the highest doses of homocysteine thiolactone 
would have resulted in embryos with cranial NTD. All embryos exposed to 
homocysteine thiolactone concentrations of 1 mM and above developed abnormally and 
exposure to 1.5 mM homocysteine thiolactone left all the embryos non-viable 
suggesting that the toxic effects of homocysteine thiolactone at this dose would prevent 
the embryos reaching the 16 somite stage of development. Homocysteine thiolactone 
treatment induced a. range of other abnormalities with the majority affecting the caudal 
end of the embryo.
Mice with null mutations in Dill and D113 exhibit defects in somite segmentation, 
suggesting that these genes may have a functional role in somite formation (De Angelis 
et al., 1997;Kusumi et al., 1998). The reduced definition of Dill expression in the 
mature somites of affected homocysteine thiolactone-treated embryos illustrates the 
abnormal segmentation and compartmentalisation of the somites as observed 
morphologically. However, the apparently normal expression of Dill and DU3 in the
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presomitic mesoderm of homocysteine thiolactone-exposed embryos suggests that the 
segmentation defects observed in the newly formed somites are unlikely to result 
directly from loss of Dll gene expression during initial somite formation.
The defects observed in this study correlate with the reported effect of homocysteine on 
neurulation stage rat embryos (VanAerts et al., 1994). In the rat, homocysteine 
treatment was embryotoxic, causing blisters and defects of the somites including 
irregular size and shape. However, there are discrepancies between my results and the 
previous study of homocysteine thiolactone treatment of mouse embryos (Hansen et al., 
2001). The authors did not find any toxic effects when mouse embryos were exposed to 
homocysteine thiolactone in whole embryo culture. Hansen et al. used the same mouse 
strain and homocysteine thiolactone was administered to the culture serum in a similar 
manner to this study. The differences in our findings are most likely due to the lower 
final concentration of homocysteine thiolactone tested in the previous study. An 
embryotoxic dose was probably not reached as the highest dose used was 0.65 mM 
(Hansen et al., 2001) compared to 1.5 mM in this study.
The effects of homocysteine treatment on the development of mouse embryos shown in 
this chapter differ from those observed in the chick embryo where homocysteine 
treatment is reported to cause heart defects and NTD (Rosenquist et al., 1996). The 
mode and dose of homocysteine application in the chick study differs greatly from the 
whole embryo culture system used in the rodent models. Rosenquist and colleagues, 
made a window in the eggshell and dropped 100 mM homocysteine thiolactone directly 
onto the inner embryonic membrane. This method involves much higher doses of
126
CHAPTER 3;Investigating the effect of homocysteine on cranial neural tube closure
homocysteine and there could also be wide variation in the actual concentration each 
embryo was exposed to, depending on the position of the embryo. Differences in the 
yolk composition of each egg may affect the metabolism of compounds applied to chick 
embryos. In fact, previous work has shown that simply making a window in the 
eggshell can be enough to induce NTD in some chick embryos (Mann and Persaud, 
1979). However, the study by Rosenquist and colleagues included numerous control 
groups suggesting this is not the cause of NTD in this study.
Not only are there differences between the outcome of homocysteine treatment of 
mammalian and chick embryos, but additional studies have led to conflicting results on 
the effect of homocysteine exposure in chick embryos. Afman and colleagues (2003a) 
found homocysteine thiolactone treatment in ovo did not cause NTD but did result in 
malformations similar to those found in rat (VanAerts et al., 1994) and mouse embryos 
(Greene et al., 2003). These abnormalities included blisters, somite deformation, caudal 
degeneration and disturbances in vein development. A later study by the Rosenquist 
group, Andaloro and colleagues (1998), repeated their original finding of a 28% NTD 
incidence after homocysteine thiolactone exposure. Further studies by Afman and 
colleagues (2003a) in which homocysteine thiolactone was applied to chick embryos in 
culture did show a transient widening of the anterior neuropore and delayed closure of 
the hindbrain neuropore. However, continued culture resulted in complete closure of the 
neural tube. Although this study did not reproduce the original in ovo results from 
Rosenquist and colleagues (1996) it does suggest that homocysteine treatment can affect 
the neurulation process. The possibility remains that if Afman and colleagues had given 
additional applications of homocysteine thiolactone throughout the culture period they
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could have produced embryos with NTD. Another study investigated the effect of 
homocysteine thiolactone on caudal neural tube closure in chick embryos and 
demonstrated that exposure of embryos to 2.5 M homocysteine thiolactone gave an age- 
dependent incidence of NTD of up to 44% (Epeldegui et al., 2002). Exposure to the 
very high concentrations of homocysteine thiolactone in this study also resulted in a 
significant number of embryos with gross abnormalities. A high incidence of spina 
bifida in the control group (10%) suggests that the white leghorn chicken strain used in 
this study was more susceptible to spinal NTD than strains used in previous studies.
One explanation for the possible differences in the effect of homocysteine on chick and 
mouse could be a species difference. Studies have shown species differences in 
response to other teratogenic agents. For example, TCDD (tetrachlorodibenzo-p-dioxin) 
has been shown to induce cleft palate when administered to mice (Neubert and 
Dillmann, 1972). In cell culture, similar effects of TCDD toxicity are seen in mouse and 
human cells although much higher doses are required in human cells to produce the 
same effects as lower doses in the mouse cells. Mechanistic studies have shown that the 
action of TCDD toxicity requires the aryl hydrocarbon receptor (Ahr) and Ahr nuclear 
translocator (ARNT) (Abbott et al., 1998). Ahr expression in human tissue is 300 times 
lower than in mice, and this difference in gene expression may relate directly to the 
difference in tissue sensitivity to TCDD teratogenesis (Abbott et al., 1999).
The toxic effect of homocysteine observed in mouse and rat embryos could be mediated 
through a direct teratogenic effect of homocysteine itself. Alternatively, an indirect
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mechanism could be envisaged, in which homocysteine influences the levels of other 
metabolites within the cell, with a consequent toxic effect.
One of the possible mechanisms for direct toxicity by homocysteine could be through 
the homocysteinylation of proteins within the cell. Homocysteinylation of proteins 
occurs via the formation of homocysteine thiolactone. The reactive thiolactone group 
can readily acylate proteins, primarily at lysine residues, under physiological conditions 
(Jakubowski, 1999). The amount of homocysteine thiolactone produced in a cell is 
dependant on the level of homocysteine, and increases when the removal of 
homocysteine, via the transulphuration pathway or remethylation to methionine, is 
inhibited (Jakubowski, 1997). Homocysteinylation can cause protein damage. For 
example, homocysteinylation of 33% of the lysine residues in methionyl-tRNA 
synthetase and 88% of lysine residues in trypsin results in complete loss of enzyme 
activity (Jakubowski, 1999). Protein homocysteinylation could therefore affect cellular 
processes, which could subsequently result in the embryotoxicity caused by elevated 
levels of homocysteine.
The teratogenic effect of homocysteine in the chick embryo has been suggested to result 
from direct inhibition of the A-Methyl-D-aspartate (NMD A) receptor (Rosenquist et al., 
1996). NMDA receptor antagonists, including dextromethorphan, could induce NTD in 
chick embryos in a similar manner to homocysteine thiolactone, although not to the 
same degree (Andaloro et al., 1998). However, administration of dextromethorphan to 
pregnant rats and rabbits did not result in any fetal malformations (Brent, 1998)
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suggesting that this may be another example of a difference in gene-teratogen 
interaction between species.
The embryotoxicity observed in mouse embryos exposed to homocysteine could also be 
mediated via an indirect mechanism in which elevated homocysteine disrupts the levels 
of other metabolites in the cell, which subsequently have a toxic effect. Van Aerts and 
colleagues (1994) suggested that the embryotoxicity observed in rat embryos was due to 
an increase in cellular SAH levels. Elevated SAH levels would affect the SAM/S AH 
ratio in the cell, which has a regulatory role in both the methylation and folate cycles 
and so could act through disruption of one or both of these pathways (Finkelstein, 
1998). At high concentrations, SAH acts as a product inhibitor of methyltransferase 
reactions, resulting in a suppression of critical methylation reactions. DNA methylation 
has an important role in the epigenetic control of the expression of some genes (Jones 
and Takai, 2001), changes which could potentially result in homocysteine-induced 
embryotoxicity. Inhibition of protein methylation has also been shown to affect the 
behaviour of proteins within the cell. In mouse cells lacking isoprenylcysteine carboxyl 
methyltransferase (ICMT), the methyltransferase responsible for the methylation of the 
Ras family of proteins, Ras proteins are mislocalised and unable to interact with 
microtubules (Chen et al., 2000;Bergo et al., 2000).
Several lines of evidence suggest that elevated homocysteine levels may influence 
methylation in vivo. DNA hypomethylation has been observed with elevated 
homocysteine levels in MTHFR-deficient mice (Chen et al., 2001) and in human 
patients suffering from hyperhomocysteinaemia (Ingrosso et al., 2003) or vascular
130
CHAPTER 3;Investigating the effect of homocysteine on cranial neural tube closure
disease (Castro et al., 2003). These studies indicate that abnormal cellular methylation 
is a possible mechanism of homocysteine-induced toxicity as changes in methylation 
have been associated with changes in homocysteine levels.
In addition to effects on the methylation cycle, the abundance of homocysteine or SAH 
can influence the folate cycle. An increase of SAH levels compared to SAM could 
increase the activity of MTHFR, driving the production of 5-methyl THF for the 
remethylation of homocysteine to methionine (Figure 1.6). This would deplete the 
availability of 5,10-methylene THF, the MTHFR substrate, for other reactions in the 
folate cycle including the de novo synthesis of dTMP and the production of THF and 
the purine ring (Figure 1.6).
In cell culture experiments, high concentrations of homocystine (the oxidation product 
of homocysteine) and methionine inhibited the de novo synthesis of dTMP (Fell and 
Selhub, 1990). This inhibition could be mediated by a reduced availability of 5,10- 
methylene THF. In addition to being the substrate for thymidylate synthase (TS) in the 
production of dTMP, 5,10-methylene THF is also required as a substrate for two other 
reactions in the cell; the production of 5-methyl THF by MTHFR and the conversion of 
5,10-methylene THF back to THF via a number of enzymatic steps (Figure 1.6). The 
synthesis of 5,10-methylene THF from THF is mediated by serine 
hydroxymethyltransferase in a serine dependent manner. It was proposed that the 
mechanism responsible for the inhibition of dTMP synthesis was the depletion of 5,10- 
methylene THF production by serine hydroxymethyltransferase. This would result from 
an increased requirement for serine in the cell, for use in the removal of excess
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homocysteine through the transulphuration pathway (Fell et al., 1990) and limiting the 
production of 5,10 methylene THF. However, there is no evidence of an active 
transulphuration pathway in neurulation stage embryos, as activities of the enzymes 
involved in this pathway are not detected in E10 rat embryos (VanAerts et al., 1995). 
Moreover, the only tissues in mammalian adults that have been reported to express the 
complete transulphuration pathway are the liver, pancreas and kidney (Finkelstein, 
1990). If the transulphuration pathway is not active in mouse embryos undergoing 
neurulation, excessive flux through this pathway would be unlikely to result from 
exposure to homocysteine thiolactone, suggesting that this is not responsible for the 
observed toxic effects.
Further evidence that TS function is not significantly compromised in homocysteine- 
treated embryos comes from an additional study carried out in our laboratory. The 
incorporation of [ H]-thymidine into DNA can be measured as one indicator of 
functional folate metabolism. An increase in the incorporation of exogenous tritium- 
labelled thymidine into DNA can indicate increased activity of the salvage pathway in 
the production of dTMP, which suggests that the thymidylate synthase-mediated de 
novo synthesis pathway is impaired. The incorporation of [ H]-thymidine into DNA in 
homocysteine thiolactone-treated embryos did not differ from control embryos, 
suggesting that homocysteine thiolactone-induced embryotoxicity in the mouse is 
unlikely to result from the inhibition of thymidylate synthase (Greene et al., 2003).
The experiments carried out in this chapter were not sufficient to establish whether the 
mechanism for homocysteine embryotoxicity is via a direct or indirect route. Further
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experiments would be needed to distinguish the exact mechanism. One approach would 
be to separate the effect of elevated SAH on the development of the embryo as opposed 
to the effect of elevated homocysteine. This could potentially be achieved by inhibition 
of SAH hydrolase, the enzyme that converts SAH to homocysteine via a reversible 
reaction. The conversion of homocysteine to SAH is favoured by enzyme kinetics and 
uses adenosine as a co-substrate. However, the rapid removal of homocysteine drives 
the reaction in the opposite direction under normal conditions (Finkelstein, 1998).
How does the toxic effect of homocysteine thiolactone observed in animal studies relate 
to the doses that may be present during human pregnancy? Elevated homocysteine 
levels have been associated with human pregnancies affected by NTD (Steegers- 
Theunissen et a l, 1994;Mills et a l, 1995). Serum homocysteine values (8.6 pM) were 
significantly higher in mothers with NTD-affected pregnancies in the low but normal 
range of vitamin B 12 serum concentration compared to vitamin B 12 matched controls 
(7.9 pM) (Mills et a l, 1995). Elevated homocysteine plasma values were also found in 
mothers of spina bifida patients; 12.5 pM compared to 10.1 pM in controls (Van der Put 
et a l, 1997a). The lowest teratogenic dose used in the present study was 500 pM, about 
50 times that found in humans. However, this dose of homocysteine thiolactone did not 
induce NTD in mouse. Although homocysteine treatment of chick embryos can induce 
NTD (Rosenquist et a l, 1996;Andaloro et a l, 1998;Epeldegui et a l, 2002) there are 
now three independent mammalian studies (VanAerts et a l, 1994;Hansen et a l, 
2001;Greene et a l, 2003) and one study in chick (Afman et a l, 2003a) in which no 
increase in the incidence of NTD was observed following homocysteine treatment. 
Taken together, these studies suggest that it is unlikely that elevated homocysteine is
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directly causal in the development of NTD. Instead it appears more likely that elevated 
homocysteine levels are an indicator of abnormalities in the folate and/or methylation 
cycles in association with NTD. The potential effect of methylation cycle disruption 
will be discussed in Chapter Four.
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4.1 INTRODUCTION
In the studies described in Chapter 3 I concluded that elevated homocysteine levels per 
se are unlikely to cause NTD directly, but are more likely to be an indicator of 
abnormalities in the folate and/or methylation cycles. Elevated homocysteine and other 
risk factors for NTD such as sub-optimal folate or vitamin B 12 status, and the 
polymorphic MTHFR variant with reduced enzyme activity (Section 1.9) could be 
associated with reduced methionine production. Methionine is the product of the 
remethylation of homocysteine via the methionine synthase mediated reaction (Figure 
4.1). Therefore, elevated homocysteine levels may indicate an abnormal flux through 
the methylation cycle.
Methionine has been suggested to be essential for normal neural tube closure to occur. 
Rat embryos cultured in cow serum throughout neurulation develop NTD unless the 
serum is supplemented with methionine (Coelho et al., 1989). In addition, canine serum 
requires supplementation with methionine and iron before it is capable of supporting the 
normal development and neural tube closure of neurulation-stage rat embryos in whole 
embryo culture (Flynn et al., 1987). These studies suggest that an adequate supply of 
methionine is required for neurulation to be successfully completed. Further in vitro 
studies have suggested that serum methionine may be a limiting nutrient in 
organogenesis-stage embryos. For example, normal rat serum which contains around 
70 pM methionine (Milakofsky et al., 1984) and can support the growth and 
development of neurulation-stage rat and mouse embryos in whole embryo culture. 
However, the majority of methionine taken up by neurulation-stage embryos is in the 
form of serum proteins rather than free methionine (Lloyd et al., 1996). Rat embryos
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undergoing neurulation are more efficient at incorporating labelled methionine as 
opposed to labelled leucine from serum proteins into embryonic tissues (Lloyd et al., 
1996) possibly suggesting a greater requirement for methionine than leucine. In 
addition, increasing the levels of free methionine and leucine available to rat embryos 
undergoing neurulation, by 11-fold, resulted in a greater accumulation of methionine in 
both the embryo and the yolk sac than leucine. These experiments suggest that normal 
leucine levels are abundant relative to the embryonic requirement for leucine, whereas 
the methionine provided by rat serum proteins and free amino acid is barely sufficient 
for the embryos needs (Pugarelli et al., 1999). These results may illustrate a high 
requirement for methionine in the developing embryo, as methionine is necessary for 
protein synthesis and a functioning methylation cycle.
Supplementation with methionine but not folic acid or vitamin B 12, has also been shown 
to reduce the incidence of NTD in the Axial defects (Axd) mouse model (Essien, 
1992;Essien and Wannberg, 1993). A delay or failure in the closure of the PNP in 
homozygous Axd mice results in tail defects or spina bifida. The incidence of NTD is 
reduced by approximately 40% after methionine administration to pregnant females at 
E8 and E9, at the beginning and during neurulation. However, a low incidence of 
exencephaly is seen in the treated group that is not present in the control group. In
7 L/contrast to the Axd  model, splotch (Sp ) homozygotes are folate-responsive in respect 
to NTD (Fleming et al., 1998). However, exposure of cultured Sp2H mouse embryos to 
methionine throughout neurulation induced NTD in 47% of heterozygote embryos, 
which normally develop without a NTD phenotype. Therefore, although methionine is 
essential for neural tube closure in several models methionine supplementation in Sp2H
137
CHAPTER 4; The effect of disrupting the methylation cycle on cranial neural tube closure
mice appears to exacerbate the genetically determined susceptibility to NTD (Fleming 
etal., 1998).
Polyamine
synthesis
Methyltransferase s Decarboxylated
SAM
SAMDC
SAH SAM
SAH hydrolase Cyclo MAT
4  SAE
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Homocysteine Methionine
MS
Folate
metabolism
THF
Figure 4.1 Simplified diagram of the methylation cycle
Key enzymes (blue text) and the sites of action of methylation cycle components and 
inhibitors utilised in this chapter (pink text) are highlighted.
Abbreviations: Cyclo, cycloleucine; MAT, methionine adenosyltransferase; MS, 
methionine synthase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; 
SAMDC, S-adenosylmethionine decarboxylase; SAE, S-adenosylethionine; THF, 
tetrahydrofolate.
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In humans, dietary studies have suggested that a high intake of methionine can reduce 
the risk of NTD. Shoob and colleagues (2001) found a 30-55% lower NTD risk among 
women whose daily dietary methionine intake was above the lowest quartile, in this 
case more than 1,580 mg/day. Another study also detected a 30-40% reduction in risk 
for an NTD-affected pregnancy among those with a daily methionine intake above the 
lowest quartile (in this study above 1,342 mg/day), irrespective of folate intake (Shaw et 
al., 1997).
Overall, several lines of evidence suggest that sufficient methionine and/or flux through 
the methylation cycle are required for neural tube closure. The requirement for 
methionine in neural tube closure is currently unknown but may be necessary for 
protein synthesis or SAM production and subsequent methylation reactions. In this 
chapter, I directly investigated whether there is any effect of disruption of the 
methylation cycle on neural tube closure. Disruption of the methylation cycle was 
achieved using the whole embryo culture technique. CD1 mice embryos were cultured, 
throughout the period of cranial neural tube closure (E8.5-E9.5), in rat serum to which 
either methionine, ethionine or cycloleucine was added. Ethionine is a non-metabolic 
competitive inhibitor of methionine for MAT, it is converted to S-adenosylethionine 
(SAE) but cannot be metabolised any further (Figure 4.1) (Miller et al., 1994). 
Cycloleucine inhibits the conversion of methionine to SAM (Figure 4.1) (Lombardini 
and Talalay, 1970).
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4.2 RESULTS
4.2.1 Methionine, ethionine and cycloleucine specifically cause 
cranial NTD in CD1 mouse embryos
The effect of methionine, ethionine and cycloleucine on the development of 
neurulation-stage embryos was investigated in non-mutant CD1 embryos cultured for 24 
hours from E8.5 (4-6 somites) to E9.5. PBS was used as a vehicle control and embryos 
from within litters were randomly allocated to different treatment groups to minimise 
any effect of litter to litter variation. At the end of the culture period embryos were 
assessed for developmental progress (as indicated by number of somites), growth and 
viability. Any morphological abnormalities were recorded for each embryo.
4.2.1.1 Methionine specifically causes cranial NTD in CD1 mouse
embryos
Exposure to methionine concentrations of up to 10 mM did not adversely affect the 
viability of the embryos as indicated by similar mean yolk sac circulation scores at the 
end of the culture period in treated and control embryos (Table 4.1). The growth and 
developmental progression of embryos during the culture, as illustrated by the mean 
crown-rump length, somite number and incidence of failed axial rotation, was not
affected by exposure to methionine (Table 4.1). Nevertheless, at methionine
concentrations of 5 mM and above, a significant number of embryos exhibited open 
cranial neural tubes compared to PBS-treated control embryos (Table 4.1). As indicated
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Table 4.1 Growth and development of mouse embryos cultured in the presence of methionine
Non-viable embryos were identified by an absence of yolk sac circulation. Cranial neural tube defects are defined as failure to complete 
cranial neural tube closure in embryos that have 16 or more somites. Values for yolk sac circulation, somite number and crown-rump 
length are given as mean ± SEM. There were no significant differences between the values (tested by one way-ANOVA). Data for failed 
axial rotation and open cranial neural tube are presented as number of embryos with percentage of total embryos in parentheses. Data for 
cranial neural tube defects are presented as number of embryos with percentage of embryos with 16 or more somites in parentheses. 
<t> (p<0.05) and * (p<0.001) indicate significant variation from control embryos cultured without methionine (tested by z-test).
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Methionine 
conc. (mM)
No.
embryos
No.
viable
embryos
Yolk Sac 
circulation
No. failed 
axial 
rotation 
(%)
0 65 61 2.59 ±0.11 11 (18.0)
0.25 3 3 3.00 ±0.00 0 (0.0)
0.5 9 9 2.67 ± 0.24 2 (22.2)
1.0 8 8 3.00 ±0.00 0 (0.0)
1.5 9 9 2.89 ±0.11 0 (0.0)
2.0 17 16 2.62 ± 0.22 1 (5.8)
3.0 3 3 2.33 ± 0.67 0 (0.0)
4.0 4 4 2.50 ± 0.29 0 (0.0)
5.0 45 42 2.73 ±0.11 4 (8.9)
10.0 41 39 2.49 ±0.14 5 (12.2)
No. open 
cranial neural 
tube (%)
No. cranial 
neural tube 
defects (%)
Somite
number
Crown- 
rump length 
(mm)
10(16.4) 4 (7.0) 19.3 ± 0.23 2.44 ± 0.04
0 (0.0) 0 (0.0) 20.3 ± 0.33 2.44 ± 0.06
2 (22.2) 1 (12.5) 18.0 ±0.54 2.27 ±0.04
1 (12.5) 0 (0.00) 18.3 ±0.42 2.20 ± 0.05
3 (33.3) 1 (14.3) 18.7 ±0.61 2.36 ± 0.08
2 (11.8) 1 (6.25) 20.1 ±0.28 2.58 ± 0.05
0 (0.0) 0 (0.0) 19.7 ±0.88 2.61 ± 0.07
0 (0.0) 1 (25.0) 20.5 ± 0.50 2.67 ± 0.07
20 (44.4)<J) 16 (40.0)* 18.9 ±0.30 2.23 ± 0.04
23 (56.1)* 21 (56.8)* 19.5 ±0.28 2.52 ± 0.04
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by the mean number of somites (approximately 19 somites) a significant number of 
these embryos were exencephalic, as they had reached the developmental stage (16 
somites or more) when cranial neural tube closure should have been completed (Table
4.1, Figure 4.2). This exencephaly occurred in the absence of any other apparent
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F ig u r e  4 .2  M e th io n in e  s p e c if ic a l ly  c a u s e s  c r a n ia l  N T D  in  C D 1  e m b r y o s
The percentage of embryos exhibiting cranial neural tube defects after exposure to 
increasing concentrations o f methionine. * indicates a significant variation from control 
embryos cultured without methionine. (p<0.001, tested by Z-test).
abnormalities or defects in the embryos. Therefore, the results indicate that methionine, 
at concentrations o f 5 mM or higher, causes exencephaly in mouse embryos through a
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specific effect rather than as a secondary result of growth retardation or other 
morphological abnormalities.
4.2.1.2 Ethionine specificaily causes NTD in CD1 mouse embryos
A series of embryos were cultured in the presence of a range of doses of ethionine and 
parameters of growth and development were measured. Exposure to ethionine 
concentrations of up to 5 mM did not result in embryotoxicity, as shown by absence of 
an effect on yolk sac circulation scores. Embryos showed normal developmental 
progression, as indicated by comparable somite numbers and incidence of failed axial 
rotation among ethionine-treated embryos and embryos cultured with PBS (Table 4.2). 
There were no differences in the mean crown-rump length between the treatment groups 
illustrating that ethionine treatment does not cause growth retardation at these 
concentrations.
Embryos cultured in the presence of 10 mM ethionine showed signs of developmental 
retardation as indicated by the significant number of embryos that failed to complete 
axial rotation. In addition, there was a noticeable, although not statistically significant, 
decrease in the mean somite number, crown-rump length and yolk sac circulation 
observed at the end of the culture period in the embryos treated with 10 mM ethionine 
compared to control embryos (Table 4.2). A large number of embryos in this treatment 
group failed to complete cranial neural tube closure by the end of the treatment period 
(Table 4.2). All of these embryos had reached at least the 16 somite stage of 
development indicating that exencephaly is induced at high incidence in embryos 
cultured in the presence of 10 mM ethionine (Table 4.2, Figure 4.3). However, a
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Table 4.2 Growth and development of mouse embryos cultured in the presence of ethionine.
Non-viable embryos were identified by an absence of yolk sac circulation. Cranial neural tube defects are defined as failure to complete 
cranial neural tube closure in embryos that have 16 or more somites. Values for yolk sac circulation, somite number and crown-rump 
length are given as mean ± SEM. There were no significant differences between the values (tested by one way-ANOVA). Data for failed 
axial rotation and open cranial neural tube are presented as number of embryos with percentage of total embryos in parentheses. Data for 
cranial neural tube defects are presented as number of embryos with percentage of embryos with 16 or more somites in parentheses. <|) 
(p<0.05) and * (p<0.001) indicate significant variation from control embryos cultured without ethionine (tested by z-test).
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Ethionine
conc.
(mM)
No.
embryos
No.
viable
embryos
Yolk sac 
circulation
No. failed 
axial 
rotation 
(%)
0.00 60 55 2.73 ±0.11 3 (5.0)
0.10 6 6 3.00 ±0.00 0 (0.0)
0.25 12 12 3.00 ±0.19 0 (0.0)
0.50 15 15 2.60 ±0.19 0 (0.0)
1.00 9 9 2.22 ± 0.28 2 (22.2)
1.50 6 6 3.00 ±0.10 0 (0.0)
2.00 15 15 2.87 ± 0.09 0 (0.0)
3.00 6 6 3.00 ± 0.00 0 (0.0)
4.00 6 6 3.00 ± 0.00 0 (0.0)
5.00 46 45 2.80 ± 0.09 3 (6.5)
10.00 16 13 2.25 ±0.31 5(31.3)<|>
No. open 
cranial 
neural tube
(%)
No. cranial 
neural tube 
defects (%)
Somite
number
Crown- 
rump length
3 (5.0) 1 (1.8) 18.9 ±0.26 2.38 ±0.03
0 (0.0) 0 (0.0) 19.0 ±0.52 2.50 ± 0.02
2 (16.7) 2 (16.7)<(> 18.0 ±0.19 2.31 ±0.07
2(13.3) 2(14.3) 19.0 ±0.50 2.37 ± 0.06
2 (22.2) 1 (12.5) 18.9 ±0.79 2.33 ± 0.07
1 (16.7) 1 (16.7) 19.6 ±0.56 2.44 ± 0.04
4 (26.7)<|> 3 (21.4)+ 19.4 ±0.60 2.55 ± 0.08
2 (33.3) 2 (33.3)+ 18.3 ±0.42 2.24 ± 0.04
1 (16.6) 1 (16.6) 20.0 ± 0.45 2.44 ± 0.06
30 (65.2)* 26 (61.9)* 19.0 ±0.38 2.30 ± 0.04
14 (87.5)* 13 (100.0)* 16.5 ±0.51 2.15 ±0.09
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The percentage o f embryos exhibiting cranial neural tube defects after exposure to 
increasing concentrations o f ethionine. * and <|> indicate significant variation from 
control embryos cultured without ethionine (p<0.001 and p<0.05 respectively, tested by 
Z-test).
number of exencephalic embryos failed to undergo axial rotation suggesting that failure 
o f cranial neural tube closure was secondary to the abnormal development o f the 
embryo at this concentration of ethionine. This is not the case at doses o f 5 mM 
ethionine and below, where there was a significant increase in the number o f embryos 
with cranial NTD compared to control embryos (Figure 4.3), without any other apparent 
detrimental effect on the developmental progression of the embryos.
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High incidences (above 10%) of exencephaly were observed in all treatment groups 
between doses of 0.25 mM and 5 mM ethionine compared to the control group in which 
2% of embryos exhibited exencephaly (Table 4.2). However, the incidence of 
exencephaly was not statistically significant for all the treatment groups possibly due to 
low sample numbers in certain groups. Significant levels of exencephaly are first 
observed at 0.25 mM suggesting that even a low level of ethionine may be deleterious 
for neural tube closure. However, it is only at concentrations of ethionine of 2 mM and 
above that consistent exencephaly was observed.
4.2.1.3 Cycloleucine causes isolated NTD in CD1 mouse embryos 
CD1 embryos were cultured in the presence of 15 mM cycloleucine for 24 hours from 
E8.5, to observe the effect on cranial neural tube closure in non-mutant embryos. This 
concentration was used because previous studies showed that there was no non-specific 
toxicity whereas higher doses may be deleterious (A.J. Copp personal communication). 
The growth, development and viability of the cycloleucine treated embryos at the end of 
the culture period were comparable to control embryos (Table 4.3), suggesting that 15 
mM cycloleucine does not have widespread embryotoxic effects. However, a significant 
proportion of cycloleucine-treated embryos (p<0.05, tested by Z-test) did exhibit cranial 
NTD; 58.3% compared to 14.3% in controls. NTD were observed in embryos with no 
other apparent defects, suggesting that cycloleucine treatment causes isolated cranial 
NTD in CD1 embryos.
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Cycloleucine 
conc. (mM)
No.
embryos
No. viable 
embryos
Yolk sac 
circulation
No. failed 
axial 
rotation 
(%)
No. open 
cranial 
neural tube 
(%)
No. cranial 
neural tube 
defects (%)
Somite
number
Crown- 
rump length 
(mm)
0 25 24 2.28 ±0.19 6 (24.0) 7(28.0) 3 (14.3) 18.6 ±0.58 2.53 ± 0.05
15 28 24 2.43 ± 0.20 5 (17.9) 18 (64.2)| 14 (58.3)$ 19.3 ±0.48 2.50 ± 0.05
Table 4.3 Growth and development of mouse embryos cultured in the presence of cycloleucine
Non-viable embryos were identified by an absence of yolk sac circulation. Cranial neural tube defects are defined as failure to complete 
cranial neural tube closure in embryos that have 16 or more somites. Values for yolk sac circulation, somite number and crown-rump 
length are given as mean ± SEM, and there were no significant differences between the values (tested by t-test). Data for failed axial 
rotation, open cranial neural tube and cranial neural tube defects are presented as number of embryos with percentage in parentheses. 
$ (p<0.05) indicates significant variation from control embryos cultured without cycloleucine (tested by z-test).
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4.2.2 The morphological appearance of exencephaly differs 
between methionine, ethionine and cycloleucine-induced 
defects
Exposure o f CD1 embryos to methionine, ethionine or cycloleucine can result in 
isolated cranial NTD. However, the varying ability of the compounds to cause 
exencephaly (ethionine appears to be more potent than methionine) suggests different 
mechanisms may be responsible for the failure o f the cranial neural tube to close. As a 
preliminary step towards addressing this question, the region of cranial neural tube that 
remains open was noted for embryos from the different treatment groups (Figure 4.5). 
Embryos that developed exencephaly when cultured with PBS showed an 
approximately even distribution of phenotypes, in terms of the region of open neural 
folds (Figure 4.4). Methionine-treated embryos tended to exhibit areas o f open neural
T r e a tm e n t %  o f  e m b r y o s n
PBS 11.1 0.0 33.3 11.1 22.2 11.1 11.1 8
Methionine 27.3 4.5 34.1 2.3 11.4 15.9 4.5 43
Ethionine 85.7 0.0 14.3 0.0 0.0 0.0 0.0 27
Cycloleucine 17.4 4.3 52.2 0.0 4.3 17.4 4.3 23
F ig u r e  4 .4  R e g io n s  o f  o p e n  n e u r a l  tu b e  in  m e th io n in e , e th io n in e  a n d  c y c lo le u c in e -
tr e a te d  e m b r y o s .
The red line illustrates the position o f open neural folds in the cranial region, examples 
of each position are shown in Figure 4.5. The data represents the proportion of embryos 
with corresponding regions o f open neural tube in each treatment group (shown as 
percentage of total embryos exhibiting exencephaly, n).
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Figure 4.5 Positions of open neural folds in the cranial region of embryos treated 
with methionine, ethionine or cycloleucine
Panels A-G show examples of embryos in groups A-G in Figure 4.4 respectively. White 
arrowheads (A-G) flank the areas of open neural tube. Examples of the different regions 
of cranial neural tube which failed to close after treatment with 5 mM methionine (B, C, 
E), 5 mM ethionine (G) and 15 mM cycloleucine (A, D, F) compared to PBS-treated 
embryos that completed cranial neural tube closure (H). Scale bars represent 200 pm.
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in the forebrain/midbrain region (Figure 4.4, Groups A-E). There were also a number of 
methionine-treated embryos in which closure of the hindbrain neuropore was 
incomplete (Figure 4.4, Group F and G). A similar variation in the region of open neural 
tube was observed in cycloleucine-treated embryos that developed exencephaly, the 
majority having a defect in the forebrain/midbrain region with a smaller number of 
embryos exhibiting an open neural tube in the hindbrain region. In contrast, all 
exencephalic embryos from the ethionine-exposed group exhibited open 
forebrain/midbrain regions. Therefore, the forebrain/midbrain region was commonly 
open in all categories, suggesting that initiation of closure at site 2 has failed. However, 
the extent of the region of open neural tube was greater in the majority of ethionine- 
treated embryos possibly indicating an additional problem with the progression of 
fusion within these embryos (Figure 4.4, Group A).
4.2.3 Different morphology through the cranial regions of treated 
embryos
In order to gain possible insight into underlying causative mechanisms for the induced 
NTD, embryos cultured in the presence of 5 mM methionine, 5 mM ethionine, 15 mM 
cycloleucine or PBS were examined at the histological level. Transverse sections 
through the cranial region of the embryos were cut and stained with haematoxylin and 
eosin prior to analysis.
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4.2.3.1 Reduced cranial mesenchyme density in methionine-treated 
embryos
On transverse sections, the histological appearance of the cranial region of methionine- 
treated embryos in which cranial neural tube closure was complete, was 
indistinguishable from that of PBS-treated control embryos. In contrast, sections 
through the cranial region of methionine-treated embryos that developed exencephaly 
showed a number of differences to sections from control embryos (Figure 4.6 compare 
E-G to B-D). The neuroepithelium of some exencephalic methionine-exposed embryos 
was noticeably thinner than that of control embryos (Figure 4.6 compare F and C). Cell 
aggregates were also observed in two out of four (50%) exencephalic methionine- 
treated embryos (Figure 4.6 E) but not in embryos from any of the other treatment
9
groups (six control embryos and six methionine-treated embryos in which neural tube 
closure was complete). In addition, all of the exencephalic methionine-treated embryos 
studied (four out of four) appeared to have a reduced cranial mesenchyme density, 
compared to embryos cultured with PBS (compare Figure 4.6 D and G). This phenotype 
was investigated further by quantitative analysis (Section 4.2.4).
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Figure 4.6 Transverse sections stained with haematoxylin and eosin, through the 
cranial region of exencephalic methionine, ethionine and cycloleucine-treated 
embryos and control PBS-treated embryos
CD1 mouse embryos were cultured for 24 hours in the presence of PBS (B-D), 5 mM 
Methionine (E-G), 5mM Ethionine (H-J) or 15 mM Cycloleucine (K-M). Transverse 
sections were taken through the cranial region of the embryos at 25% (B, E, H, K), 50% 
(C, F, I, L) and 100% (D, G, J, M) of the distance between the cranial limit of the 
embryos and the first section showing the optic vesicles (dotted lines in A). Sections 
shown are from a normal control embryo (B-D) and treated embryos that failed to 
complete cranial neural tube closure (E-M). Regions of open cranial neural tube are 
indicated by Ex. The neural epithelium of methionine and ethionine exposed embryos 
appears thinner than that of control and cycloleucine-treated embryos (C, F, I, L, black 
arrowheads). The density of the cranial mesenchyme also seems to differ in methionine 
and cycloleucine-treated embryos compared to control or ethionine-treated embryos (D, 
G, J, M indicated by *). Methionine exposure appears to result in a reduced cranial 
mesenchyme density while cycloleucine exposure seems to increase the density of the 
cranial mesenchyme. Cell aggregates were observed in the mesenchyme of methionine- 
treated embryos (E, arrow). Scale bars represent 200 pm. Abbreviations; Ex; 
exencephaly, Meth; methionine, Eth; ethionine, Cyclo; cycloleucine.
155
CHAPTER 4; The effect of disrupting the methylation cycle on cranial neural tube closure
B.E.H.K.
C.F.LL"* 
D.G.J.M
Cyclo
156
CHAPTER 4; The effect of disrupting the methylation cycle on cranial neural tube closure
4.2.3.2 The cranial neuroepithelium is less thick in ethionine-treated 
embryos
Sections through the cranial region of ethionine-treated embryos that had completed 
cranial neural tube closure appeared very similar to sections taken through PBS-treated 
embryos. The neuroepithelium appears thinner in 80% (4 of 5 embryos) of the 
exencephalic embryos compared to the neuroepithelium in control embryos (Figure 4.6 
compare I and C). In addition, the neuroepithelium of ethionine-treated embryos 
appears thinner than the neuroepithelium of embryos exposed to cycloleucine that 
developed cranial NTD suggesting that this phenotype is specific to ethionine treatment, 
rather than simply an effect of failure to complete cranial neural tube closure (Figure 4.6 
compare I to L). Unlike methionine-treated embryos, the cranial mesenchyme of the 
affected ethionine exposed embryos does not appear to differ in density compared to 
control embryos.
4.2.3.3 Increased cranial mesenchyme density in cycloleucine-treated 
embryos
On histological sections an increase in cranial mesenchyme density appears to be 
present in both affected (three of five embryos) and unaffected (three of five embryos) 
cycloleucine-treated embryos when compared to control embryos (Figure 4.6 L). 
However, there does not appear to be any difference between the neuroepithelium of 
cycloleucine-treated embryos and PBS-treated embryos, with no apparent effect of 
completion or failure of cranial neural tube closure.
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4.2.4 Quantitative analysis of neuroepithelial thickness and
cranial mesenchyme density in methionine, ethionine, 
cycloleucine and PBS-treated embryos
Initial analysis of transverse sections through the cranial region suggested that there are 
differences in mesenchyme density and neuroepithelial thickness in treated embryos 
compared to control embryos. In order to make a quantitative comparison of 
neuroepithelial width and cranial mesenchyme density, measurements were taken as 
described in Section 4.2.4.1. Embryos exposed to 5 mM methionine, 5 mM ethionine 
and 15 mM cycloleucine were investigated, as these treatments resulted in isolated 
cranial neural tube defects, without affecting the viability, growth or development of the 
embryo. Embryos from each treatment were separated for analysis, according to 
whether cranial neural tube closure had been successful or not, and compared to PBS- 
treated embryos in which cranial neural tube closure was complete in all embryos.
4.2.4.1 Method for quantitative analysis of neuroepithelial thickness
In order to identify sections at comparable axial levels in different embryos, the optic 
vesicles were used as a morphological landmark. The most anterior section that showed 
the optic vesicle was labelled ‘a’. All the remaining sections between section ‘a’ and the 
most anterior point of the embryo were counted, the section positioned a quarter of the 
distance between the last section and section ‘a’ was then labelled ‘b’ (Figure 4.7 A). 
These sections were photographed using a digital camera attached to a Zeiss Axiophot 2 
microscope and the images were imported into Adobe Photoshop v6.0 where all further 
analysis was carried out.
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Figure 4.7 Quantitative analysis of transverse sections, stained with haematoxylin 
and eosin, through the cranial region of methionine, ethionine, cycloleucine and 
PBS-treated embryos
The analysis of transverse sections through the cranial region of treated or control 
embryos was carried out at the level of the optic vesicles (A, dotted white line labelled 
a) and 25% of the distance between the most anterior point of the embryo and the optic 
vesicles (A, dotted white line labelled b). Neuroepithelial thickness measurements were 
made on sections a (C) and b (B). On section b, measurements were taken 25% and 
75% along the length of both sides of the neuroepithelium, (B, black lines). In the 
sections labelled a (C), measurements were taken level with the front of the optic 
vesicles (OV) in the forebrain (FB) neuroepithelium (C, black lines) and half way along 
the neuroepithelium of the hindbrain (HB) (C, black lines). The cranial mesenchymal 
cell density was measured on sections a (C) and a+2 (D). Cells were counted in boxes 
of specific size and position on the section, in a central region (D, black arrow) and two 
lateral areas (D, black arrowheads). Scale bars represent 200 pm.
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The thickness of the neuroepithelium was measured in sections ‘a’ and ‘b \  In section 
‘b’ the apico-basal thickness of the neuroepithelium was measured at 25% and 75% of 
the total dorso-ventral length of the neuroepithelium (Figure 4.7B). The mean of the 
four measurements (Table 4.5) for each embryo was used in the final analysis. In 
section ‘a’ measurements were taken half way along the length of the neuroepithelium 
on each side of the hindbrain (Figure 4.7C) and at the level of the front of the optic 
vesicles in the forebrain neuroepithelium (Figure 4.7C). There were statistically 
significant differences between the hindbrain and forebrain measurements in one of the 
treatment groups (Table 4.4). Therefore, comparisons between treatment groups were 
carried out separately for both areas of the neural tube. The mean of the two 
measurements of the hindbrain or forebrain neuroepithelium (Table 4.5) was used in the 
final analysis. Analysis was performed ‘blind’ to embryo treatment
4.2.4.2 Neuroepithelial thickness in treated embryos compared to control 
embryos
Sections at the level of the anterior limit of the optic vesicle contain both forebrain 
neuroepithelium and hindbrain neuroepithelium (Figure 4.7C). Measurements were 
made on both regions and in the majority of the treatment groups the forebrain 
neuroepithelium was slightly thicker than the hindbrain neuroepithelium. This was not 
the case in cycloleucine treated embryos, in which the hindbrain neuroepithelium was 
thicker in both the exencephalic and normal embryos (Table 4.4). The differences 
between the forebrain and hindbrain measurements within each treatment group were 
not large enough to be statistically significant, with the exception of the ethionine- 
treated embryos that completed cranial neural tube closure (Table 4.4). In these
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Treatment/
phenotype
No. of 
embryos
No. of 
measurements
HB mean (pm) 
± SEM
FB mean (pm) 
± SEM
PBS-C 6 10 34.9 ±1.0 36.5 ±1.0
M-C 6 10 37.2 ±2.0 38.0 ±3.0
M -0 4 8 40.4 ± 2.0 44.6 ± 2.0
E-C 3 6 27.0 ±2.0* 38.6 ±1.0*
E-0 5 8 35.2 ±4.0 40.2 ±4.0
C-C 3 6 42.7 ± 2.0 41.6 ±3.0
C-0 5 10 41.0 ±1.0 40.5 ± 5.0
Table 4.4 Comparison of the apical-basal thickness of the hindbrain and forebrain 
neuroepithelium in cultured embryos.
The number of embryos studied in each treatment group is stated with the number of 
actual measurements recorded. Some measurements could not be made, due to damaged 
sections. * indicates statistical differences between hindbrain (HB) and forebrain (FB) 
measurements identified by t-test (p<0.05).
Treatment abbreviations: PBS, PBS-treated embryos; M, methionine-treated embryos; 
E, ethionine-treated embryos; C, cycloleucine-treated embryos.
Phenotype abbreviations: C, embryos that completed cranial neural tube closure; O, 
embryos that failed to complete cranial neural tube closure.
embryos, the forebrain neuroepithelium was significantly thicker than the hindbrain 
neuroepithelium (Table 4.4). Comparisons between treatment groups were therefore 
carried out separately on both the forebrain neuroepithelium and the hindbrain 
neuroepithelium.
There are no differences in neuroepithelial thickness between methionine or 
cycloleucine-treated and control embryos. (Table 4.5, Figure 4.8). Ethionine-treatment 
results in reduced thickness of the cranial neuroepithelium in the midbrain compared to
Treatment/
phenotype
Number
of
embryos
section ‘a’ FB section ‘a’ HB section ‘b’ MB
n mean neuroepithelial 
thickness (pm) ± SEM
n mean neuroepithelial 
thickness (pm) ± SEM
n mean neuroepithelial 
thickness (pm) ± SEM
PBS-C 6 10 36.5 ± 1.0 10 34.1 ± 1.0 24 49.6 ± 1.0
M-C 6 10 38.0 ±3.0 10 37.2 ± 2.0 24 45.9 ±2.0
M-O 4 8 44.6+1.0 8 40.4 ± 1.0 16 51.1 ±1.0
E-C 3 5 38.6 ±2.0 6 27.0 ± 2.0 12 39.2 ±1.0*
E-0 5 10 40.2 ± 4.0 8 35.2 ±4.0 10 41.3 ±1.0*
C-C 5 10 41.6 ±3.0 9 42.7 ± 2.0 17 50.6 ±2.0
C-O 5 10 40.5 ± 2.0 10 41.0 ± 1.0 10 43.6 ±2.0
Table 4.5 Neuroepithelial thickness measurements in cranial sections after whole embryo culture with PBS, 5 mM methionine, 5 
mM ethionine or 15 mM cycloleucine.
The number of embryos studied in each treatment group is stated with the number of actual measurements recorded (n). Some 
measurements could not be made, due to damaged sections. Section ‘a’ and ‘b’ and positions of measurements are as described in Section
4.2.4.1. * indicates neuroepithelial thickness that statistically differs (p<0.001) from that of PBS control embryos, tested by one-way 
ANOVA for each treatment group, followed by TUKEY test for pair-wise comparisons.
Abbreviations: FB, forebrain; HB, hindbrain; MB, midbrain. Treatment abbreviations: PBS, PBS-treated embryos; M, methionine-treated 
embryos; E, ethionine-treated embryos; C, cycloleucine-treated embryos. Phenotype abbreviations: C, embryos that completed cranial 
neural tube closure; O, embryos that failed to complete cranial neural tube closure.
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Figure 4.8 Measurement of the width of the neuroepithelium in embryos after 24 hours culture in the presence of PBS, S mM 
methionine, S mM ethionine or 15 mM cycloleucine.
Data is presented as mean ± SEM. * indicates significant variation from PBS-treated control embryos that completed closure of the cranial 
neural tube (p<0.001 tested by one-way ANOVA for each treatment group, followed by TUKEY test for pair-wise comparisons). Sections 
‘a’ and ‘b’ and measurement positions are as described in Section 4.2.4.1.
Abbreviations, FB, forebrain neuroepithelium; HB, hindbrain neuroepithelium; MB, midbrain neuroepithelium. Treatment abbreviations: 
PBS, PBS-treated embryos; M, methionine-treated embryos; E, ethionine-treated embryos; C, cycloleucine-treated embryos. Phenotype 
abbreviations: C, embryos that completed cranial neural tube closure; O, embryos that failed to complete cranial neural tube closure.
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PBS-treated embryos irrespective of whether the neural tube has completed closure or 
not (Table 4.5, Figure 4.8). These observations suggests that ethionine-treatment has an 
effect on the thickness of the neuroepithelium, but that this is unlikely to be the cause of 
cranial NTD as this difference is seen in ethionine-treated embryos that complete cranial 
neural tube closure.
4.2A .3 Quantitative analysis of mesenchymal cell density in transverse
sections through the cranial region of cultured embryos 
In order to identify sections at comparable levels in different embryos, the optic vesicles 
were used as a morphological landmark. The most anterior section that included the 
optic vesicle was labelled ‘a’ (as in Section 4.2.4.1). The second section posterior to 
section ‘a’ was labelled ‘a+2’ (Figure 4.7 A). Consecutive sections were not used, to 
ensure the same cell was not counted twice, in both sections. These sections were 
photographed using a digital camera attached to a Zeiss Axiophot 2 microscope and the 
images were imported into Adobe Photoshop v6.0 where all further analysis was carried 
out.
The morphology of transverse sections through the cranial region of embryos at level 
‘a’ at this developmental stage gives useful landmarks for comparable counting between 
embryos. These are not present in more anterior sections as the amount of mesenchyme 
decreases. Three regions within each section were analysed, a central region and two 
lateral regions. The number of cells within a certain area was counted and the value was 
normalised to the number of cells/mm . Cells overlapping the area boundaries were only 
counted on two sides (the top and right hand side of the box) to provide uniform
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analysis and avoid over-estimation of cell numbers. The central area was defined by a 
box, 8.5% of the section width by 33.3% of the section width, placed immediately under 
the floorplate of the forebrain neural tube. The lateral areas were defined by boxes, 
8.5% of the section width by 16.7% of the section width, placed laterally in line with the 
central area adjacent to the surface ectoderm (Figure 4.7D). Data from both sections (‘a’ 
and ‘a+2’) were combined to give one value (the mean of four measurements, Table 
4.6) for the lateral mesenchyme density in each embryo and one value (the mean of two 
measurements, Table 4.6) for the central mesenchyme density in each embryo. Analysis 
was performed ‘blind’ to embryo treatment.
4.2.4.4 Cranial mesenchyme density in treated and control embryos
In all of the treatment groups, the mesenchyme density in lateral regions was much 
higher than the density in the central region and data for the two regions were therefore 
analysed separately. In the central and lateral regions, ethionine-treated embryos that 
failed to complete cranial neural tube closure had a significantly reduced mesenchyme 
density compared to PBS control embryos or ethionine-treated embryos that had 
completed cranial neural tube closure (Table 4.6, Figure 4.9). There was also a 
significant reduction in the lateral mesenchyme density of methionine-treated embryos 
that failed to complete cranial neural tube closure when compared to PBS-treated and 
methionine-treated embryos in which the cranial neural tube had closed (Table 4.6, 
Figure 4.9). The observed reduction in central mesenchyme density of methionine- 
treated embryos compared to control embryos does not reach a statistically significant 
level. The observed reduction in mesenchyme density does not appear to be an effect of 
failure to close the cranial neural folds, as exencephalic cycloleucine-treated embryos
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did not exhibit reduced lateral or central mesenchyme density compared to control 
embryos (Table 4.6, Figure 4.9).
Treatment/
phenotype
No. of 
embryos
Lateral boxes Central boxes
n Mean cells/mm2 
(±SEM)
n Mean cells/mm2 
(+SEM)
PBS-C 6 24 7621.3 ±344.5 12 3055.9 ±200.4
M-C 6 24 7143.9 ±437.7 12 3120.3 ±212.1
M -0 4 16 4492.4 ± 424.0* 8 2115.9 ±364.5
E-C 3 12 7913.4 ±415.7 6 3592.0 ± 260.9
E-0 5 20 3934.2 ± 639.7* 9 1499.1 ±265.2*
C-C 5 20 6480.5 ± 488.8 6 3947.5 ± 128.7
C-0 5 18 6937.6 ± 365.5 8 3805.9 ±157.0
Table 4.6 Cranial mesenchyme density measurements in sections after whole 
embryo culture with PBS, 5 mM methionine, 5 mM ethionine or 15 mM 
cycloleucine.
Measurement positions are as described in section 4.2.4.1., some measurements could 
not be made, due to damaged sections. The mean mesenchyme density for each 
treatment group is shown as mean cells/mm2 ± SEM. * indicates density that statistically 
differs (p<0.001) from the PBS control embryos and morphologically different embryos 
exposed to the same treatment (M-0 compared to M-C and E-0 compared to E-C). 
Statistical differences were tested by one-way ANOVA for each treatment group, 
followed by TUKEY test for pair-wise comparisons.
Abbreviations: n, number of measurements; Treatment abbreviations: PBS, PBS-treated 
embryos; M, methionine-treated embryos; E, ethionine-treated embryos; C, 
cycloleucine-treated embryos. Phenotype abbreviations: C, embryos that completed 
cranial neural tube closure; O, embryos that failed to complete cranial neural tube 
closure.
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Figure 4.9 Mesenchyme density in the cranial region of embryos after 24 hours in culture in the presence of PBS, 5 mM 
methionine, 5 mM ethionine or 15 mM cycloleucine.
Data are presented as mean ± SEM. * indicates a significant variation (p<0.001) from PBS control embryos and morphologically different 
embryos exposed to the same treatment (M-O compared to M-C and E-0 compared to E-C). Statistical differences were tested by one-way 
ANOVA for each treatment group, followed by TUKEY test for pair-wise comparisons. Measurement positions are as described in section
4.2.4.1. Treatment abbreviations: PBS, PBS-treated embryos; M, methionine-treated embryos; E, ethionine-treated embryos; C, 
cycloleucine-treated embryos. Phenotype abbreviations: C, embryos that completed cranial neural tube closure; O, embryos that failed to 
complete cranial neural tube closure.
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4.2.5 Whole mount TUNEL analysis of methionine and ethionine- 
treated embryos
To investigate the cause of the decreased cranial mesenchyme density observed in 
affected methionine and ethionine-treated embryos, whole mount TUNEL was carried 
out on embryos after culture. Cells undergoing apoptosis were labelled in order to 
identify any gross differences in apoptosis levels between treated and control embryos.
TUNEL labelled cells were observed in the cranial mesenchyme of PBS and treated 
embryos. A cluster of labelled cells was observed above the first branchial arch and 
probably corresponds to cell death in migrating neural crest cells (Mirkes et a l 2001) 
(Figure 4.10 A,C,E black arrows). There were a few TUNEL-positive cells scattered 
throughout the cranial mesenchyme of all treated embryos with a condensation of 
labelled cells on the otic vesicle (Figure 4.10 A,C,E *). The number of labelled cells 
varied slightly with each embryo but there were no obvious gross differences in the area 
or relative number of labelled cells between the treatment groups.
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Figure 4.10 Whole mount TUNEL on methionine, ethionine and PBS-treated CD-I 
embryos.
Whole mount TUNEL was carried out on CD1 embryos after 24 hours culture in the 
presence of PBS (A,B), 5 mM methionine (C,D) or 5 mM ethionine (E,F). Lateral 
(A,C,E) and corresponding dorsal (B,D,F) views are shown. Some methionine and 
ethionine-treated embryos developed exencephaly (regions of open neural tube are 
flanked by white arrowheads; C,E). Labelled cells appear purple/blue (black arrows 
B,D,F) and were observed throughout the cranial mesenchyme (A,C,E) and 
neuroepithelium (B,D,F) of all embryos studied. Heavy staining was observed above the 
proximal region of the first branchial arch (black arrows in A,C,E) and at the edge of 
the otic vesicle (* in A,C,E) of all embryos. No gross differences were detected 
between embryos from different treatment groups. Scale bars represent 200 pm.
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4.2.6 Quantitative analysis of proliferation and cell death in 
methionine and ethionine-treated embryos
No obvious differences were detected in levels of apoptosis in PBS, methionine or 
ethionine-treated embryos by whole mount TUNEL. However, the embryos that 
underwent whole mount TUNEL had all reached a developmental stage (16 somites) 
when neural tube closure should have been completed. The statistically significant 
reductions in the density of the cranial mesenchyme in ethionine and methionine- 
exposed embryos at this same developmental stage, suggested that the causes of cell 
number decrease could have acted earlier, possibly during neural tube closure. 
Therefore, analysis of apoptosis levels should also be carried out during this earlier 
developmental period. An increase in the apoptosis rate in the cranial region of 
methionine or ethionine-treated embryos could be postulated to account for a reduced 
cell density in this region at a later stage. Alternatively a reduction in the cell 
proliferation rate could also have this effect. Therefore, in order to investigate the 
possible mechanisms that cause the reduced cranial mesenchyme cell density in 
methionine and ethionine-treated embryos, the levels of apoptosis and proliferation 
were investigated in 12-15 somite stage embryos after culture in the presence of PBS, 
5 mM methionine, 5 mM ethionine or 15 mM cycloleucine. At this stage, neural tube 
closure is in progress, and not complete in any of the embryos. Hence, factors that 
inhibit closure might be detectable at this stage.
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4.2.6.1 Method for quantitative immunohistochemical analysis of 
proliferation and apoptosis in methionine, ethionine and cycloleucine- 
treated and control embryos 
E8.5 embryos were cultured until just before completion of cranial neural tube closure 
(for 16 hours, from the 4-6 to 12-15 somite stages) in the presence of methionine, 
ethionine, cycloleucine or PBS as a vehicle control. Transverse sections were taken 
through the cranial region and alternate pairs were placed on separate slides for 
immunohistochemical analysis of proliferation (anti-phosphorylated histone H3) and 
apoptosis (anti-activated caspase 3) as described in Section 2.7. The latter approach was 
preferred to whole mount TUNEL to allow quantitative analysis.
As in previous analysis, the optic vesicles were used as a landmark to ensure 
comparable sections were used in each embryo. The most anterior section showing optic 
vesicles was labelled ‘c \  One section from the next two pairs both rostrally (‘b’ and ‘a’) 
and caudally (‘d’ and ‘e’) were also used for further analysis (Figure 4.11). Labelled 
cells in the mesenchyme of each section were counted, and the total number of cells in 
the mesenchyme of each section was counted. Initial studies showed that the total cell 
number and labelling indices in section ‘c’ were very similar to the mean total number 
and indices for each section in an embryo (Table 4.7, Table 4.8). Therefore, for each 
embryo total cell counts were only carried out on section ‘c’ and this number was used 
to calculate the labelling indices. Within each treatment group there were no significant 
differences between developmental stages (12, 13, 14 or 15 somite stage embryos, 
tested by one-way ANOVA). Therefore, all the data for each treatment group were 
combined for the final analysis.
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Figure 4.11 Sections used to calculate labelling indices for apoptosis and 
proliferation in the cranial mesenchyme of embryos after 16 hours culture in the 
presence of methionine, ethionine, cycloleucine or PBS.
After 16 hours in whole embryo culture alternate pairs of transverse sections were taken 
through the cranial region of CD1 embryos and underwent immunohistochemistry with 
an antibody against phosphorylated histone H3 (A-E). Sections used to quantity levels 
of proliferation are shown in panels A-E. Equivalent sections were used for 
quantification of apoptosis after immunohistochemistry with anti-activated caspase-3 
antibodies. The anterior-most section showing the optic vesicles (C and dotted line in F) 
was used as a landmark to ensure comparisons between embryos were carried out at the 
same axial level. Additional sections used were the 4th and 8th sections anterior (B and A 
respectively) and posterior (D and E respectively) to section C. Labelled cells 
(arrowheads in D) were counted in all five sections and the total number of cells in 
section C was used to give an index of labelled cells for each embryo. F, shows a 
typical PBS-treated embryo at 12 somite stage. Scale bars represent 100 pm (A-E) or 
200 pm (F). Abbreviations; CM, cranial mesenchyme; FB, presumptive forebrain; HB, 
presumptive hindbrain; OV, optic vesicles; N, rostral extremity of notochord
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Table 4.7 Initial counting strategy for anti-phosphorylated histone H3 labelled cells 
in the cranial mesenchyme in sections through PBS-treated embryos.
Four PBS-treated embryos were used to establish an appropriate counting strategy to 
determine the percentage of labelled cells in the cranial mesenchyme of treated embryos 
after culture. The total number of cells in each section was counted, as was the number 
of labelled cells. The labelling index for each section was calculated by dividing the 
number of labelled cells by the total cell number and multiplying by 100. The mean 
number of total cells, labelled cells and labelling indices are shown for each embryo ± 
SEM. The final column (Averaged data) indicates the labelling index when the mean 
number of labelled cells from all five sections were divided by the total number of cells 
in section ‘c’ and multiplied by 100. For each embryo the labelling index calculated in 
this fashion was within 5 % of the labelling index in each section, and therefore further 
indices were calculated using the total cell number from section ‘c \
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Embryo
L2305
Section position mean ± SEM Averaged
data
a b c d e
Total cell 
number
544 671 782 924 965 777.2 ± 78.3 782
No. of labelled 
cells
21 18 33 24 38 26.8 ±3.8 26.8
Labelling
index
3.9 2.7 4.2 2.6 3.9 3.4 ±0.3 3.4
Embryo
L2301
Section position mean ± SEM Averaged
dataa b c d e
Total cell 
number
467 625 565 629 709 599.0 ± 40.2 565
No. of labelled 
cells
16 26 35 11 25 22.6 ± 4.2 22.6
Labelling
index
3.4 4.2 6.2 1.7 3.5 3.8 ±0.7 4.0
Embryo
L2194
Section position mean ± SEM Averaged
data
a b c d e
Total cell 
number
305 343 439 535 603 445.0 ± 56.2 439
No. of labelled 
cells
45 37 44 35 51 42.4 ± 2.9 42.4
Labelling
index
14.8 10.8 10.0 6.5 8.5 10.1 ±1.4 9.6
Embryo
L2196
Section position mean ± SEM Averaged
dataa b c d e
Total cell 
number
82 199 216 289 231 198.4 ±33.3 216
No. of labelled 
cells
10 20 20 32 39 24.2 ±5.1 24.2
Labelling
index
12.2 10.1 9.3 11.1 16.9 11.9 ± 1.3 11.2
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Table 4.8 Initial counting strategy for anti-activated caspase 3 labelled cells in the 
cranial mesenchyme in sections through PBS-treated embryos.
Four PBS-treated embryos were used to establish an appropriate counting strategy to 
determine the percentage of labelled cells in the cranial mesenchyme of treated embryos 
after culture in a similar manner to that described previously (Table 4.7). The mean 
number of total cells, labelled cells and the labelling indices are shown for each embryo 
± SEM. The final column shows the Average data (see Table 4.7) which for each 
embryo was within 5 % of the mean labelling index in each section, and therefore 
further indices were calculated using the total cell number from section ‘c \
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Embryo
L2705
Section position mean ± SEM Averaged
data
a b c d e
Total cell 
number
231 303 284 353 362 306.6 ±23.9 284
No. of labelled 
cells
2 10 2 6 18 7.6 ±3.0 7.6
Labelling
index
0.9 3.3 0.7 1.7 5.0 2.3 ± 0.8 2.7
Embryo
L2706
Section position mean ± SEM Averaged
dataa b c d e
Total cell 
number
395 424 432 405 364 404.0 ± 12.0 432 |
No. of labelled 
cells
7 3 6 5 4 5.0 ±0.7 5.0
Labelling
index
1.8 0.7 1.4 1.2 1.1 1.2 ±0.2 1.2
Embryo
L2194
Section position mean ± SEM Averaged
dataa b c d e
Total cell 
number
212 355 443 437 443 378.0 ± 44.7 443
No. of labelled 
cells
2 9 3 2 2 3.6 ± 1.4 3.6
Labelling
index
0.9 2.5 0.7 0.5 0.5 1.0 ±0.4 0.8
Embryo
L2196
Section position mean ± SEM Averaged
dataa b c d e
Total cell 
number
128 202 296 295 286 241.4 ±33.4 296
No. of labelled 
cells
1 1 3 4 3 2.4 ±0.6 2.4
Labelling
index
0.8 0.5 1.0 1.4 1.0 0.9 ± 0.2 0.8
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4.2.6.2 Analysis of proliferation in the cranial mesenchyme of methionine,
ethionine and cycloleucine-treated embryos 
There were no statistically significant differences between the proliferation levels in any 
of the treatment groups. However, there was a non-significant decrease in the 
percentage of phosphorylated histone H3 positive cells in methionine-exposed embryos 
compared to PBS-exposed control embryos (Table 4.9, Figure 4.12). In these studies the 
embryos were analysed at a developmental stage before NTD are apparent, such that 
embryos could not be separated according to whether they would develop NTD or 
complete cranial neural tube closure. This might have lead to masking of an effect in the 
potentially exencephalic embryos by those developing normally. However, there were 
similar data ranges within treatment groups when compared to the control group, where 
all embryos are expected to complete cranial neural tube closure (Figure 4.12). These 
data suggest that the reduced cell density in methionine and ethionine-treated embryos 
is unlikely to arise from reduced cell proliferation and may be secondary to failure of 
the neural tube to close.
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Treatment No. of 
somites
No. of 
embryos
n Index ± SEM
12 3 15 7.76 ±1.35
PBS 13 3 14 8.73 ±1.73
14 5 25 8.10 ±0.73
15 6 29 7.25 ±1.35
12 7 31 5.96 ± 0.43
5 mM 13 1 5 5.40 ± 0.00
Methionine 14 3 14 5.70 ±1.72
15 4 17 8.83 ± 0.74
12 1 5 6.20 ± 0.00
5 mM 13 2 10 6.60 ±0.10
Ethionine 14 3 15 8.63 ± 0.20
15 3 15 7.63 ± 0.54
12 1 5 9.60 ± 0.00
15 mM 13 2 9 6.60 ± 1.20
Cycloleucine 14 2 10 9.60 ± 0.80
15 4 20 7.18 ±0.45
Table 4.9 Cranial mesenchyme proliferation in embryos after culture with PBS, 
5 mM methionine, 5 mM ethionine or 15 mM cycloleucine
Embryos at the 12-15 somite-stages of cranial neural tube closure were analysed for 
each treatment group. The number of embryos studied in each treatment group at each 
somite stage is stated with the number of actual measurements recorded (n). Some 
measurements could not be made, due to damaged sections. There were no statistically 
significant differences between the mean indices of each embryo group between or 
within the treatment groups, as tested by One-way ANOVA.
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Figure 4.12 Cranial mesenchyme proliferation in embryos at the stage of cranial 
neural tube closure after culture with PBS, 5 mM methionine, 5 mM ethionine or 
15 mM cycloleucine
Data is presented as mean ± SEM. Embryos at the 12-15 somite-stages of development 
were pooled together for each treatment group. The number o f embryos analysed in 
each treatment group is shown within each bar. Abbreviations, Meth; 5 mM methionine, 
Eth; 5 mM ethionine, Cyclo; 15 mM cycloleucine
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4.2.6.3 Apoptosis levels in the cranial mesenchyme of methionine, 
ethionine and cycloleucine-treated embryos compared to control 
embryos
Although the whole mount TUNEL experiments did not suggest there were increased 
apoptosis levels, it is possible that the reduced density in the cranial mesenchyme of 
methionine and ethionine-treated embryos at E9.5 may be due to subtle increases in 
apoptosis levels as opposed to decreased proliferation. The number of cells undergoing 
apoptosis during neural tube closure were analysed by immunohistochemistry with anti­
activated caspase 3 antibodies (Section 4.2.6.1).
The level of apoptosis in the cranial mesenchyme of ethionine-exposed embryos is very 
similar to that of PBS-exposed embryos. The methionine and cycloleucine treatment 
groups have a higher index of cells labelled for activated caspase 3 than the control 
group, but these changes are not statistically significant (Table 4.10, Figure 4.13). These 
experiments cannot distinguish between affected and unaffected embryos in the 
treatment groups, leaving the possibility of ‘normal’ embryos masking an effect present 
in potential exencephalic embryos.
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Treatment No. of 
somites
No. of 
embryos
n Index ± SEM
12 3 15 2.6311.09
PBS 13 4 19 3.28 ± 2.48
14 4 19 8.1313.31
15 3 15 2.1010.47
12 4 20 5.5312.38
5 mM 13 1 5 1.4010.00
Methionine 14 3 15 7.93 12.07
15 2 9 8.05 1 0.85
12 0 0 0.0010.00
5 mM 13 2 9 5.7512.75
Ethionine 14 1 5 1.6010.00
15 5 25 4.1811.53
12 1 5 2.6010.00
15 mM 13 1 4 2.4010.00
Cycloleucine 14 1 5 9.1010.00
15 3 14 9.5312.16
Table 4.10 Cranial mesenchyme apoptosis in embryos after culture with PBS, 
5 mM methionine, 5 mM ethionine or 15 mM cycloleucine
Embryos at the somite-stages of cranial neural tube closure were analysed for each 
treatment group. The number of embryos studied in each treatment group at each somite 
stage is stated with the number of actual measurements recorded (n). Some 
measurements could not be made, due to damaged sections. There were no statistically 
significant differences between the mean indices of each somite-stage embryo group 
between or within the treatment groups, as tested by One-way ANOVA.
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10
PBS Meth Eth
Treatment group
Cyclo
Figure 4.13 Cranial mesenchyme apoptosis levels in embryos at the time of cranial 
neural tube closure after culture with PBS, 5 mM methionine, 5 mM ethionine or 
15 mM cycloleucine
Data is presented as mean ± SEM. Embryos at the 12-15 somite-stages of development 
were pooled together for each treatment group. The number o f embryos measured in 
each treatment group is shown within each bar. Abbreviations, Meth, 5 mM methionine; 
Eth, 5 mM ethionine; Cyclo, 15 mM cycloleucine.
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4.2.7 Can co-treatment with folic acid prevent methionine or 
ethionine-induced NTD?
In this study, disruption of the methylation cycle causes NTD. Folic acid prevents many 
cases of NTD in humans and folic acid supplementation would be predicted to drive the 
flux through both the folate and methylation cycles. Therefore, it was of interest to 
determine whether folic acid can prevent NTD induced by methionine or ethionine 
treatment. Embryos were cultured for 24 hours in the presence of 5 mM methionine, 5 
mM ethionine or PBS as a vehicle control, as described previously (Section 4.2). In 
addition, 500 pM folic acid was also added to the culture serum of some treatment 
groups at the start of the culture period. This concentration of folic acid was shown to 
effectively prevent NTD in the Splotch NTD mouse model in whole embryo culture 
(Fleming et al., 1998). Embryos were analysed as previously described (Section 4.2)
Culture of embryos in the presence of 5 mM methionine or 5 mM ethionine did not 
adversely affect the viability, growth or health of embryos (Table 4.11, Table 4.12) 
consistent with the findings described in Section 4.2.1. Embryos cultured with 
methionine alone developed cranial NTD in a significant proportion of embryos (37%), 
similar to my previous results (40%, Section 4.2.1.1). As before, NTD were also evident 
in the ethionine-exposed embryos with an incidence of 57%, compared to 61.9% 
previously (Section 4.2.1.2). Culture in the presence of methionine or ethionine and 
folic acid did not affect the development, health or viability of the embryos as measured 
by somite number, yolk sac circulation and heart beat respectively. There were no 
statistically significant differences between the treatment groups and control embryos in 
any of the parameters measured at the end of the culture period (Table 4.11, Table
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4.12). Moreover, there was no reduction in the number of embryos developing cranial 
NTD in the presence of methionine or ethionine with folic acid compared to those 
without folic acid (Table 4.11, Table 4.12). In contrast, there were slight (but not 
significant) increases in the percentage of embryos developing NTD in the additional 
presence of folic acid, (methionine alone 37%, plus folic acid 48%) (ethionine alone 
57.1%, plus folic acid 65.4%). These results suggest that folic acid does not have a 
preventative effect on the production of cranial NTD by excess methionine or ethionine.
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Treatment No.
embryos
No. live 
embryos
Yolk Sac 
circulation
No. failed 
axial 
rotation 
(%)
No. cranial 
open 
neural tube 
(%)
No. cranial 
neural tube 
defects (%)
Somite
number
Crown- 
rump length 
(mm)
PBS 13 13 2.92 ± 0.08 0 (0.0) 0 (0.0) 0 (0.0) 20.0 ± 0.52 2.41 ± 0.08
5 mM 
Methionine
27 27 2.89 ± 0.08 0 (0.0) 10(37.0)$ 10(37.0)$ 20.3 ± 0.32 2.43 ± 0.05
5 mM 
Methionine 
and 500 pM 
folic acid
25 23 2.60 ±0.18$ 0 (0.0) 12 (48.0)$ 12 (48.0)$ 20.3 ± 0.45 2.40 ± 0.06
Table 4.11 Growth and development of mouse embryos cultured in the presence of methionine with or without folic acid
Dead embryos were identified by an absence of yolk sac circulation and were excluded from analysis. Cranial neural tube defects are 
defined as failure to complete cranial neural tube closure in live embryos that have 16 or more somites. Values for yolk sac circulation, 
somite number and crown-rump length are given as mean ± SEM. $ indicates significant variation from control embryos (p<0.05, tested by 
one-way ANOVA). Data for failed axial rotation and open cranial neural tube are presented as number of embryos, with percentage of total 
embryos in parentheses. Data for cranial neural tube defects are presented as number of embryos, with percentage of embryos with 16 or 
more somites in parentheses. $ indicates significant variation from control embryos (p<0.05, tested by z-test). There were no significant 
differences between values obtained for embryos cultured with methionine alone or with methionine and folic acid.
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Treatment No.
embryos
No. live 
embryos
Yolk Sac 
circulation
No. failed 
axial 
rotation 
(%)
No. cranial 
open 
neural tube
(%)
No. cranial 
neural tube 
defects (%)
Somite
number
Crown- 
rump length 
(mm)
PBS 6 6 3.00 ±0.00 0 (0.0) 0 (0.0) 0 (0.0) 20.2 ± 0.60 2.40 ± 0.05
5 mM 
Ethionine 23 23 2.96 ±0.04 3 (13.4) 14 (60.9)J 12(57.1) 19.6 ±0.48 2.47 ± 0.06
5 mM 
Ethionine 
and 500 juM 
folic acid
26 26 2.89 ± 0.08 2 (7.7) 17 (65.4)J 17 (65.4)J 20.8 ± 0.35 2.48 ± 0.06
Table 4.12 Growth and development of mouse embryos cultured in the presence of ethionine with or without folic acid
Cranial neural tube defects are defined as failure to complete cranial neural tube closure in embryos that have 16 or more somites. Values 
for yolk sac circulation, somite number and crown-rump length are given as mean ± SEM. There were no significant differences between 
the values (tested by one-way ANOVA). Data for failed axial rotation and open cranial neural tube are presented as number of embryos, 
with percentage of total embryos in parentheses. Data for cranial neural tube defects are presented as number of embryos, with percentage 
of embryos with 16 or more somites in parentheses J indicates significant variation from control embryos (p<0.05, tested by z-test). There 
were no significant differences between values obtained for embryos cultured with ethionine alone or with ethionine and folic acid.
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4.3 DISCUSSION
In this chapter, treatment of non-mutant embryos throughout cranial neural tube closure 
with methionine, ethionine or cycloleucine resulted in the development of isolated 
NTD. These compounds are predicted to disrupt of perturb the methylation cycle 
suggesting that this metabolic cycle is essential for closure of the cranial neural tube. 
Inhibition of the methylation cycle, by SAH-hydrolase or MAT inhibitors, has also been 
shown to cause a delay in closure of the anterior neuropore in cultured chick embryos, 
supporting a role for the methylation cycle in cranial neural tube closure (Afman et al., 
2005).
The process of cranial neural tube closure appears to be very sensitive to disruption in 
mouse, being susceptible to disruption by many teratogens (Copp et al., 1990) and 
numerous single gene mutations. Thus the majority of mouse NTD models exhibit 
exencephaly (Juriloff et al., 2000;Copp et al., 2003b). In this study cranial neural tube 
defects were observed in the absence of growth retardation, delayed developmental 
progress or any other gross morphological defects suggesting that exposure to 
methionine, ethionine and cycloleucine has specific effects on processes required for 
cranial neural tube closure. Thus, the development of NTD in treated embryos does not 
appear to be secondary to other teratogenic effects of these treatments. The extent of the 
open region of the cranial neural folds differs between the treatment groups suggesting 
that different mechanisms may be involved in the production of exencephaly for each 
treatment. In addition, the morphology of the cranial region in exencephalic embryos 
differs between methionine, ethionine and cycloleucine-treated embryos.
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Although initial observations suggested that both methionine and ethionine-treated 
embryos exhibit thinner neuroepithelium compared to control embryos, subsequent 
quantitative analysis showed that the decrease was statistically significant only in 
ethionine-treated embryos. In addition, this difference was present in the midbrain of all 
ethionine-treated embryos irrespective of whether or not the cranial neural tube 
completed closure, suggesting that the reduced thickness of neuroepithelium in 
ethionine-exposed embryos was not instrumental in failure of closure. Therefore, the 
differences in the thickness of neuroepithelium in cultured embryos was not 
investigated any further in this study.
Cell aggregates were observed in a subset of methionine-treated embryos. The type of 
cells that make up the aggregates was not investigated further in this study. Further 
work using cell-specific markers could determine the composition of the cell aggregates 
and may suggest possible roles in the production of NTD. For example, it is possible 
that the aggregates consist of neural crest cells that have delaminated from the neural 
folds but became arrested during their migration. The role of the aggregates in the 
production of methionine-induced NTD is unclear.
Exencephalic methionine and ethionine-exposed embryos exhibited reduced density of 
the cranial mesenchyme that was not observed in exencephalic, cycloleucine-exposed 
embryos or embryos that completed cranial neural tube closure in any treatment group. 
The observed decrease in cranial mesenchyme density in methionine and ethionine- 
treated embryos could potentially be secondary to the NTD as there were no differences 
in the cranial mesenchyme density of methionine or ethionine-treated embryos that
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completed neural tube closure. However, embryos-exposed to cycloleucine that failed to 
complete cranial neural tube closure did not exhibit a reduced cranial mesenchyme 
density which argues against a secondary effect and suggests a possible role in the 
development of methionine and ethionine-induced cranial NTD.
Cranial mesenchyme is believed to play a role in cranial neurulation by providing 
mechanical support for the elevation and apposition of the cranial neural folds which 
enables neural tube closure to occur (Morriss et al., 1978b) (Section 1.2.1). In support 
of this idea, disruption of the integrity of the cranial mesenchyme has been implicated in 
the development of exencephaly in some genetic mouse NTD models. For example, 
homozygous Cartl mutant embryos develop cranial neural tube defects in the midbrain 
region. Histological analysis of Cartl mutant embryos showed a reduction in cell 
number in the forebrain cranial mesenchyme during cranial neurulation, E9 (Zhao et al., 
1996). Increased levels of apoptosis in cells of the forebrain mesenchyme were detected 
in Cartl mutant embryos and are proposed to have resulted in the reduced cell density 
and subsequent cranial NTD (Zhao et a l , 1996). In addition, homozygous twist mutant 
embryos exhibit abnormal cranial mesenchyme prior to cranial neural tube closure and 
subsequently develop cranial NTD (Chen et al., 1995). Therefore, methionine and 
ethionine-treatment may induce cranial NTD in embryos by disrupting the integrity of 
the cranial mesenchyme. There is no evidence suggesting that this mechanism may be 
involved in the production of cycloleucine-induced NTD.
Methionine and ethionine treatments were initially predicted to induce NTD through 
different mechanisms. One explanation for reduced cell density following methionine or
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ethionine treatment could be a reduced rate of cellular proliferation. Both treatments 
have the potential to disrupt the SAM: SAH ratio which could affect the regulation of 
MTHFR and lead to the redistribution of folate cycle intermediates (Kutzbach and 
Stokstad, 1971). This could subsequently lead to the suppression of dTMP synthesis or 
purine production therefore inhibiting DNA synthesis and limiting proliferation. 
Alternatively methionine and/or ethionine treatment could affect the viability of cells 
within the cranial mesenchyme leading to premature cell death. In order to investigate 
these possible mechanisms the cranial mesenchyme proliferation and apoptosis levels of 
treated embryos were compared to those of control embryos.
Quantitative data of embryos during cranial neural tube closure showed that exposure to 
methionine or cycloleucine caused increased, but not statistically significant, levels of 
apoptosis compared to PBS or ethionine-treated embryos. In addition, analysis of the 
number of cells in M-phase of the cell cycle, as an indicator of proliferation rates in the 
cranial mesenchyme of cultured embryos showed reduced but not significant levels of 
proliferation in methionine-treated embryos compared to control embryos. The roles of 
proliferation and apoptosis rates in the cranial mesenchyme of methionine-treated 
embryos in the production of cranial NTD are not clear. A non-significant but apparent 
elevation in apoptosis level and slight reduction in proliferation levels in the cranial 
mesenchyme of methionine-treated embryos may together account for the subsequent 
reduced cell density. However, as the changes were not statistically significant no firm 
conclusions can be drawn.
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No differences in proliferation levels in the cranial mesenchyme of ethionine or 
cycloleucine-treated embryos were detected when compared to PBS-treated embryos. 
As there is no evidence of reduced proliferation or increased apoptosis in the 
mesenchyme of exencephalic ethionine-treated embryos, I cannot rule out the 
possibility that the reduction in cell density is a secondary effect to failure of closure of 
the neural folds. Reduced mesenchyme density has been suggested to be a secondary 
effect to exencephaly in rat embryos cultured in diluted cow serum (Coelho and Klein, 
1990). Cultured rat embryos exhibit reduced cranial mesenchyme density and cranial 
NTD, however, supplementation with methionine rescues the NTD phenotype but does 
not increase the cranial mesenchyme density suggesting that the cranial NTD are not 
caused by the reduced number of cranial mesenchyme cells (Coelho et a l , 1990).
In considering the mode of action at the biochemical level, the production of ethionine 
and cycloleucine-induced NTD are likely to involve similar mechanisms as both 
compounds inhibit SAM synthesis. Ethionine is an analogue of methionine that 
competes for MAT and is subsequently converted to SAE. SAE does not undergo any 
further metabolism, theoretically resulting in the decreased production of SAM and 
thereby limiting the supply of methyl groups for donation in the methyltransferase 
reactions. Cycloleucine is a chemical inhibitor of SAM-synthase that could also result in 
a reduction of available SAM. However, morphological analysis of ethionine and 
cycloleucine-treated embryos showed differences that may suggest different modes of 
action for the two treatments in the development of cranial NTD. SAE does not undergo 
further metabolism within the methylation cycle but has been shown to have a similar 
effect to SAM on the regulation of CBS (Miller et a l, 1994). Although CBS is not
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believed to be active in neurulation-stage embryos (VanAerts et al., 1995), these 
findings suggest SAE can be substituted for SAM in its regulatory roles and therefore, 
may affect the activity of MTHFR. Cycloleucine treatment would be unlikely to have 
this effect.
Methionine treatment was expected to act in an opposite manner to ethionine and 
cycloleucine treatment. Instead of limiting SAM production, increased methionine 
levels were expected to allow increased SAM production, possibly driving the flux 
through the methylation cycle.
Further experiments carried out in our laboratory have measured the levels of SAM and 
SAH in embryos that had been cultured for 17 hours (from E8.5 to E9) in the presence 
of 5mM methionine, 5 mM ethionine, 15 mM cycloleucine or PBS. All three treatments 
gave statistically significant reductions in the SAM:SAH ratio compared to PBS-treated 
embryos (Table 4.13). Thus, the mechanisms underlying the induction of NTD by 
ethionine, ethionine or cycloleucine treatment may all involve suppression of 
methylation reactions.
As expected, methionine-treatment results in an increase in SAM levels, whereas 
ethionine treatment results in reduced SAM levels, however, these changes are not 
statistically significant and are not primarily responsible for the changes in the 
SAM:SAH ratios. All three treatments result in elevated SAH levels compared to 
control embryos. The importance of SAM production in cell survival has led to the 
highly regulated control of SAM levels in the cell. Cells in the neurulation-stage
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Treatment
group
No.
samples
SAM (nmole/mg 
protein)
SAH (nmole/mg 
protein)
Ratio 
SAM: SAH
PBS 5 3.79 ± 0.54 0.024 ± 0.004 167 ±12.4
Methionine 5 4.40 ± 0.46 0.043 ± 0.006 104 ± 4.7*
Ethionine 5 2.67 ± 0.25 0.034 ± 0.004 79 ± 3.2*
Cycloleucine 5 3.68 ± 0.45 0.031 ±0.004 120 ± 7.5*
Table 4.13 Quantification of SAM and SAH in cultured embryos
SAM and SAH were quantified by liquid chromatography coupled to tandem mass 
spectrometry. Samples consisted of 2-4 embryos pooled from a specific treatment group 
after whole embryo culture for 17 hours in the presence of 5 mM methionine, 5 mM 
ethionine, 15 mM cycloleucine or PBS. Values were normalised to protein content and 
are expressed as mean ± SEM. * indicates significant difference from the values of 
PBS-treated controls, P<0.05 tested by one-way ANOVA followed by the TUKEY test 
for pair-wise comparisons. (K. Burren, A.J. Copp, and N.D.E. Greene, personal 
communication)
mammalian embryo express the non-liver specific MAT isoform (MAT II) and 
therefore are relatively unaffected by fluctuations in methionine availability, because of 
a negative feedback inhibition mechanism. That is, SAM inhibits MAT II at 
concentrations only slightly higher than normal SAM intracellular levels ensuring 
cellular SAM levels are relatively constant (Finkelstein, 1990). The subsequent 
clearance of SAH is dependent on the rapid removal of homocysteine and adenosine. In 
the embryo, this may be a rate-limiting step as the methionine synthase-mediated 
reaction is the only pathway present that is capable of removing homocysteine from the 
cell. Delay in the removal of homocysteine may result in a build up of SAH levels in the 
cell as SAH-hydrolase favours the formation of SAH in the presence of homocysteine
198
CHAPTER 4; The effect of disrupting the methylation cycle on cranial neural tube closure
(Finkelstein, 1998). SAH is a potent product inhibitor of methyltransferases (Zappia et 
al., 1969). Therefore, SAH-mediated inhibition of methyltransferases by the treatments 
could potentially result in global hypomethylation, which may result in disrupted gene 
expression or protein function during neurulation. The fact that all three treatments 
change the methylation ratio within the embryo and cause cranial NTD may suggest a 
role for changes in cellular methylation processes in causing the observed NTD 
phenotypes.
During DNA methylation, methyl groups are transferred from SAM to cytosine residues 
primarily located in CpG islands that are generally clustered in the promoter regions of 
genes. DNA methylation has an important role in the epigenetic control of the 
expression of some genes. Although the mechanism is unclear, it has been suggested 
that methyl-cytosine binding proteins (MeCP) bind to methylated cytosine preventing 
the binding of transcription factors and so repressing gene expression (Hendrich and 
Bird, 1998;Jones et al., 2001). Another theory suggests that MeCP-binding proteins 
recruit histone deacetylases that induce chromatin compaction and gene silencing 
(Malone et al., 2001). Changes in DNA methylation of genes involved in neural tube 
closure could potentially lead to defects in the process of neurulation. For example, in 
vivo exposure to 5-azacytidine, a cytidine analogue that is incorporated into DNA but 
cannot be methylated, causes exencephaly in mice and rat embryos (Takeuchi et al., 
1978;Takeuchi et al., 1985). Experiments carried out in our laboratory have shown that 
in vitro exposure of mice embryos to 5-azacytidine also induces cranial NTD (K. 
Burren, and N.D.E. Greene, Personal communication). In addition, mice lacking DNA
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methyltransferase 3b (Dnmt3b) develop cranial NTD (Okano et al., 1999), suggesting 
that inhibition of DNA methylation is sufficient to prevent neural tube closure.
DNA hypomethylation has been observed with elevated homocysteine levels in 
MTHFR-deficient mice (Chen et al., 2001) and in human patients suffering from 
hyperhomocysteinaemia (Ingrosso et al., 2003). Although elevated homocysteine is a 
risk factor for NTD, as described in Section 1.9, NTD have not been described in either 
of these studies. Moreover, in Chapter 3 I showed that homocysteine treatment does not 
result in cranial NTD in mouse embryos. If homocysteine teratogenesis acted through 
elevated SAH levels I would expect a similar phenotype as observed in treatments that 
do raise SAH levels within the embryo, that is methionine, ethionine and cycloleucine 
treatment. It is possible that changes in the methylation ratio and subsequent SAH- 
mediated hypomethylation is responsible for the methionine, ethionine and 
cycloleucine-induced NTD. These observations may suggest that homocysteine 
embryotoxicity is mediated through elevated levels of homocysteine per se, possibly by 
affecting yolk sac function and causing general toxicity at a dose that does not result in 
the elevation of SAH levels to a concentration that can disrupt cranial neural tube 
closure.
In addition to DNA, SAM is also the methyl donor for the methylation of proteins and 
phospholipids and it has been suggested that changes in protein methylation could affect 
cranial neural tube closure. Embryos cultured in cow serum exhibit NTD that are 
thought to be due to methionine deficiency (Coelho et al., 1989). Coelho and colleagues 
(1990) detected differences in the levels of methylated amino acids in neural tube
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proteins between methionine-supplemented cultures, in which embryos completed 
neural tube closure, and un-supplemented cultures, in which embryos developed cranial 
NTD. The reduction in methylation appears to be specific for proteins of the neural tube 
as the differences were not detected in heart proteins of the same embryos (Coelho et 
al., 1990). In microfilament associated proteins from unsupplemented-embryo neural 
tube, the reduction of the proportion of methylated amino acids suggests that defective 
microfilament contraction could be involved in the production of cranial NTD caused 
by methionine-deficiency. In support of this idea, cytoskeletal proteins: p-actin, ap- 
tubulin and neurofilament L have been identified as proteins that are methylated during 
neurulation (Moephuli et al., 1997). The localisation of p-actin and ap-tubulin to the 
basal and apical cytoplasm in neuroepithelial cells is disrupted in mouse embryos 
cultured in methionine-deficient serum (Moephuli et al., 1997). Moreover, the integrity 
of the actin cytoskeleton has been shown to be essential for normal cranial neural tube 
closure to occur (Ybot-Gonzalez et al., 1999) suggesting that this could be disrupted by 
aberrant methylation of cytoskeletal proteins.
In addition to methyltransferase-mediated reactions, SAM is required for polyamine 
synthesis. Therefore, treatments that affect the production of SAM may have an effect 
on polyamine biosynthesis. Polyamine synthesis is essential for embryo survival 
(Pendeville et al., 2001;Nishimura et al., 2002) but has not been investigated in relation 
to neural tube closure. Therefore the effects of changes in polyamine synthesis on 
cranial neural tube closure are currently unknown.
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Interestingly, concomitant treatment with folic acid did not reduce the incidence of 
methionine or ethionine-induced NTD. It is possible that the concentration of folic acid 
(500 pM) used in these experiments was not sufficient to counteract the relatively high 
concentrations of 5 mM methionine and ethionine, and that higher doses of folic acid 
might have had a protective effect. However, this dose was sufficient to prevent NTD in 
mice caused by a mutation in the Pax3 gene (Fleming et al., 1998). The results in this 
chapter therefore suggest that folic acid does not prevent NTD through rectifying 
cellular processes affected by excess methionine or ethionine. This may be because folic 
acid treatment acts to prevent NTD by stimulating the folate cycle and allowing 
increased proliferation, whereas I did not find evidence that defective proliferation is 
solely responsible for the production of methionine or ethionine-induced cranial NTD.
In this chapter, I have shown that the integrity of the methylation cycle is required for 
normal cranial neural tube closure to occur. Further work investigating changes in 
DNA/protein methylation in methionine, ethionine and cycloleucine-treated embryos 
could address the possibility that changes in cellular methylation are responsible for the 
induction of NTD by defects in the methylation cycle.
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5.1 INTRODUCTION
Mutations in the Pax3 locus in mice occur in the Splotch mutant mouse. There are six 
variants of the Splotch allele, and those that allow development to proceed beyond
2 f - fneurulation result in NTD among other defects (Section 1.10.1). The Splotch mouse 
carries a 32 base pair deletion in the paired homeodomain of the Pax3 gene, resulting in 
a truncated protein and a homozygous phenotype that includes exencephaly and/or spina 
bifida (Section 1.10.1) (Epstein et al., 1991). The Splotch NTD phenotype has been 
shown to be rescued by p53 deficiency, following intercrosses of p53 knockout and 
Splotch mice (Pani et al., 2002). None of the intercrossed embryos exhibited NTD (from 
a total of five) compared to 100 % of Sp/Sp embryos. The authors suggested that Pax3 
regulates neural tube closure by inhibiting p53-dependent apoptosis such that in the 
Pax3 deficient Sp/Sp embryos there is an excess of p53-dependent apoptosis. In a 
previous study investigating apoptosis in E l0.5 Splotch embryos, a high concentration 
of apoptotic cells was observed in the neural folds surrounding the open regions of the 
neural tube (Phelan et al., 1997). In addition, down-regulation of Pax proteins induced 
apoptosis in cell culture experiments (Bemasconi et al., 1996). The results of these 
studies have led to the suggestion that NTD in Splotch mutant embryos are caused by 
excessive apoptosis. This idea is supported by previous studies in which excess 
apoptosis has been suggested to be causal in other mouse mutants (Zhao et a l, 
1996;Martinez-Barbera et al., 2002). However, to date there has not been a detailed 
analysis of apoptosis rate in Splotch mutant embryos at the specific stages prior to and 
during neural tube closure.
2 0 4
CHAPTER 5;Investigation of the causes of cranial NTD in Splotch2H mice
This study was designed to determine if the levels of apoptosis during cranial
-y j j  ^  i t  ■y j_T
neurulation in Sp /Sp embryos differ from those in wild type embryos. Splotch 
embryos at three stages of development, E8.5, E9.5 and E l0.5, underwent whole mount 
TUNEL to identify apoptosis patterns in embryos of each genotype. Further studies 
utilising immunohistochemistry allowed quantitative analysis of apoptosis and 
proliferation in the cranial neuroepithelium of Splotch2H embryos immediately prior to 
and following cranial neural tube closure. Additional analysis was carried out to
y r r
investigate apoptosis in relation to Pax3 expression in the neuroepithelium of Splotch 
embryos at the developmental stage immediately prior to cranial neural tube closure.
5.2 RESULTS
5.2.1 Whole mount TUNEL in Splotch2H embryos during neural 
tube closure
To investigate the possibility that increased apoptosis is responsible for inducing NTD
i r r  ^  I J
in homozygous Splotch embryos, whole mount TUNEL was carried out on Splotch 
embryos at stages throughout cranial neurulation (E8.5, E9.5 and E l0.5). Cells 
undergoing apoptosis were labelled and cell death patterns were compared between
f-fhomozygous and wild type Splotch embryos.
At E8.5 whole mount TUNEL staining on wild type embryos showed few positive cells 
suggesting that only a few cells distributed throughout the embryo are undergoing 
apoptosis (Figure 5.1 A, C). No major differences were observed in the distribution or
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Figure 5.1 Whole mount TUNEL on E8.5 Splotch2H embryos
Wild type (A, C) and homozygous (B, D) E8.5 Splotch2H embryos after whole mount 
TUNEL. Ventral (A, B) and dorsal (C, D) views of the cranial region are shown. 
TUNEL positive cells are coloured purple (indicated by black arrows). There were no 
noticeable differences in distribution or quantity of TUNEL positive cells between the 
splotch2H genotypes. This figure represents data from at least 6 embryos of each 
genotype. Scale bars represent 200 pm.
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quantity of apoptotic cells in the cranial region of wild type and homozygous mutant 
embryos at this stage of development (Figure 5.1).
By E9.5 apoptotic cells are detected in specific areas in the embryo as shown by whole 
mount TUNEL staining (Figure 5.2). Clusters of apoptotic cells have previously been 
described in non-mutant mouse embryos at this stage of development. Cell death in the 
mesenchyme of the first and second branchial arches has previously been suggested to 
be occurring in neural crest cell derivatives (Mirkes et al., 2001). TUNEL positive cells 
have also been detected in the neuroepithelium of the hindbrain (Mirkes et al., 2001) 
and cell death has been described along the dorsal midline after neural tube closure has 
occurred (Schluter, 1973). Clusters of cells undergoing programmed cell death have 
also been observed surrounding the otic placode (Abbott et al., 1995) and at the most 
rostral point of the neural tube (Geelen and Langman, 1977) in E9.5 mouse embryos. 
Wild type embryos were found to exhibit cell death in these areas at this stage of 
development (Figure 5.2).
Whole mount TUNEL staining of embryos at E9.5, just following the completion of 
cranial neural tube closure, differs in Sp2H/Sp2H embryos compared to wild type 
littermates. There appear to be a slight increase in the number of TUNEL positive cells 
in the region surrounding the otic vesicles and in the cranial mesenchyme in Sp2H/Sp2H 
embryos compared to wild type littermates (Figure 5.2 A,B). The distinct line of cell 
death along the midline of the fused neural tube in the forebrain and midbrain in wild 
type embryos is missing or incomplete in Sp2H/Sp2H embryos (Figure 5.2 C,D). All the 
homozygous mutant embryos studied at this developmental stage exhibited
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Figure 5.2 Whole mount TUNEL on E9.5 Splotch211 embryos
Wild type (A, C, E) and homozygous (B, D, F) E9.5 Splotch2H embryos after whole 
mount TUNEL, labelled cells appear purple. Lateral (A, B), ventral (C, D) and 
corresponding dorsal (E, F) views are shown. All Sp2H/Sp2H embryos examined 
developed cranial NTD, and the regions of open neural tube are flanked by white 
arrowheads (B). There appears to be a greater number of TUNEL positive cells around 
the otic vesicle (black arrows in A, B, E and F) and in the cranial mesenchyme (asterix 
in B) in Sp2H/Sp2H embryos compared to wild type littermates. The distinct pattern of 
apoptotic neural epithelial cells along the fused neural tube in the forebrain is less 
distinct in homozygous embryos compared to wild type embryos (black arrowheads in 
D and C). However, the number and position of apoptotic cells in the fused or open 
midbrain/hindbrain neural tube appear similar in all Splotch2H genotypes (black 
arrowheads in E and F). This figure represents data from at least 5 embryos of each 
genotype. Scale bars represent 200 pm.
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exencephaly. The pattern of apoptotic cells in the neuroepithelium of the hindbrain 
appeared unchanged between the different Splotch2H genotypes (although this was a 
comparison of open and closed neural tube) (Figure 5.2 E,F).
At E10.5, defined patterns of apoptosis were observed in mouse embryos (Figure 5.3 
A). When the pattern of apoptosis in Sp2H/Sp2H embryos is compared to that of wild type 
littermates a number of differences were seen. The TUNEL staining in the somites of 
homozygous embryos is more diffuse than in wild type embryos (Figure 5.3 A,B) and 
there is an increase in the number of TUNEL positive cells in the cranial mesenchyme 
in all Sp2H/Sp2H embryos studied, compared to their wild type littermates. A line of 
apoptotic cells can be seen at the midline of the fused neural tube in the forebrain of 
wild type embryos, as described previously in E9.5 wild type embryos. This line is 
missing or incomplete, even though the neural tube has fused, in all homozygous 
embryos studied (Figure 5.3 C,D). These observations are comparable to previous 
reports of apoptosis in Splotch embryos at this stage of development (Dickman et a l , 
1999).
5.2.2 Method for quantitative analysis of proliferation and 
apoptosis levels in Splotch2H embryos during cranial neural 
tube closure
Whole mount TUNEL staining suggested that there may be slight increases in the 
number of cells undergoing cell death in the cranial region of Sp2H/Sp2H embryos during 
neurulation, but this appears restricted to the mesenchyme not the neural tube. These 
findings are not in agreement with the suggestion of increased apoptosis as a causative
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Figure 5.3 Whole mount TUNEL on E l0.5 Splotch2H embryos
Wild type (A, C) and homozygous mutant (B, D) embryos underwent whole mount 
TUNEL, with positive cells stained purple. Sp2H/Sp2H embryos exhibit exencephaly (Ex, 
in D; the region o f open cranial neural tube is flanked by white arrowheads, B) and/or 
spina bifida (SB, in D; the region o f open caudal neural tube is flanked by black 
arrowheads, B). There appears to be an increased level of apoptosis in the cranial 
mesenchyme of homozygous embryos compared to wild type littermates (asterix in B 
and A). The defined patterns o f apoptotic cells observed in the somites (white arrow in 
A) and along the fused forebrain neural tube (black arrows in C) of wild type embryos 
are lost in homozygous embryos (white arrow in B and black arrows in D). This figure 
represents data from at least 5 embryos o f each genotype. Scale bars represent 500 pm.
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factor in Splotch2H NTD. However, the embryos that underwent whole mount TUNEL 
had either reached a developmental stage at which cranial neural tube closure should 
have been completed or were at an earlier developmental age. In order to detect whether 
changes in cell death may play a role in the development of cranial NTD in Splotch2H 
embryos it is necessary to analyse embryos temporally closer to the closure events. An 
immunohistochemical approach was used to generate quantitative data regarding the 
incidence of cell death in relation to cranial neural tube closure in Splotch2H embryos. In 
parallel, proliferation was also analysed in these embryos.
Litters from Splotch2H heterozygous matings were collected at E9 and E9.5 and 
embryos at developmental stages immediately prior to (13-15 somite-stages) and 
following (18-20 somite-stages) cranial neural tube closure were prepared for 
immunohistochemistry (Section 2.7). Coronal sections were taken through the cranial 
region and alternate pairs were placed on separate slides for immunohistochemical 
analysis of apoptosis (anti-activated caspase 3 antibody) and proliferation (anti- 
phosphorylated histone H3 antibody) as described in Section 2.7.
The first section in which distinct branchial arches were present was used as a landmark 
and labelled section 3. One section from the next two pairs dorsally (sections 2 and 1) 
were also photographed for further analysis (Figure 5.4). The number of labelled cells in 
the neuroepithelium of each of the three sections were counted and added to give the 
total number of labelled cells. The area of the neuroepithelium was measured on each 
section using Openlab 4.0.4 (Improvision) (Figure 5.4). The mean measurement for
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Figure 5.4 Analysis of apoptosis and proliferation in the cranial neuroepithelium of 
Splotch2H embryos.
Alternate pairs o f coronal sections were taken through the cranial region of Splotch2H 
embryos and underwent immunohistochemistry with an antibody against 
phosphorylated histone H3 (A-D) or activated caspase 3. Sections used to quantify 
levels o f proliferation are shown in panels A-C, with a higher magnification view of C 
in panel D. Equivalent sections were used for quantification o f apoptosis. The first 
section showing distinct branchial arches (A) was labelled section 3 and used as a 
landmark to ensure comparisons between embryos were carried out at the same axial 
level. Additional sections used were the 4th and 8th sections dorsal to section 3 (B and C 
respectively). Labelled cells (arrowheads in D) were counted and the area o f 
neuroepithelium was measured on each section (dotted line in D) in order to calculate 
the number of labelled cells/1000 pm2 of neuroepithelium for each embryo. Scale bars 
represent 200 pm (A-C) or 100 pm (D).
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each of the three sections were added together to give the total neuroepithelial area. The 
number of labelled cells per 1000 pm2 of neuroepithelium (NE) was then calculated for 
each embryo as follows:
No. total labelled cells
(total area of NE/1000)
= Labelled cells/1000 p tm 2 NE
5.2.3 Proliferation and apoptosis levels in the cranial 
neuroepithelium of E9 Splotch2H embryos
Apoptosis levels in the cranial neuroepithelium of Splotch2H embryos immediately prior 
to neural tube closure were investigated (Table 5.1). There were no statistically 
significant differences between the total neuroepithelial area measured between 
embryos of the different Splotch2H genotypes (tested by one-way ANOVA, Table 5.1). 
Although the Sp2H/Sp2H group did have non-significantly larger neuroepithelial areas 
than the other two genotypes this may be due to slight differences in the angle of the 
sections. When the number of labelled cells/1000 pm2 neuroepithelium were compared
1 TJ
between the Splotch genotypes, a trend was immediately apparent (Table 5.1, Figure 
5.5). The results suggest that there is an increase in apoptosis in Sp2H/Sp2H embryos
■J T J
compared to Sp /+  which in turn exhibit higher levels of apoptosis compared to +/+ 
embryos. However, the differences between the genotype groups do not reach a 
statistically significant level (tested by one-way ANOVA).
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Embryo mean NE area Total NE Total no. labelled
No pm2 ± SEM area pm2 labelled cells/1000 pm2
cells NE
+/+
1 14680.4 ±2663.2 44041.1 1 0.02
2 13720.3 ±364.9 14460.9 7 0.17
3 - - - -
Sp2H/+
4 29653.7 ± 348.5 59307.5 0 0.00
5 12437.2 ±336.5 37311.6 23 0.62
6 11241.8 ±1081.6 33725.4 7 0.21
Sp2H/Sp2H
7 15804.0 ±2132.8 47412.0 1 0.02
8 19101.3 ±525.7 57304.0 2 0.03
9 34480.0 ± 1452.8 68960.1 17 0.25
10 35317.2 ±7723.7 105951.5 45 0.42
11 21071.9 ±4868.6 63215.8 62 0.98
SLMMARY
Splotch2H 
Genotype
No. of 
embryos
No. of 
sections
mean NE area 
(pm2 ± SEM)
mean labelled 
cells /1000 pm2 
NE ± SEM
+/+ 2 6 42601.0 ±1440 0.095 ± 0.08
Sp2H/+ 3 8 43448.2 ± 7997 0.277 ±0.18
Sp2H/Sp2H 5 14 68568.7 ±10002 0.340 ±0.18
Table 5.1 Anti-activated caspase 3 antibody labelling in the neuroepithelium of E9 
Splotch21* embryos
For each embryo, the mean neuroepithelial area (± SEM) of the sections analysed, and 
the total neuroepithelium area in pm for each embryo (the sum of the mean 
neuroepithelial areas for each section) were measured. The total number of labelled 
cells in the sections investigated for each embryo were counted and used to calculate the 
number of labelled cells/1000 pm2 of neuroepithelium. Some measurements/counts 
could not be made due to damaged sections. A summary of the data giving the mean
y j r
values for embryos of each Splotch genotype is given. There were no significant 
differences between the genotype groups for either the mean area of neuroepithelium
•y
measured or the number of labelled cells/1000 pm NE (tested by one-way ANOVA). 
Abbreviation: NE, neuroepithelium.
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F ig u r e  5 .5  A p o p to s is  in  t h e  n e u r o e p ith e l iu m  o f  E 9  Splotch211 e m b r y o s .
The mean number o f cells labelled with anti-activated caspase 3 antibody in the studied 
region of cranial neuroepithelium o f Splotch2H embryos was calculated and normalised 
to area o f neuroepithelium. There are no statistically significant differences between the 
number of labelled cells/1000 pm2 of neuroepithelium across the genotypes (tested by 
one-way ANOVA).
In sections that underwent immunohistochemistry with antibodies raised against 
phosphorylated histone H3 (Table 5.2) the neuroepithelial area for the Sp2H/Sp2H group 
was slightly larger than that o f the other two genotype groups. However, there were no 
statistically significant differences between the different genotypes for the mean total 
neuroepithelial area (tested by one-way ANOVA, Table 5.2). This corresponds with the
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Embryo mean NE area Total NE Total no. labelled
No pm2 ± SEM area pm2 labelled cells/1000 pm2
cells NE
+/+
1 12238.9 ±814.7 36716.6 28 0.76
2 10842.2 ± 1192.6 21684.4 27 1.25
3 14917.01604.8 44751.0 47 1.05
Sp2H/+
4 - - - -
5 13559.71671.9 40679.2 59 1.45
6 11286.1 1717.7 33858.2 37 1.09
Sp2H/Sp2H
7 19093.61 1071.5 57280.9 47 0.82
8 21391.61514.1 64174.7 42 0.65
9 30028.71 1156.1 90086.1 80 0.89
10 37582.1 ±3835.2 112746.2 63 0.56
11 17222.0174.3 17222.0 22 1.28
S i rMMARY
Splotch211
Genotype
No. of
embryos
No. of 
sections
mean NE area 
(pm21 SEM)
mean labelled 
cells 11000 pm2
NE 1 SEM
+/+ 3 8 34384.016760 1.0210.14
Sp2H/+ 2 6 37268.713411 1.2710.18
Sp2H/Sp2H 5 13 68302.01 16121 0.8410.13
Table 5.2 Anti-phosphorylated histone H3 antibody labelling in the 
neuroepithelium of E9 Splotch211 embryos
For each embryo, the mean neuroepithelial area (± SEM) of the sections analysed, and 
the total neuroepithelium area in pm for each embryo (the sum of the mean 
neuroepithelial areas for each section) were measured. The total number of labelled 
cells in the sections investigated for each embryo were counted and used to calculate the 
number of labelled cells/1000 pm of neuroepithelium. Some measurements/counts 
could not be made due to damaged sections. A summary of the data giving the mean
9 f - fvalues for embryos of each Splotch genotype is given. There were no significant 
differences between the genotype groups for either the mean area of neuroepithelium 
measured or the number of labelled cells/1000 pm2 NE (tested by one-way ANOVA). 
Abbreviation: NE, neuroepithelium.
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F ig u r e  5.6 P r o li fe r a t io n  in  th e  n e u r o e p ith e l iu m  o f  E9 Splotch2H e m b r y o s .
The mean number o f cells labelled with anti-phosphorylated histone H3 antibody in the
• • 2 H  •cranial neuroepithelium o f Splotch embryos was calculated and normalised to area of 
neuroepithelium. There were no statistically significant differences between the number 
of labelled cells/1000 pm2 of neuroepithelium across the genotypes (tested by one-way 
ANOVA).
data collected for the sections used to investigate apoptosis in these embryos (Table 
5.1). In addition, there were no differences in the number o f labelled cells/1000 pm2 of  
neuroepithelium between the Splotch2H genotypes (Table 5.2, Figure 5.6).
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5.2.4 Proliferation and apoptosis levels in the cranial 
neuroepithelium of E9.5 Splotch2H embryos
In embryos at the 18-20 somite stage, immediately following cranial neural tube
2Hclosure, the area of neuroepithelium appears to increase with the number of Splotch 
alleles present (Table 5.3 and Table 5.4). However, this trend is not statistically 
significant (tested by one-way ANOVA) and is thought to result from slight differences 
in angle of section as there were no differences in the crown-rump length measurements 
between the genotype groups. Results from sections labelled for apoptotic cells (Table 
5.3) show a trend between the Splotch2H genotypes. There appears to be fewer cells
■y T j  •y i t  J f - f
undergoing cell death in the neuroepithelium of Sp /Sp embryos compared to Sp "7+  
and +/+ embryos. However, the differences between the genotypes among E9.5 
embryos are not statistically significant (tested by one-way ANOVA, Table). This trend 
is in contrast to the pattern observed in Splotch2H embryos immediately prior to cranial 
neural tube closure (Table 5.1).
Analysis of phosphorylated-histone H3 positive cells in the neuroepithelium at this later 
stage of development showed that the number of labelled cells per area of 
neuroepithelium was comparable between the genotypes (Table 5.4). These findings 
suggest that there are no differences between the levels of proliferation in the cranial 
neuroepithelium in Splotch2H embryos of different genotypes (Table 5.4, Figure 5.8).
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Embryo mean NE area pm2 ± Total NE Total no. labelled cells/1000
No. SEM area pm2 labelled cells pm2 NE
+/+
1 15746.8 ±997.3 47240.3 16 0.34
2 21116.1 ±800.7 63348.4 26 0.41
3 35360.3 ±9174.6 106080.8 111 1.05
Sp2H/+
4 27249.2 ± 1224.1 81747.8 137 1.68
5 19432.5 ±817.5 58297.5 8 0.14
6 20295.0 ± 1366.6 60884.9 17 0.28
7 37090.4 ± 5807.2 111271.1 12 0.11
8 35443.7 ± 1029.1 106331.1 91 0.86
9 19712.4 ±2910.6 59137.0 5 0.08
10 45625.4 ± 509.9 136876.1 27 0.20
11 23960.7 ±2222.1 71882.0 2 0.03
12 18887.0 ± 1490.2 56661.0 50 0.88
13 19498.8 ±3173.8 58496.3 45 0.77
Sp2H/Sp2H
14 28329.9 ± 5099.6 84989.6 5 0.06
15 61730.8 ±5683.7 185192.4 56 0.30
16 - - - -
SUMMARY
Splotch211
Genotype
No. of 
embryos
No. of 
sections
mean NE area 
(pm2 ± SEM)
mean labelled cells 
/1000 pm2 NE ± SEM
+/+ 3 9 72223.2 ± 17555 0.60 ± 0.23
Sp2H/+ 10 29 80158.5 ± 8977 0.50 ±0.17
Spm/Sp2H 2 6 135091.0 ±50101 0.18 ±0.12
Table 5.3 Anti-activated caspase 3 antibody labelling in the neuroepithelium of 
E9.5 Splotch211 embryos
For each embryo the mean neuroepithelial area (± SEM) of the sections analysed, and 
the total neuroepithelium area in pm for each embryo (the sum of the mean 
neuroepithelial areas for each section) were measured. The total number of labelled 
cells in the sections investigated for each embryo were counted and used to calculate the 
number of labelled cells/1000 pm of neuroepithelium. Some measurements/counts 
could not be made due to damaged sections. A summary of the data giving the mean
•y j t
values for embryos of each Splotch genotype is given. There were no significant 
differences between the genotype groups for either the mean area of neuroepithelium 
measured or the number of labelled cells/1000 pm NE (tested by one-way ANOVA). 
Abbreviation: NE, neuroepithelium.
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Figure 5.7 Apoptosis in the neuroepithelium of E9.5 Splotch2H embryos.
The number of cells labelled with anti-activated caspase 3 antibody in the cranial 
neuroepithelium o f Splotch2H embryos was calculated and normalised to area of 
neuroepithelium. There were no statistically significant differences between the number 
o f labelled cells/1000 pm2 o f neuroepithelium across the genotypes (tested by one-way 
ANOVA).
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Embryo mean NE area pm2 ± Total NE Total no. labelled cells/1000
No. SEM area pm2 labelled cells pm2 NE
+/+
1 18263.2 ±1154.8 54789.6 38 0.69
2 21143.8 ±588.7 63431.4 51 0.80
3 19371.0 ± 1975.2 58113.1 73 1.23
Sp2H/+
4 24162.1 ±2669.9 72486.4 54 0.74
5 19724.5 ±209.6 59173.5 32 0.54
6 20772.1 ± 1035.4 62316.1 64 1.03
7 40999.2 ±4627.1 122997.6 110 0.89
8 39703.6 ± 1064.1 119110.9 80 0.67
9 19292.9 ±3237.0 57878.7 48 0.85
10 46659.3 ± 1946.3 93318.6 94 1.01
11 22481.1 ±281.9 67443.3 84 1.25
12 15757.3 ±3392.2 47272.1 41 0.87
13 23621.1 ±4413.1 70863.4 83 1.17
Sp2H/Sp2H
14 27170.1 ± 1354.8 81510.3 101 1.24
15 44545.8 ± 7070.3 133637.4 124 0.93
16 22376.2 ±4286.5 67128.8 39 0.58
SUMMARY
Splotch211
Genotype
No. of
embryos
No. of 
sections
mean NE area 
(pm2 ± SEM)
mean labelled cells 
/1000 pm2 NE ± SEM
+/+ 3 9 58778.0 ±2516 0.91 ±0.17
Sp2H/+ 10 29 63031.6 ± 10569 0.90 ± 0.07
Sp2H/Sp2H 3 9 94092.2 ± 20204 0.92 ±0.19
Table 5.4 Anti-phosphorylated histone H3 antibody labelling in the 
neuroepithelium of E9.5 Splotch211 embryos
For each embryo the mean neuroepithelial area (± SEM) of the sections analysed, and 
the total neuroepithelium area in pm for each embryo (the sum of the mean 
neuroepithelial areas for each section) were measured. The total number of labelled 
cells in the sections investigated for each embryo were counted and used to calculate the
"S
number of labelled cells/1000 pm of neuroepithelium. Some measurements/counts 
could not be made due to damaged sections. A summary of the data giving the mean 
values for embryos of each Splotch2H genotype is given. There were no significant 
differences between the genotype groups for either the mean area of neuroepithelium 
measured or the number of labelled cells/1000 pm NE (tested by one-way ANOVA). 
Abbreviation: NE, neuroepithelium.
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Figure 5.8 Proliferation in the neuroepithelium of E9.5 Splotch2H embryos.
The mean number o f cells labelled with anti-phosphorylated histone H3 antibody in the 
cranial neuroepithelium o f Splotch2H embryos was calculated and normalised to area of 
neuroepithelium. There were no statistically significant differences between the number 
o f labelled cells/1000 pm2 of neuroepithelium across the genotypes (tested by one-way 
ANOVA).
5.2.5 Method for quantitative analysis of apoptosis in the Pax3 
expression domain of the cranial neuroepithelium in E9 
Splotch2H embryos
Results in Section 5.2.3 suggested that there may be an increase in the number o f cells 
undergoing apoptosis in the cranial neuroepithelium of E9 Sp2H/Sp2H embryos compared
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to +/+ littermates. Although the difference was not statistically significant I decided to 
investigate this further by determining whether the apparent increase in cell death is 
located in the area in which Pax3 is expressed in the neuroepithelium at this 
developmental stage.
Whole mount in situ hybridisation of antisense Pax3 probes with non-mutant mouse 
embryos was used to define Pax3 expression boundaries in the neuroepithelium in E9 
embryos. Vibratome sections were photographed and transferred to Photoshop v6.0 
where the lengths of total neural tube and Pax3 expression were measured (Figure 5.9).
*) f-TThese measurements should be comparable to Splotch embryos as the expression of 
Pax3 in the neural tube of homozygous Splotch embryos is apparently normal and has 
been shown not to differ from that of wild type littermates (Dickman et al., 1999).
The extent of Pax3 expression in the neuroepithelium of four embryos was used as
01-fguidance for the analysis in Splotch embryos (Table 5.5, Figure 5.9). There was some 
variation in the Pax3 expression limit between the embryos investigated. Therefore, the 
boundaries were defined by the regions that were Pax3 positive and negative in all the 
embryos (Table 5.5). The Pax3 positive expression boundary in the neuroepithelium 
was defined in the dorsal region (0.38 of the total neuroepithelial length). The Pax3 
negative region was the ventral half of the neural tube (0.50 of the total neuroepithelial 
length). The region between these two domains was labelled the overlap zone and 
represented the region of the neural tube in which cells from different embryos were 
positive or negative for Pax3. Cells located in this area were excluded from this study.
2 2 4
CHAPTER 5; Investigation of the causes of cranial NTD in Splotch2H mice
Proportion of NT 
length expressing Pax3
Proportion of NT 
length not expressing 
Pax3
Side of Neural 
tube
LHS RHS LHS RHS
Embryo 1 0.48 0.47 0.52 0.53
Embryo 2 0.47 0.49 0.53 0.51
Embryo 3 0.40 0.39 0.60 0.61
Embryo 4 0.48 0.49 0.52 0.51
Estimated 
proportion limit
0.38 0.50
Table 5.5 Pax3 expression in coronal sections through the cranial region of E9 
embryos
Measurements were made to establish the extent of Pax3 expression in E9 mouse 
embryos. After whole mount in situ hybridisation the length of neural tube expressing 
Pax3 was measured as a proportion of the total neural tube length (Figure 5.9). A value 
below the smallest proportion for each domain was used as the limit for which I was 
confident that Pax3 is, or is not, expressed. Abbreviations: LHS, left hand side; RHS, 
right hand side; NT, neural tube.
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Figure 5.9 Pojc5 expression boundaries in the neural tube of E9 mouse embryos.
Measurements of coronal sections through the cranial region of E9 mouse embryos after 
whole mount in situ hybridisation with Pax3 probe (Table 5.5) were used to define the 
Pax3 expression boundary. The extent of Pax3 expression (blue/purple staining and 
dotted lines in A) was measured as a proportion of the neural tube length. The smallest 
proportions of Pax3-expression and non-P&xi expression along the neural tube were 
used to define a Pax3 positive domain and a Pax3 negative domain, the area in between 
is described as the overlap zone (C). These boundaries were used to calculate probable 
Pax3 expression domains for the E9 Splotch2H sections that had undergone 
immunohistochemistry with anti-activated caspase 3 antibody (B). Labelled cells 
(arrows in B) were counted in the Pax3 positive and negative domains. Scale bars 
represent 100 pm.
Neural l ube 
length 
0 t
0.38
0.50
Pax3 +ve 
domain
Overlap zone
Pax3 -ve 
domain
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5.2.6 Apoptosis in the Pax3 expression domain in the cranial 
neuroepithelium of E9 Splotch2H embryos
The number of labelled cells each side of the predicted Pax3 expression boundary was 
counted on each section (Table 5.6). The total number of labelled cells in areas that 
were predicted to be positive or negative for Pax3 expression were calculated for each 
embryo and the ratio of Pax3 expressing : non Paxi-expressing labelled cells was 
calculated for each embryo (Table 5.6).
The increased number of labelled cells observed in Sp2H/Sp2H embryos was not 
restricted to the Pax3 expressing region of the neural tube; in fact the opposite is
OJ-f i i jobserved. The majority of apoptotic cells in the neuroepithelium of Sp /Sp embryos 
were located in the ventral neural tube, which does not express Pax3 (Table 5.6).
■J I T
However, in Sp /+ embryos the opposite effect is seen with the majority of cell death 
occurring in the Pax3 expressing region of the neuroepithelium. The location of cells 
undergoing apoptosis in wild type embryos is similar to homozygous embryos, that is 
the majority of cell death occurs in the ventral neural tube.
2 2 7
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Embryo
No.
Total no. of 
labelled 
cells
Labelled 
cells in Pax3 
+ve domain
Labelled cells 
in Pax3 -ve 
domain
Labelled 
cells in 
overlap zone
Pax3 +ve / 
Pax3 -ve
+/+
1 1 0 1 0 0/1
2 7 1 6 0 1/6
Sp2H/+
3 0 0 0 0 0/0
4 23 19 3 1 19/3
5 7 5 1 1 5/1
Sp2H/Sp2H
6 1 0 1 0 0/1
7 2 2 0 0 2/0
8 17 2 13 2 2/13
9 45 3 39 3 3/39
10 62 5 54 3 5/54
Table 5.6 Apoptosis in the neuroepithelium of £9 Splotch2H embryos with regard to
Pax3 expression
The number of labelled cells in the Pax3 positive (+ve) domain and Pax3 negative (-ve) 
domains (as defined in Section 5.2.6) of cranial neuroepithelium in embryos prior to 
neural tube closure.
5.3 DISCUSSION
At E8.5, the developmental stage preceding cranial neural tube closure, there were no 
changes in the number or distribution of TUNEL-positive cells observed in Sp2H/Sp2H 
embryos compared to wild type littermates. However by E9.5, when cranial neural tube 
closure should have been completed, differences in the pattern of apoptotic cells were 
observed. Interestingly, an increase in the number of TUNEL-positive cells was 
observed in the cranial mesenchyme of E9.5 and E l0.5 Splotch2H homozygous embryos 
compared to wild type embryos. Increased apoptosis in the cranial mesenchyme has 
been suggested to be responsible for the incidence of exencephaly exhibited by Cart-1
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mice (Zhao et a l , 1996). However, the increase in cell death in the cranial mesenchyme
9 /■/of Splotch homozygous embryos was not detected prior to neural tube closure (E8.5) 
and so could be unrelated or secondary to failure of the neural tube to close. Therefore, 
it would be interesting to see if this increase in apoptosis is present in Sp2H/Sp2H 
embryos that do not develop exencephaly (all Sp2H/Sp2H embryos studied in this chapter 
exhibited exencephaly). However, as Pax3 is not expressed in the cranial mesenchyme 
and is believed to act in a cell autonomous manner in the neuroepithelium (Mansouri et 
al., 2001) this was not investigated further in this study.
The pattern of TUNEL-positive cells at E l0.5 also shows differences between the
Splotch genotypes. The lack of labelled cells that I observed at the midline of the
fused neural tube in the forebrain/midbrain has been described previously in E l0.5 
91/
Splotch embryos in which no apoptotic cells were observed in fused regions of the 
entire neural tube (Phelan et al., 1997). The normal cell death in this area is believed to 
facilitate cell reorganisation after fusion has occurred. In contrast, it does not appear to 
be necessary for fusion to occur, as shown by the fact that the area of neural tube in 
which this line of apoptotic cells is missing has already completed closure. As discussed 
in Section 1.6.2.3, apoptosis is believed to be necessary for cranial neurulation to occur. 
There appears to be two roles for apoptosis in the process of cranial neurulation, firstly 
the correct regulation of apoptosis in the neuroepithelium and cranial mesenchyme may 
be essential for the apposition and fusion of the neural folds, as indicated by mouse 
NTD models in which apoptosis is misregulated resulting in either increased or 
decreased levels of apoptosis in the neuroepithelium or the cranial mesenchyme 
(Section 1.6.2.3, Table 1.1). The second role of apoptosis is the reorganisation along the
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midline following fusion. The results in this thesis suggest this process is not essential 
for the closure of the forebrain region during cranial neurulation.
The somites of E l0.5 Sp2H/Sp2H embryos also exhibited differences in the pattern of 
TUNEL-positive cells compared to wild type littermates. Pax3 is expressed in the 
dermomyotome (Goulding et al., 1991), and is believed to regulate the structural
? J-forganisation of the somites (Mansouri et al., 2001). Splotch homozygous mutant 
embryos exhibit disturbed somite boundaries (Henderson et al., 1999;Schubert et al.,
2001) and, it is therefore perhaps not surprising that the pattern of cell death in the 
somites of Sp2H/Sp2H embryos differs from that of wild type littermates .
J T J  J I T
If excess apoptosis is responsible for the development of NTD in Sp /Sp embryos we 
would expect to see changes in the number of TUNEL-positive cells before or during 
neural tube closure. However, changes in TUNEL-positive cell distribution in the
j  r j
cranial region of homozygous Splotch embryos were only observed after closure 
should have been completed (E9.5). Therefore, analysis of embryos at developmental 
stages closer to the time of cranial neural tube closure was used in the subsequent 
experiments.
Immediately prior to cranial neural tube closure (13-15 somite-stage) embryos showed a 
trend towards increased apoptosis in the cranial neuroepithelium with the number of 
mutant Pax3 alleles present, whereas the opposite trend was observed in slightly older 
embryos at the 18-20 somite stage. However, in neither case did the differences between 
the genotypes reach statistical significance suggesting that the observed variation may
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not be biologically relevant. The finding of opposite effects at two temporally close 
stages also supports this idea.
Pax3 acts in a cell autonomous manner in the neural tube (Mansouri et a l, 2001). 
Therefore, if the loss of Pax3 function resulted in the induction of apoptosis we would 
expect to observe increased cell death in the Paxi-expressing area of the 
neuroepithelium of homozygous mutant embryos compared to wild type littermates. 
Further experiments investigating the location of cells undergoing cell death in relation 
to Pax3 expression were thus used as a more sensitive measurement of the effect of loss 
of Pax3 function on apoptosis levels. There was no increase in the number of activated 
caspase-3 positive cells in the Pocd-expressing area of the cranial neuroepithelium in E9 
homozygous Sp2H/Sp2H embryos compared to wild type and heterozygous littermates in 
which the neural tube closes. These findings suggest that cranial NTD in Splotch2H 
mutants is not induced by excess apoptosis in response to reduced Pax3 function.
Additional experiments carried out in our laboratory support these results. If excess
JTJ
apoptosis was responsible for the production of exencephaly in Splotch embryos,
• y r j
direct inhibition of this process should potentially rescue the NTD. Splotch embryos 
were cultured throughout the period of neural tube closure, E8.5-E10, in the presence of 
the caspase inhibitor Z-VAD-FMK (Van Noorden, 2001). In contrast to the expected 
rescue effect of this treatment, an increased incidence of exencephaly was observed in 
Sp2H/Sp2H embryos exposed to Z-VAD-FMK compared to PBS treated controls. 
Moreover, a low incidence of exencephaly was observed in heterozygous embryos 
which would normally complete cranial neural tube closure (N.D.E. Greene, Personal
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communication). These results further suggest that excess apoptosis is not the cause of 
exencephaly in Sp2H/Sp2H embryos.
Previous studies in which it was suggested that NTD in Splotch embryos are a result of 
excess apoptosis have all used the Splotch mouse model, a different Splotch variant to 
the one used in this chapter. The different Splotch alleles can result in production of 
different proteins with variation in the functional domains that are present, leading to 
the possibility that Pax3 in different Splotch variants act in different ways (Section
1.10.1). Therefore, the functional capability of alleles in certain pathways may differ 
and should not be assumed to be the same for Splotch and Splotch . The effects of the 
Splotch and Splotch2H mutations on the functional capability of the resultant Pax3 
protein is unclear, both are thought to result in null proteins. It is possible that there
2 f - fcould be some residual function, particularly in Splotch mice as the paired box 
domain of the Pax3 protein is not affected by the 32 base pair deletion and has been 
shown to have independent binding ability in in vitro studies (Chalepakis et a l , 1994). 
Alternatively, if both mutations do result in null proteins, differences in the genetic 
background of the mice strains may account for differences between the Splotch alleles. 
Changing the genetic background has been shown to affect the phenotype penetrance in
2 J-fdifferent mouse mutants, including curly-tail (Neumann et al., 1994) and Splotch 
(Fleming et al., 2000).
Despite the differences in the Splotch alleles used in previous studies and the current 
study, our results, which suggest that excess apoptosis is not the cause of NTD in
USplotch embryos, is likely to hold true for all Splotch variants. For example, the
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analysis of apoptosis in Splotch embryos in the previous studies have all been carried 
out at E l0.5, a developmental stage after cranial neural tube closure should have been 
completed (Phelan et al., 1997;Pani et al., 2002). Therefore, the increased levels of 
apoptosis observed in these studies could be secondary to the failure of the neural tube 
to complete closure rather than directly causative. Moreover, previous studies have not 
indicated an excess of apoptosis in the neural tube in the absence of Pax3 expression. 
For example, some Pax3-mediated responses have been shown to be cell type specific. 
In a study using chimeric embryos, Paxi-deficiency in cells of the lateral 
dermomyotome induced excess apoptosis, whereas, this effect was not detected in 
Paxi-deficient cells of the neural tube (Mansouri et al., 2001). In addition, excess 
apoptosis was observed in newly formed somites of Splotch mutant embryos but not in 
the neural tube or mature somites (Borycki et a l , 1999).
The structure of the Pax3 protein allows specific binding to a large array of DNA 
sequences, permitting Pax3 to function in the activation or repression of a broad 
spectrum of genes involved in a variety of pathways (Machado et a l, 2001). Pax3 can 
act as a transcriptional repressor as well as an activator (Machado et a l, 2001). 
Inactivation of p53 by transcriptional repression has been shown to be mediated by 
Pax2, Pax5 and Pax8 but not Pax3 (Stuart et al., 1995) suggesting that Pax3 is unlikely 
to suppress apoptosis via the repression of p53. Therefore the rescue effect observed on 
the Splotch NTD phenotype by intercrosses with p53 knockout mutants (Pani et a l,
2002) could be acting through a different pathway than apoptosis.
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In addition to an anti-apoptotic role, Pax3 has also been suggested to play a role in 
regulating cell cycle progression and cell differentiation. The NTD phenotype of 
Splotch mutants could be postulated to arise from a disruption in these pathways.
2 j-i
Therefore, in parallel with analysis of cell death, proliferation levels in Splotch 
embryos were investigated in order to assess cell cycle progression in the 
neuroepithelium of mutant embryos. The proliferation levels did not differ between 
genotypes at either E9 or E9.5 stages, immediately prior to and following cranial neural 
tube closure. These results suggest that lack of Pax3 function does not affect
2 f j
proliferation and therefore, cell cycle progression, in the neuroepithelium of Splotch 
embryos during cranial neural tube closure.
Pax3 has been shown to play a role in maintaining an undifferentiated cell phenotype. 
For example, transfection of antisense Pax3 RNA into an undifferentiated neuronal cell 
line led to cellular differentiation, suggesting that Pax3 expression is necessary to 
maintain the undifferentiated phenotype (Reeves et al., 1999). In addition, Pax3 
expression in Schwann cell precursors is downregulated immediately prior to terminal 
differentiation (Kioussi et al., 1995) and the DNA-binding activity of Pax3 has also 
been shown to be rapidly downregulated during neuronal cell differentiation (Reeves et 
al., 1998). Pax3 can also inhibit the differentiation of cultured myoblast cells (Epstein et 
al., 1995) and adult melanocyte stem cell differentiation (Lang et al., 2005). Therefore, 
it is possible that premature differentiation of cells in the neuroepithelium of Splotch2H 
mutant embryos may be involved in the failure of the neural folds to complete closure.
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A possible alternation in differentiation would also be consistent with the reported 
rescue of Splotch NTD in p53/Splotch double mutants (Pani et al., 2002). The p53 
protein is activated in response to stress signals and can result in cellular apoptosis, cell 
cycle arrest, senescence or cell differentiation (Vousden and Lu, 2002). It is possible 
that the rescue effect of /?5J-deficiency on the NTD phenotype of Splotch mutant 
embryos (Pani et al., 2002) was mediated through an alternative function such as 
suppression of differentiation rather than through changes in apoptosis. Experiments 
carried out in this chapter did not detect any differences in the number of cells
Of-f OJ-fundergoing proliferation in the neuroepithelium of Sp /Sp embryos compared to wild 
type littermates which may suggest that misregulation of cell cycle checkpoint control is 
an unlikely candidate for the mode of NTD rescue by /?53-deficiency. However, it is 
possible that loss of p53 function may rescue Sp/Sp NTD by causing a delay in cellular 
differentiation. A number of in vitro and in vivo assays have demonstrated that adding 
exogenous wild-type p53 to undifferentiated cells can result in progression from an 
undifferentiated to a more differentiated state (Almog and Rotter, 1997;Hall and Lane, 
1997) and, as discussed earlier, Pax3 has been shown to inhibit cell differentiation in 
some systems. Therefore, it could be hypothesised that Sp/Sp NTD are induced by 
premature cellular differentiation which could then be rescued by a delay in 
differentiation caused by p53-deficiency. Further work investigating cellular 
differentiation in both mouse models would be needed to test this possibility.
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6.1 INTRODUCTION
The ability of peri-conceptional folic acid supplementation to prevent up to 70% of 
human NTD is generally accepted, although it is unclear how folates act to prevent the 
development of NTD. It is possible that folic acid supplementation may rescue some 
NTD by overcoming a defect in folate metabolism. In several cases it has been 
suggested that folate-responsive NTD mouse models have defects in folate metabolism 
(Section 1.10.2.2). For example, folate-binding protein 1 (Folbpl) null homozygous 
embryos, in which folate transport is limited, develop NTD if rescued from embryonic 
lethality by folic acid treatment (Piedrahita et a l, 1999). In addition, it has been
2 Msuggested that Poxi-deficient Sp homozygous embryos have impaired folate 
metabolism (Fleming et a l, 1998) (Section 1.10.1). Moreover, exposure of mouse 
embryos to valproic acid (VPA) induces NTD (Padmanabhan et a l, 2003) and the mode 
of teratogenic action for VPA has been proposed to include an effect on folate 
metabolism and homocysteine remethylation (Hishida and Nau, 1998).
In humans, folate deficiency is unlikely to be sufficient to cause NTD alone, but it is 
possible that a slight deficiency may be pathogenic when in association with a maternal 
or fetal metabolic abnormality in folate metabolism. Several folate-related risk factors 
for NTD have been identified (Section 1. 9) and there is additional evidence that 
impaired maternal folate metabolism may play a role in some NTD cases. For example, 
women who have had two previous pregnancies affected by NTD required a higher 
dietary folate intake to achieve the same 5-methyl tetrahydrofolate levels as control 
women (Lucock et a l, 1994), suggesting a defect in folate metabolism. There are 
obvious difficulties in studying folate metabolism in human embryos during
2 3 7
CHAPTER 6; Detection of folate cycle abnormalities in cell culture by the deoxyuridine
monophosphate suppression test
neurulation. So far only one study has used tissue arising from the early embryo itself to 
examine folate metabolism in relation to NTD. Habibzadeh and colleagues (1993) used 
trophoblast cells isolated from NTD-affected and unaffected (control) fetuses at 16-20 
weeks of gestation. Cell culture experiments showed a delay in the incorporation of 
labelled 5-methyl tetrahydrofolate in NTD-affected samples compared to control 
samples. This lag in incorporation suggests a disturbance in uptake or utilisation of 5- 
methyl tetrahydrofolate and therefore a defect of folate metabolism in some of the 
NTD-derived samples (Habibzadeh et al., 1993). However, although trophoblast cells 
are derived from the same embryonic tissue as the fetus they are specialised in that they 
undergo non-random X chromosome inactivation unlike other embryonic tissues 
(Hemberger, 2002). Therefore, there is still a need for direct analysis of folate 
metabolism in non-specialised embryonic tissues from NTD-affected pregnancies.
The aim of this study was to test the hypothesis that a defect in the metabolism of folate 
derivatives in the embryo is associated with the development of NTD. In order to detect 
a wide range of folate-related defects the deoxyuridine monophosphate (dUMP) 
suppression test was used (Figure 6.1). The dUMP suppression test analyses the ability 
of cells to provide the folate intermediate 5,10-methylene tetrahydrofolate (5,10- 
methylene THF) and, was established as an indicator of defective DNA metabolism in 
patients with megaloblastic anemia (Killmann, 1964). Impaired DNA metabolism in 
these patients is caused by an inadequate supply of 5,10-methylene THF, a substrate for 
the de novo pathway of pyrimidine biosynthesis. In these patients, a limited supply of 
5,10-methylene THF indicates defective folate and/or vitamin B 12 supply. The dUMP 
suppression test can also indicate efficacy of the folate cycle (Section 1.10.1), for
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example dUMP suppression test scores of colonocytes from folate-deficient rats showed 
reduced suppression compared to folate-replete rats. Moreover, the reduction was 
rectified by the addition of folinic acid to the culture medium demonstrating the validity 
of dUMP suppression test as a measure of folate status (Cravo et a l, 1991). 
Traditionally the dUMP suppression test was applied to bone marrow suspension 
cultures, however, it has also been adapted for use in whole embryo culture (Fleming et 
al., 1998).
Folate cycler 5,10-methylene
tetrahydrofolate Dihydrofolate
D e n o v o
pathway
Exogenous
dUMP
Pyrimidines
Salvage
pathway
Thymidine
Exogenous
[3H]-thymidine
Measure [3H]-thymidine 
incorporation in DNA
Figure 6.1 The deoxyuridine suppression test
Manipulation of the de novo and salvage pathways in pyrimidine biosynthesis are used 
to detect abnormalities in folate metabolism. The incorporation of exogenous [3H]- 
thymidine into DNA via the salvage pathway is measured. Exogenous dUMP drives the 
folate cycle, producing pyrimidines via the de novo pathway and thereby suppressing 
the incorporation of [ H]-thymidine into DNA. The ability of dUMP to suppress [ H]- 
thymidine incorporation is reduced when the folate cycle is impaired. Abbreviations; 
TS, thymidylate synthase; TK, thymidine kinase; dUMP, deoxyuridine monophosphate; 
dTMP, deoxythymidine monophosphate.
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In this chapter, the dUMP suppression test has been adapted for use with embryonic 
fibroblast cells derived from human fetuses. Three groups of samples have been 
collected; cells from fetuses with NTD (NTD samples), normal fetuses (normal 
controls) and fetuses with malformations other than NTD (affected controls). 
Fibroblastic cell lines were established from foetal skin, cartilage, umbilical cord or 
amniotic fluid samples by the Cytogenetics Department at Great Ormond Street 
Hospital. Parameters for cell number, test duration and reagent concentrations were 
initially established. Inhibitors of the folate and methylation cycle were then used in 
order to test whether the dUMP suppression test can detect abnormalities in folate 
metabolism in cell culture using these parameters. Aminopterin, 5-fluorouracil and 
cycloleucine inhibit folate and methionine metabolism at different points of the cycle 
(Figure 6.2) and so allow analysis of the sensitivity of the dUMP suppression test.
The uracil analogue, 5-fluorouracil, produces an active metabolite, 5- 
fluorodeoxyuridine monophosphate, that is a tight-binding inhibitor of thymidylate 
synthase (TS) and therefore can inhibit the conversion of dUMP to deoxythymidine 
monophosphate (dTMP) (Figure 6.2) (Myers et a l , 1975). Aminopterin is a folate- 
analogue that once transported into the cell is polyglutamated and subsequently binds to 
dihydrofolate reductase (DHFR), inhibiting its activity and thus the conversion of 
dihydrofolate to tetrahydrofolate (Figure 6.2) (McGuire, 2003). Cycloleucine is an 
inhibitor of methionine adenosyltransferase (MAT), the methylation cycle enzyme that 
mediates the conversion of methionine to S-adenosylmethionine (Figure 6.2) 
(Lombardini et al., 1970).
2 4 0
Figure 6.2 A simplified diagram of the folate and methylation cycles
Inhibitors and their site of action are shown in pink. Key enzymes are in blue and the exogenous agents utilised in the dUMP suppression 
test are shown in green.
Abbreviations: AP, aminopterin; Cyclo, cycloleucine; DHF, dihydrofolate; DHFR, dihydrofolate reductase; dUMP, deoxyuridine 
monophosphate; dTMP, deoxythymidine monophosphate; FU, 5-fluorouracil; MAT, methionine adenosyltransferase; SAH, S- 
adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate; TS, thymidylate synthase.
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6.2 RESULTS
Initial tests were designed to establish parameters for cell number, and concentration 
and length of treatment with [ H]-thymidine in order to allow reproducible, measurable 
tritium incorporation into DNA. In all the experiments the amount of [ H]-thymidine 
incorporated into DNA is expressed as cpm/pg protein. The percentage by which dUMP 
suppresses [3H]-thymidine incorporation was calculated as follows:
Me an [3H]- thymi dine Me an [3H]- thymi dine
= incorporation without dUMP ~ incorporation with dUMP xl()0
Mean [3H]-thymi dine incorporation without dUMP
A mouse fibroblastic cell line, 3T3, was initially used to validate detection of folate- 
related defects by the dUMP suppression test in cell culture so as not to exhaust 
precious human samples.
6.2.1 Dose-dependant suppression of [3H]-thymidine DNA 
incorporation by dUMP
A series of dUMP concentrations, from 1 pM to 500 pM, were added to mouse 
fibroblast cultures with 0.5 pCi/ml [3H]-thymidine. The addition of dUMP resulted in a 
dose-dependent suppression of [3H]-thymidine incorporation in mouse fibroblasts 
(Figure 6.3). The degree of suppression increases with dUMP concentration up to 
50 pM when it reached a plateau of approximately 70% (data points at 500 pM are not
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shown). These results show that exogenous dUMP can suppress the incorporation of 
exogenous [3H]-thymidine into DNA in cultured mouse cells.
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Figure 6.3 The dose-dependent suppression of [3H]-thymidine incorporation into 
DNA by deoxyuridine monophosphate in mouse fibroblast cells
The magnitude of suppression increases with the concentration of dUMP used. Each 
data point represents the mean ± SEM from at least 3 experiments.
Concentrations of dUMP ranging from 1 pM to 500 pM are able to suppress the 
incorporation of [3H]-thymidine into DNA in mouse embryonic fibroblast cells and this 
concentration range was therefore used with human normal control cells. As for mouse 
cells, a series of dUMP concentrations were added to human fibroblast cultures together
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with [3H]-thymidine. The addition of dUMP resulted in a dose-dependent suppression 
of [3H]-thymidine incorporation into DNA in human fibroblasts (Figure 6.4). The 
degree of suppression increases with the dUMP concentration up to 50 pM when it 
reached a plateau of approximately 80% (data points at 500 pM are not shown).
120
co
(0
oQ.
100 -
ooc 80 -
a>
c
-g
E>»JC
60 -
I
I
CO 40 -<4—o
co
'</>
CO 20 -
2
CLQ_3
CO
0 20 40 60 80 100
dUM P concentration (pM)
Figure 6.4 Dose-dependent suppression of [3H]-thymidine incorporation into DNA 
by deoxyuridine monophosphate in human fibroblast cells
[ H] thymidine incorporation into the DNA of human embryonic fibroblasts is 
suppressed by the presence of dUMP. The degree of suppression increases with the 
concentration of dUMP. Data points represent the mean ± SEM of at least three 
experiments.
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Human embryonic fibroblast cells appear to be more sensitive to the dUMP suppression 
of [3H]-thymidine incorporation than mouse embryonic fibroblasts. Lower doses of 
dUMP have a greater effect on [3H]-thymidine incorporation in human cells than 
equivalent dUMP doses in mouse cells (compare Figure 6.3 to Figure 6.4).
6.2.2 Detection of impaired folate metabolism by the dUMP 
suppression test in mouse fibroblasts
Before the dUMP suppression test could be carried out on human samples an 
appropriate dose of dUMP for the test needed to be established. An appropriate dose 
would need to induce a large percentage suppression of [3H]-thymidine incorporation 
but still allow detection of possible abnormalities in folate metabolism. Therefore initial 
inhibition studies with mouse fibroblasts were carried out using a series of dUMP 
concentrations (10 pM, 15 pM and 50 pM) and inhibitors of the folate or methylation 
cycles (Section 6.1). These studies showed that 10 pM dUMP was capable of inducing a 
relatively large suppression of [ H]-thymidine incorporation but appeared to not be high 
enough to mask deficiencies in folate metabolism. In the subsequent inhibitor 
experiments with human normal control cells, this concentration of dUMP was therefore 
used.
6.2.2.1 Inhibition of [3H]-thymidine incorporation into DNA by 5-fluorouracil
Previously 50 pM FU has been used to demonstrate that the dUMP suppression test can 
be used to assess folate status in rat colonic epithelium (Cravo et al., 1991). Therefore, 
this concentration of FU was initially used to test the sensitivity of the dUMP
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suppression test in mouse embryonic fibroblast cells. The total protein measured in 
samples cultured with 50 pM FU was noticeably lower than that of cultures with [ H]- 
thymidine, with or without dUMP, suggesting that FU is toxic at this concentration. 
Lower concentrations of FU, 25 pM and 35 pM, did not affect the viability of cultures 
as indicated by total protein content and therefore these concentrations were used in this 
study.
The incorporation of [ H]-thymidine into the DNA of mouse fibroblast cells was 
suppressed by dUMP in a dose-dependent manner as described previously (Section
6.2.1). Although 10 pM dUMP does not significantly suppress incorporation compared 
to cells treated with [3H]-thymidine alone, 15 pM and 50 pM dUMP do cause 
significant suppression (Figure 6.5). Addition of 25 pM FU results in a statistically 
significant increase in the incorporation of tritium-labelled thymidine into DNA at all 
the dUMP concentrations tested, compared to cells treated with the equivalent dUMP 
dose alone (Figure 6.5). At the higher concentration (35 pM), FU significantly inhibited 
the dUMP mediated suppression of [3H]-thymidine incorporation at 10 pM and 15 pM 
dUMP. Similar levels of [ H]-thymidine incorporation were detected in all experiments 
that included the inhibitor, suggesting that 25 pM FU is sufficient to inhibit thymidylate 
synthase (Figure 6.5), resulting in increased incorporation of thymidine generated 
through the de novo pathway.
In human cells, 10 pM dUMP significantly suppressed the incorporation of [3H]- 
thymidine compared to cells exposed to [3H]-thymidine alone (Figure 6.6). The addition 
of FU at a concentration of 25 pM eliminated the suppression of [3H]-thymidine by
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•  3 •  •Figure 6.5 Inhibition of the dUMP mediated suppression of [ H]-thymidine 
incorporation into DNA by 5-fluorouracil in mouse fibroblast cells.
Data is described as the percentage of [3H]-thymidine incorporated into DNA with 
respect to the [3H]-thymidine alone treatment, which is normalised to 100%. For each 
treatment, data is presented as mean ± SEM of three separate experiments. * indicates 
statistically significant variation from the thymidine alone treatment. <|> indicates 
statistically significant variation from the equivalent thymidine plus dUMP treatment 
group (p<0.05 tested by one-way ANOVA followed by TUKEY test for pairwise 
comparisons).
Abbreviations: Thy, [3H]-thymidine; dUMP, deoxyuridine monophosphate; FU, 5- 
fluorouracil.
Figure 6.6 Inhibition of the dUMP mediated suppression of [3H]-thymidine 
incorporation into DNA by 5-fluorouracil in human fibroblast cells.
' l
Data is described as the percentage of [ H]-thymidine incorporated into DNA with 
respect to the [3H]-thymidine alone treatment, which is normalised to 100%. For each 
treatment, data is presented as mean ± SEM of three separate experiments. * indicates 
statistically significant variation from the thymidine alone treatment. <|) indicates 
statistically significant variation from the thymidine plus dUMP treatment group 
(p<0.05 tested by t-test).
.Abbreviations: Thy, [3H]-thymidine; dUMP, deoxyuridine monophosphate; FU, 5- 
fluorouracil.
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dUMP, as shown by the significant increase in [3H]-thymidine incorporation compared 
to cells exposed to dUMP only. These results show that (using 10 pM dUMP) the 
dUMP suppression test in human embryonic fibroblasts is sensitive to inhibition of 
folate metabolism by FU (Figure 6.6).
6.2.2.2 Inhibition of [3H]-thymidine incorporation into DNA by aminopterin
In whole embryo culture, the addition of 2 mM aminopterin (AP) was sufficient to 
inhibit DHFR and reduced the dUMP mediated suppression of [3H]-thymidine 
incorporation into the DNA of neurulation-stage mouse embryos (Fleming et al., 1998). 
Therefore, this concentration of AP was initially used in the dUMP suppression test 
with mouse embryonic fibroblast cells. However, this concentration was cytotoxic and 
so lower doses of 10 pM and 100 pM AP were used in further experiments. As 
predicted, all the doses of dUMP tested result in a significant suppression of [ H]- 
thymidine when compared to cells treated with [ H]-thymidine alone (Figure 6.7). 
Addition of AP at both concentrations significantly increases the amount of [ H]- 
thymidine incorporated into mouse fibroblast DNA compared to cells exposed to the 
same concentration of dUMP alone. Similar levels of [3H]-thymidine incorporation 
were detected in cells treated with both AP concentrations suggesting that the lower 
dose, 10 pM, is sufficient to inhibit DHFR activity (Figure 6.7).
As in the previous experiment (Section 6.2.2.1), human embryonic fibroblasts exposed 
to 10 pM dUMP incorporate significantly lower levels of [3H]-thymidine compared to 
those exposed to [3H]-thymidine alone (Figure 6.8). Addition of 10 pM AP appears to
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Figure 6.7 Inhibition of the dUMP mediated suppression of [3H]-thymidine 
incorporation into DNA by aminopterin in mouse fibroblast cells.
Data is described as the percentage of [3H]-thymidine incorporated into DNA with 
respect to the [3H]-thymidine alone treatment, which is normalised to 100%. For each 
treatment, data is presented as mean ± SEM of at least three separate experiments. * 
indicates statistically significant variation from the thymidine alone treatment. 
<|) indicates statistically significant variation from the equivalent thymidine plus dUMP 
treatment group (p<0.05 tested by one-way ANOVA followed by TUKEY test for 
pairwise comparisons).
Abbreviations: Thy, [3H]-thymidine; dUMP, deoxyuridine monophosphate; AP, 
aminopterin.
Figure 6.8 Inhibition of the dUMP mediated suppression of [3H]-thymidine 
incorporation into DNA by aminopterin in human fibroblast cells.
Data is described as the percentage of [ H]-thymidine incorporated into DNA with 
respect to the [ H]-thymidine alone treatment, which is normalised to 100%. For each 
treatment, data is presented as mean ± SEM of three separate experiments. * indicates 
statistically significant variation from the thymidine alone treatment. <|> indicates 
statistically significant variation from the thymidine plus dUMP treatment group 
(p<0.05 tested by t-test).
Abbreviations: Thy, [3H]-thymidine; dUMP, deoxyuridine monophosphate; AP, 
aminopterin.
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eliminate the dUMP-induced suppression of [3H]-thymidine incorporation as shown by 
the significant increase in the percent of [3H]-thymidine incorporated into cells treated 
with AP compared to those treated with dUMP only (Figure 6.8). These results suggest 
that using the parameters described here, the dUMP suppression test can detect 
abnormalities that affect the activity of DHFR and therefore the flux through the folate 
cycle in human or mouse embryonic fibroblasts.
6.2.2.3 Lack of inhibition of [3H]-thymidine incorporation into DNA by
cycloleucine
Cycloleucine has previously been used with the dUMP suppression test in whole 
embryo culture to demonstrate the ability of the test to detect defects in the methylation 
cycle (Fleming et al., 1998). The concentration used in that study was 15 mM 
cycloleucine and therefore was the starting concentration used in this study with mouse 
embryonic fibroblasts. Addition of cycloleucine at 15 mM did not have a detrimental 
effect on the viability of the cells and was subsequently used, along with 30 mM 
cycloleucine, for further experiments. As with the previous experiments, [3H]-thymidine 
incorporation into mouse or human fibroblast DNA is suppressed in a dose-dependent 
manner by dUMP (Figure 6.9 and Figure 6.10). However, unlike the previous 
experiments addition of the inhibitor, in this case cycloleucine, did not result in a
• •  •  lsignificant increase of [ H]-thymidine incorporation into DNA. Neither concentration of 
cycloleucine was sufficient to affect the suppression of [3H]-thymidine incorporation by 
dUMP (Figure 6.9 and Figure 6.10). These results suggest that the dUMP suppression 
test, with the parameters described, is unable to detect abnormalities in the methylation 
cycle in human or mouse embryonic fibroblasts.
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Figure 6.9 Lack of inhibition of the dUMP mediated suppression of [3H]-thymidine 
incorporation into DNA by cycloleucine in mouse fibroblast cells.
Data is described as the percentage of [3H]-thymidine incorporated into DNA with 
respect to the [3H]-thymidine alone treatment, which is normalised to 100%. For each 
treatment, data is presented as mean ± SEM of at least three separate experiments. * 
indicates statistically significant variation from the thymidine alone treatment. (p<0.05 
tested by one-way ANOVA followed by TUKEY test for pairwise comparisons). 
Abbreviations: Thy, [3H]-thymidine; dUMP, deoxyuridine monophosphate; cyclo, 
cycloleucine.
Figure 6.10 Lack of inhibition of the dUMP mediated suppression of [3H]- 
thymidine incorporation into DNA by cycloleucine in human fibroblast cells.
-l
Data is described as the percentage of [ H]-thymidine incorporated into DNA with
' l
respect to the [ H]-thymidine alone treatment, which is normalised to 100%. For each 
treatment, data is presented as mean ± SEM of three separate experiments. * indicates 
statistically significant variation from the thymidine alone treatment (p<0.05 tested by 
one-way ANOVA followed by TUKEY test for pairwise comparisons).
Abbreviations: Thy, [ H]-thymidine; dUMP, deoxyuridine monophosphate; cyclo, 
cycloleucine.
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6.2.3 dUMP suppression test of human embryonic fibroblasts 
derived from fetuses with NTD
6.2.3.1 Summary of human samples
Human fetal samples were collected over a four-year time period and allocated to one of 
three groups (NTD, control or affected control) depending on ultrasound and/or post­
mortem examinations. Fetal samples were sent to GOSH cytogenetics lab where 
fibroblastic cell lines were established using standard techniques (Boyle and Griffin, 
2001) (Figure 6.11). There were similar success rates for each group of samples with 
93% of all samples producing cell lines (Table 6.1). Established cell lines were 
transferred to ICH and, among these, a number (21%) failed to grow sufficiently to 
produce enough cells for the dUMP suppression test to be carried out. Certain cell lines 
were also lost owing to contamination and these samples are described as discarded. 
There was a higher percentage of control cell lines discarded compared to NTD-derived 
cell lines (Table 6.1).
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Group No.
samples
collected
(%)
No. cell 
lines 
established 
(%)
No. 
established 
cell lines 
discarded 
(%)
No. 
established 
cell lines failed 
dUST (%)
No. 
established 
cell lines 
analysed (%)
NTD 34 (40.0) 32 (94.1) 7(21.9) 3 (9.4) 22 (68.8)
NC 27 (31.8) 25 (92.6) 11 (44.0) 7 (28.0) 7 (28.0)
AC 21 (24.7) 19(90.5) 13 (68.4) 2(10.5) 4(21.1)
UK 3 (3.5) 3 (100) 3 (100) 0 (0.0) 0 (0.0)
Total 85(100) 79 (92.9) 34 (43.0) 12(15.2) 33 (41.8)
Table 6.1 Summary of human samples collected for dUMP suppression test 
investigation.
Data for the number of samples collected are given with the percentage of total samples 
in parentheses. Data for the number of cell lines established are given with the number 
as a percentage of collected samples for that group in parentheses. Data for cell lines 
that were discarded, failed the dUMP suppression test (dUST) or for which analysis was 
completed are given as number of samples with percentage of established cell lines for 
that group in parentheses. Cell lines were discarded when samples became contaminated 
or failed to grow. Samples were considered to fail the dUST test when results were 
inconsistent. Abbreviations: AC, affected controls; NC, normal controls; NTD, NTD 
affected foetuses; UK, unknown.
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Figure 6.11 Human embryonic fibroblast cell lines
Cell lines were established from samples from human fetuses. The examples shown 
include cell lines from each group; normal control (A), affected control (B) and NTD- 
affected (C) which were derived from amniotic fluid (A and B) and skin (C) samples. 
The morphology o f the cell lines was identical despite the different fetal phenotypes or 
the different sources of the fibroblasts. Scale bars represent 200 pm.
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For cell lines that did produce enough cells for the dUMP suppression test to be carried 
out, at least two wells were used for each treatment in every experiment. Thus, a 
minimum of four cultures were tested -  two with [ H]-thymidine alone and two with 
[ H]-thymidine and dUMP. To ensure accurate, consistent results, the wells with cells 
exposed to the same treatments were required to have [3H]-thymidine incorporation 
within a coefficient of variation (CV) of 15%. The CV provides a relative measure of 
data dispersion compared to the mean and was calculated as follows:
Standard deviation 
CV =   X1 0 0
Mean
Tests in which the variation between cells of the same treatment was larger than 15% 
were considered to have failed the test. A relatively low proportion (15.2% of 
established cell lines (26.7% of samples that underwent test)) of cell lines failed to give 
consistent results in the dUMP suppression test (Table 6.1).
6.2.3.2 Results of the dUMP suppression test on human embryonic
fibroblast cells
Control samples (normal and affected) were grouped together for comparison with 
NTD-affected samples. Comparison of the mean gestational age at which samples were 
collected showed no statistical differences between the control group and samples 
derived from NTD-affected pregnancies (Table 6.2). However, there was a statistically 
significant difference in the mean dUMP suppression score between NTD-derived and 
control cell lines (Table 6.2, Figure 6.12, t-test p<0.05), indicating that some NTD- 
derived samples have a lower dUMP suppression test score than control cell lines. This
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is also suggested by the fact that the seven lowest dUMP suppression scores in this 
study occurred in NTD-affected samples (Figure 6.12). In addition, when the 
distribution of dUMP suppression scores for each group are analysed, the skewed NTD 
data compared to the control distribution is evident (Figure 6.13). These results suggest 
that some NTD-affected embryos may have impaired folate metabolism as indicated by 
a reduced dUMP suppression test score. There are a number of variables that may affect 
the results of the dUMP suppression test, however, low sample numbers have made it 
difficult for statistical assessment. I am therefore unable to assess the effect of 
gestational age, tissue source or subtype of NTD on the dUMP suppression test scores 
in this study. However, no obvious correlations were observed (Table 6.3).
2 6 0
Group No.
samples
analysed
NTD subtype (%) Average 
gestational age 
sample collected 
(weeks ± SEM)
Tissue type (%) MeandUST 
score 
(% ± SEM)An SB UK
Amnio Skin/
cartilage/
placenta
UK
NTD 22 6 (27.3) 14 (63.6) 2(9.1) 18.2 ±0.93 4(18.2) 13 (59.1) 5 (22.7) 36.7 ± 1.78*
Control 11 NA 18.2 ±0.59 9(81.8) 2(18.2) 0 (0.00) 42.7 ±1.81
Table 6.2 Summary of human samples used in the dUMP suppression test investigation.
Values are given as sample number with percentage of total samples in parentheses. Gestational age of samples in weeks is given as mean 
± SEM, there were no statistical differences between the treatment groups as tested by t-test. * indicates significant variation from the 
control score as tested by t-test p<0.05. Abbreviations: Amnio, amniotic fluid; AC, affected controls; An, anencephaly; dUST, dUMP 
suppression test; SB, spina bifida; NA, not applicable; NC, normal controls; NTD, NTD affected fetuses; UK, unknown.
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Figure 6.12 dUMP suppression test results for human embryonic fibroblast cell lines
The percentage suppression of [3H]-thymidine incorporation (cpm/pg protein) by addition of 10 pM dUMP to human embryonic 
fibroblasts. Coloured data points represent individual samples that have been separated into sample type groups; affected control (AC, 
yellow circles), normal control (NC, green squares) and NTD-affected samples (NTD, red triangles). Black data points represent the mean 
± SEM for control (circle) and NTD-affected (triangle) samples.
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NTD samples
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% dUMP suppression
Figure 6.13 Distribution of the suppression of [3H]-thymidine incorporation into 
DNA by dUMP in human embryonic fibroblast cells
The percentage o f suppression of [3H]-thymidine incorporation by dUMP in human 
fibroblast cell lines have been arranged to show the sample group distribution. Bars 
represent the percent of total samples in each group that gave a dUMP suppression score 
within the given range. Abbreviations: dUMP, deoxyuridine monophosphate.
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Table 6.3 dUMP suppression test scores for human embryonic fibroblast samples
Details are given for each individual sample in which successful dUMP suppression 
tests were carried out. Abbreviations: AC, affected control samples; An, anencephaly; 
Amnio, amniotic fluid; dUST, dUMP suppression test; NC, normal control samples; 
NTD, NTD-affected samples; SB, spina bifida; UK, unknown.
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Group/
Sample
number
NTD
subtype
Tissue source Gestational age 
(weeks)
dUST score 
(%)
NTD
1 An Placenta UK 35.2
2 An Cartilage/skin UK 43.2
3 SB Cartilage/skin 13.0 16.1
5 SB Amniotic fluid 21.7 47.3
6 SB Skin 17.7 38.8
7 An Skin UK 35.1
8 An Skin/placenta 17.0 24.7
9 SB Amniotic fluid 25.0 31.0
10 SB Skin 22.1 32.5
34 SB Skin 18.7 26.5
37 An UK 11.3 39.9
39 An UK 12.3 33.3
40 SB Skin 19.0 41.9
45 SB Skin/placenta 21.1 38.5
47 UK UK UK 37.3
48 SB Amniotic fluid UK 48.7
49 UK Skin UK 42.6
53 SB Cartilage/skin 18.0 30.8
65 SB UK 20.3 37.4
71 SB UK 16.9 32.3
81 SB Amniotic fluid 15.4 42.8
82 SB Cartilage/ placenta 19.0 52.8
NC
12 Amniotic fluid 16.7 37.8
13 Amniotic fluid 17.0 39.6
14 Amniotic fluid 17.0 51.5
19 Amniotic fluid 20.3 42.9
23 Amniotic fluid 16.7 52.9
24 Amniotic fluid 15.9 41.9
88 Amniotic fluid 16.7 43.9
AC
4 Amniotic fluid 21.0 36.8
35 Amniotic fluid 19.9 47.8
66 Cartilage 18.1 33.9
68 Skin/cartilage/
placenta
21.1 40.6
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6.3 DISCUSSION
In this chapter, the dUMP suppression test was adapted for use with mammalian 
fibroblastic cell lines. Exogenous dUMP suppressed the incorporation of exogenous 
[3H]-thymidine into DNA in a dose-dependent manner in both mouse 3T3 and human 
fibroblastic cell lines. These results are in accordance with the original observations 
using the dUMP suppression test in bone marrow suspension cultures (Killmann, 1964) 
and demonstrate that these fibroblast cells possess both the de novo and salvage 
pathway of dTMP synthesis. Moreover, experiments using the folate cycle inhibitor 5- 
fluorouracil are consistent with the known action of FdUMP, a derivative of FU, as a 
potent inhibitor of thymidylate synthase and therefore the de novo synthesis pathway in 
which dUMP is converted to dTMP. The presence of 5-fluorouracil or aminopterin (a 
DHFR inhibitor) completely counteracted the suppression of [ H]-thymidine 
incorporation into DNA by dUMP. In fact, the presence of the inhibitors resulted in an 
increase in [ H]-thymidine incorporation compared to cells exposed to [ H]-thymidine 
alone, suggesting that both inhibitors were successful in inhibiting the de novo pathway. 
These results indicate that the dUMP suppression test, as adapted in this study, is 
capable of detecting inhibition of the folate cycle and therefore may be capable of 
detecting genetically determined defects in folate metabolism.
Inhibition of the methylation cycle by cycloleucine did not result in changes in the 
dUMP suppression test score suggesting that the dUMP suppression test, when using 
the conditions described in this chapter, cannot detect defects in the methylation cycle. 
Cycloleucine inhibits the conversion of methionine to S-adenosylmethionine (SAM) by 
methionine adenosyltransferase (MAT), and is capable of inducing cranial NTD in non-
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mutant mouse embryos as described in chapter 4 (L.P.E. Dunlevy, K.A. Burren, K. 
Mills, L.S.Chitty, A.J. Copp and N.D.E. Greene. Submitted). There are several possible 
explanations for why the inhibition of MAT by cycloleucine was not detected by the 
dUMP suppression test in this study. It is possible the cycloleucine concentrations used 
were not high enough to cause an effect. However, cycloleucine has previously been 
shown to reduce MAT activity by 50% at concentrations as low as 2.4 mM (Lombardini 
et al., 1970) or 4 mM in cell culture (Gomes et al., 1998). Moreover, at the lowest 
concentration used in this study (15 mM) cycloleucine has been shown to affect the 
SAM/SAH ratio in cultured mouse embryos (Chapter 4). Therefore, it is unlikely that 
the cycloleucine concentrations used in this study were inadequate to inhibit MAT and 
more likely that the sensitivity of the test is currently unable to detect inhibition of the 
methylation cycle. This is perhaps due to a feedback response of folate metabolism 
allowing adaptation to reduced MAT activity (Finkelstein, 1990).
When human fibroblastic cell lines were used, a number of the samples did not give a 
final dUMP suppression test score for a variety of reasons including, poor cell 
proliferation, contamination or inconsistent results. Cells were likely to be less robust as 
they are primary cell lines. The success rate differed greatly between the cell line groups 
(NTD compared to control cell lines. p=0.001, tested by Chi-squared) even though 
events such as contamination were random. One possible reason for the differences in 
success rate for each group may be due to the type of tissue source for each cell line. 
For ethical reasons all normal control cell lines were derived from amniotic fluid 
samples whereas the majority of cell lines from NTD-affected embryos were derived 
from skin, cartilage or placenta samples. The majority of cell lines derived from
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affected controls were also sourced from amniotic fluid samples (Table 6.4). 
Established cell lines derived from tissues other than amniotic fluid had a greater 
success rate than those from amniotic fluid samples (Table 6.4), resulting in a larger 
number of NTD-derived cell lines completing the dUMP suppression test than control 
cell lines.
Although the source of the cell lines may have affected the success rate for dUMP 
suppression test completion it does not appear to have affected the dUMP suppression 
test score as there are no obvious correlations between tissue source and dUMP 
suppression test score in the NTD and AC groups (Section 6.2.3.2).
Group No. of established cell lines derived 
from each source (%)
No. of established cell lines 
discarded/failed dUST (%)
Amnio Tissue Unknown Amnio Tissue Unknown
NTD 11 (34.4) 16 (50.0) 5 (15.6) 7 (63.6) 3(18.8) 0 (0.0)
NC 25 (100.0) 0 (0.0) 0 (0.0) 18 (72.0) 0 (0.0) 0 (0.0)
AC 15 (78.9) 4(21.1) 0 (0.0) 13 (86.7) 2 (50.0) 0 (0.0)
Table 6.4 Source of established cell lines
The majority of control cell lines (NC, normal controls and AC, affected controls) were 
derived from amniotic fluid samples whereas the majority of NTD samples were 
derived from other tissue sources. A larger proportion of established cell lines derived 
from amniotic fluid samples were discarded or failed the dUMP suppression test than 
those from other sources in all three groups. Tissue sources include skin, cartilage and 
placenta. Abbreviations: Amnio, amniotic fluid sample; dUST, deoxyuridine 
monophosphate suppression test.
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There is a statistically significant difference in the mean dUMP suppression test score 
between the control group and NTD-affected cell lines suggesting that some NTD- 
derived samples may have impaired folate metabolism. The inhibitor studies carried out 
in this chapter suggest that defects in the methylation cycle will not be detected by the 
dUMP suppression test, using the current conditions. Therefore, the low dUMP 
suppression test scores appear to indicate defects within the folate cycle itself. It is 
possible that defects in folate transport may be present although the ability of the dUMP 
suppression test to detect these types of defects has not been analysed in this study. 
Therefore, this study supports the findings of Habibzadeh and colleagues (1993) in 
suggesting that some NTD-affected fetuses may have intrinsic defects in folate 
metabolism.
Several folate-related environmental risk factors for NTD in human embryos are known, 
such as maternal folate, vitamin B 12 and homocysteine levels (Section 1.9). However, 
these can be discounted as the cause of abnormal dUMP suppression scores in this study 
as the cell lines underwent several passages in uniform conditions, suggesting that 
intrinsic, genetically-determined defects may be involved. In the embryo such defects 
could interact with environmental risks and summate to cause NTD, as discussed 
previously (Section 1.9). Many genetic risk factors have been investigated in individuals 
with NTD, patient groups usually consisting of children or young adults with spina 
bifida as anencephaly is not compatible with life. There is some evidence for intrinsic, 
folate-related genetic risk factors although it is currently limited. Associations of NTD 
risk with polymorphisms in folate-related genes (such as MTHFR C667T (Shields et a l, 
1999)) in some populations suggest that the genotype of the embryo could affect folate
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metabolism. Some polymorphisms have been shown to affect protein function, for 
example, individuals homozygous for the MTHFR 677 T allele produce a thermolabile 
variant of the enzyme with reduced activity (Frosst et a l, 1995). These findings suggest 
that some embryos may have an impaired ability to metabolise folates during neural 
tube closure.
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7.1 GENERAL DISCUSSION
The overall aim of this thesis was to investigate the role of the folate and methylation 
cycles in the cause and prevention of NTD. To achieve this goal the initial approach 
taken was to investigate the effect of methylation cycle intermediates and inhibitors on 
cranial neural tube closure (Chapter 3 and 4). Exposure of non-mutant mouse embryos 
to homocysteine, methionine or the MAT inhibitors, cycloleucine and ethionine, was 
investigated. The results in chapter 3 show that homocysteine is embryotoxic but does 
not induce NTD. This suggests that elevated levels of homocysteine are not directly 
causal in the production of cranial NTD. However, it appears that the integrity of 
methylation cycle is essential for cranial neural tube closure to occur, as both excess 
methionine and inhibition of MAT resulted in cranial neural tube defects (Chapter 4). 
Further investigations (courtesy of K. Burren) have showed that inhibition of MAT and 
treatment with excess methionine result in increased SAH levels (Chapter 4) and 
suggest that the toxicity caused by homocysteine treatment shown in Chapter 3 was a 
result of the increased homocysteine levels per se not subsequent increases in SAH 
levels.
Further experiments could determine the mode of action of homocysteine toxicity. The 
general embryotoxicity observed after homocysteine treatment could have been caused 
by a toxic effect of homocysteine per se on the yolk sac, reducing the amount of 
nutrients that could reach the embryo. Elevated homocysteine levels have previously 
been reported in association with vascular disease (Hankey and Eikelboom, 
1999;Ueland and Vollset, 2004). Alternatively, protein homocysteinylation may be 
responsible as discussed in Section 3.3.
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Whole embryo culture is a useful tool in investigating the direct effect of a treatment on 
embryonic development, however, the true physiological processes are more 
complicated. Mammalian development occurs within the maternal environment, and 
effects of the maternal metabolism on the treatment compound before it reaches the 
embryo are therefore integral in understanding the complete effect of the treatment. To 
that end, in vivo experiments would allow the investigation of the effect of elevated 
maternal homocysteine levels on the development of non-mutant embryos. Differences 
in the one-carbon metabolism pathways in adult and embryonic tissues may result in 
alternative results for the effect of elevated maternal homocysteine levels on embryonic 
neural tube closure.
Experiments are being carried out to further investigate the mechanisms underlying the 
ability of methionine, ethionine and cycloleucine to induce cranial NTD. These 
experiments may shed light on particular events that are crucial for cranial NTD. The 
measurement of SAH and SAM levels in embryos cultured in this thesis has shown that 
methionine, ethionine and cycloleucine treatment can change the ratio of these 
compounds (SAH and SAM) in the cell (Chapter 4). This could affect methylation of a 
wide range of biomolecules including DNA, proteins and lipids. Further studies could 
investigate the effect of changes in the methylation ratio on particular methylation 
events. For example, in order to investigate whether the changes in SAH:SAM ratio are 
sufficient to induce changes in DNA methylation and subsequently whether these 
changes are able to alter gene expression could be tested by measuring global and 
specific DNA methylation in cultured embryos. In addition, possible changes in protein 
methylation could be investigated. There are many possible methylation targets and it
2 7 4
CHAPTER 7;General Discussion
would be difficult to investigate each one individually. However, candidates could be 
suggested by previous evidence of a role in the process of neurulation, for example 
cytoskeletal proteins. Apart from changes in cellular methylation processes, treatment 
with methionine, ethionine or cycloleucine may also affect polyamine synthesis, as 
SAM is a precurser of this process. The effect of misregulation of polyamine synthesis 
on neural tube closure is currently unknown and is therefore an area of interest for 
further studies.
The data presented in this thesis has added weight to the argument that elevated levels 
of homocysteine are not directly causal in the production of NTD (VanAerts et al., 
1994;Hansen et al., 2001;Greene et a l , 2003). These results suggest that elevated 
homocysteine levels in maternal plasma are probably an indicator of other defects in 
one-carbon metabolism that may increase risk of NTD as opposed to being the direct 
causative agent.
An important area of research is the investigation of whether other agents besides folic 
acid, can help prevent neural tube defects in humans. A few studies have highlighted an 
increased risk for developing NTD associated with low maternal dietary methionine 
intake (Shaw et al., 1997;Shoob et al., 2001) and supplementary methionine has been 
suggested as a candidate to be used in combination with folic acid in the prevention of 
NTD . However, the experiments carried out in this thesis show that great care needs to 
be taken as supplementation with methionine may have an unanticipated effect, such 
that use as a preventative method against the development of NTD may be contra­
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indicated. Methionine supplementation could potentially increase rather than decrease 
the risk of a NTD-affected pregnancy.
The action of folic acid in the prevention of NTD is unknown and experiments in this 
thesis have attempted to elucidate possible answers. Folic acid treatment did not rescue 
the NTD induced by methionine or ethionine treatment in whole embryo culture. These 
results suggest that folic acid cannot prevent the occurrence of NTD caused by defects 
in the methylation cycle. Higher doses could be tested, and recent reports suggest that 
folic acid supplements can affect DNA methylation in the offspring (Waterland and 
Jirtle, 2003).
In order to understand the role of folic acid in preventing NTD in a particular model it is 
useful to initially understand the cause of the defects. Experiments utilising the folic
1  r r
acid-responsive mouse model Splotch were carried out in order to investigate the 
mechanisms involved in the production of cranial NTD by Pax3-deficiency (Chapter 5). 
Analysis of apoptosis and proliferation in the neuroepithelium of mutant embryos
-y rr
suggest that the Splotch NTD phenotype is not induced by excess apoptosis in the 
neural tube. This in turn suggests that folic acid rescue of Splotch2H NTD is not 
facilitated by reduction or compensation for excess cell death in the neuroepithelium. 
Previous suggestions that NTD in the Splotch2H mutant embryos is caused by excess 
apoptosis and prevented by folic acid through stimulation of proliferation are unlikely to 
be correct. Therefore, the future direction of this investigation should address the other 
known functions of Pax3. Investigation into the role of Pax3 in cellular differentiation 
in the neural tube may suggest possible mechanisms of NTD production in Splotch2H
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embryos. In order to approach this, the question whether Paxi-deficency in the neural 
tube of homozygous Splotch2H embryos results in premature cellular differentiation 
should be tested. The analysis of cell-type specific gene expression and protein levels in 
the neuroepithelium of Splotch211 mutant embryos compared to wild type littermates 
could be carried out in order to identify those genes that are misregulated when Pax3 
function is lost. In addition, in order to assess the mode of action of folate-prevention of 
NTD in this mouse model, folic acid treated embryos could be examined for correction 
of key gene/protein expression changes.
Many potential risk factors have been described for the production of NTD in humans 
and, in order to establish whether intrinsic defects in folate metabolism in the embryo 
could be involved in determining susceptibility to NTD, folate metabolism in human 
embryonic fibroblastic cell lines was investigated (Chapter 6). The dUMP suppression 
test was adapted for use with these cell lines and was shown to be able to detect 
inhibition of folate metabolism by specific inhibitors. However, inhibition of the 
methylation cycle enzyme, MAT, was not detectable. The dUMP suppression test was 
used with human embryonic fibroblast cells and showed that NTD-derived cell lines 
gave a significantly lower mean dUMP suppression test score than cell lines derived 
from control embryos. These results suggest that embryos may have intrinsic defects in 
folate metabolism. This is the first time cells from the embryo proper have been shown 
to exhibit defects in the folate cycle in association with NTD.
The use of the dUMP suppression test for analysis of human embryonic cell lines could 
potentially provide a useful tool in investigating folate metabolism abnormalities in
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association with human NTD. In the course of this present study, cell line aliquots were 
stored for possible future analysis, including screening for possible genetic determinants 
of the abnormal dUMP suppression test results. Subsequently these samples have been 
screened for known polymorphisms in folate-related genes that have been identified as 
possible risk factors for developing NTD (Table 7.1, Section 1.9). Although some 
polymorphisms are present in NTD-affected samples there are currently insufficient 
numbers to establish possible links between genotype, phenotype and dUMP 
suppression test scores. However, it is clear that the abnormal results in the dUMP 
suppression test do not result from the TT C677T MTHFR genotype, the genotype for 
which there is so far the strongest evidence for a link to NTD (Van der Put et a l , 2001). 
Further work is continuing on the stored samples, including investigations of levels of 
folate metabolites in order to define possible specific defects in the folate cycle in those 
samples with low dUMP suppression test scores.
Overall, it appears that the flux through the methylation and folate cycles during the 
period of neurulation is of critical importance for the successful closure of the neural 
tube. Understanding the manner in which variations in the environment and 
embryonic/maternal genotype interact and influence neural tube closure will contribute 
greatly to understanding the causes of NTD.
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Table 7.1 The genotype of the successful dUST cell lines for several known 
polymorphisms in folate-related genes
Cell pellets from each cell line were stored for genotype analysis of potential genetic 
risk factors for NTD. The polymorphisms investigated were MTHFR C677T (Frosst et 
a!., 1995), MTHFR A1298C (Van der Put et a l , 1998), MTHFRD1 G1958A (Brody et 
al., 2002), DHFR 19 bp deletion (Johnson et a l , 2004), GCPII C1565T (Vieira et al., 
2005), MTR A2756G (Leclerc et a l , 1996) and MTRR A66G (Leclerc et a l , 1998). 
Wild type alleles are depicted as 1 and the alternative as 2. Results courtesy of Dr. K. 
Doudney. Abbreviations: DHFR, dihydrofolate reductase; dUST, deoxyuridine 
monophosphate suppression test; GCPII, glutamate carboxypeptidase II; MTHFR, 
methylene-tetrahydrofolate reductase; MTHFRD1, methylenetetrahydrofolate 
dehydrogenase /methenyltetrahydrofolate cyclohydrolase /formyltetrahydrofolate 
synthetase; MTR, methionine synthase; MTRR methionine synthase reductase.
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Cell MTHFR MTHFR MTHFR DHFR GCPII MTR MTRR dUST
line 677 1298 D1 del score
No.
NTD
1 12 11 12 12 11 11 12 35.2
2 12 12 11 22 11 11 22 43.2
3 12 - - 11 11 11 22 16.1
5 12 11 12 11 11 11 12 47.3
6 12 11 11 12 11 11 11 38.8
7 11 11 12 11 11 11 12 35.1
8 11 12 12 12 11 11 12 24.7
9 11 22 12 11 11 11 12 31.0
10 12 12 11 11 11 11 12 32.5
34 12 12 11 12 11 22 12 26.5
37 12 11 12 11 11 22 12 39.9
39 12 11 12 22 11 11 12 33.3
40 12 11 12 12 11 11 11 41.9
45 12 11 12 12 11 11 12 38.5
47 12 12 11 12 11 11 22 37.3
48 11 12 11 11 11 11 11 48.7
49 11 11 12 22 11 11 22 42.6
53 12 11 11 12 11 11 12 30.8
65 12 12 12 12 11 11 12 37.4
71 - - - - - - 32.3
81 12 11 11 11 11 11 11 42.8
82 12 11 22 12 11 22 12 52.8
Control
4 11 12 22 12 11 11 12 36.8
12 11 12 12 22 11 11 12 37.8
13 12 11 11 12 11 11 12 39.6
14 - - - - - - - 51.5
19 - - - - - - - 42.9
23 - - - - - - - 52.9
24 11 12 12 11 11 11 12 40.7
35 11 11 11 11 11 11 12 47.8
66 - - - - - - - 33.9
68 11 12 11 12 11 22 11 40.6
88 - - - - - - - 43.9
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Amendments
8.1 WHOLE EMBRYO CULTURE
In the whole embryo culture experiments throughout the thesis, there was a variation in 
the number of control embryos exhibiting NTD. This variation is probably due to an 
improvement in my culturing technique as the project progressed. It is also possible 
there were differences in the quality of rat serum. However, in each experiment, 
embryos in control and treatment groups were cultured simultaneously such that the 
effect of batch to batch variation in rat serum on data would be minimised.
The rat serum used for culture would have contained endogenous levels of methionine 
high enough to ensure neural tube closure could occur. These levels of methionine were 
not measured in this thesis and are an additional source of variability in these 
experiments. Steps were taken to reduce the effect of the variability. Before 
exsanguination all rats were keep in our animal facility and fed the same chow for 6 
days, then the serum taken from 30 rats were pooled together before aliquots were made 
and stored. Experiments were then carried out using serum from the same batch for both 
control and treated groups. In addition, methionine levels in rat serum have been 
measured in other studies (pg 136) (Milakofsky et al, 1984) and were found to be a 
fraction of the concentrations that we found were capable of inducing NTD (70 pM in 
serum compared to 5 mM added).
After embryo culture, individual embryos were given a number code which was 
recorded with the treatment and post-culture measurements for the embryo. The embryo 
was identified by the number alone throughout all subsequent processes. Hence all
immunohistochemistry and histological analyses were carried out blind to the embryo 
treatment until after all the sectioning, labelling and counting had been carried out.
Measurements taken after whole embryo culture included somite number, crown-rump 
length, yolk sac circulation score and whether cranial neural tube closure had been 
completed. As the project developed I noticed the area of neural tube that remained 
open differed between exencephalic embryos. Subsequently I recorded which area of 
the cranial neural tube remained open after culture. This delay in recording the detail of 
closure failure is responsible for the discrepancies in the number of embryos in each 
group in Figure 4.4 compared to the total number of embryos cultured. Unfortunately 
this delay in recording information leads to low numbers of embryos for the analyses, 
particularly in the control group.
8.2 WHOLE MOUNT TUNEL
Figure 4.10. There appear to be slight differences in the whole mount TUNEL staining 
of PBS-treated control embryos to non-cultured wild type Splotch2H embryos stained at 
a later date (Figure 5.2). There are slightly more labelled cells in the mesenchyme and 
slightly less in the hindbrain of cultured embryos. This could be due to differences in 
the developmental stage of the embryos, although both groups of embryos were at E9.5 
they varied in somite stages between 16 and 20. The differences could alternatively be 
due to effects of whole embryo culture. Direct comparison at the time between whole 
mount TUNEL staining of uncultured CD1 embryos at E9.5 with the PBS-treated 
cultured embryos could have demonstrated whether whole embryo culture was 
responsible for the observed differences, however, these experiments were not carried 
out.
8.3 CHAPTER SIX
The differences observed in the survival and completion of the dUMP suppression test 
in cells from amniotic fluid samples compared to those derived from other tissues 
suggests that there are intrinsic differences in the cultures established from different 
tissue sources. Therefore, a comparison of dUMP suppression test scores of samples 
taken from the same tissue source should be considered.
NTD Control
47.3 37.8
31.0 39.6
dU suppression 48.7 51.5
test scores 42.8 42.9
52.9
41.9
43.9
36.8
47.8
Mean ± SEM 42.5 ± 4.02 43.9 ± 1.92
Table 8.1 Comparison of dUMP suppression test scores of human samples derived 
from amniotic fluid samples
dUMP suppression test scores of cells derived from amniotic fluid samples were 
compared for NTD-affected and control fetuses. There was no statistically significant 
difference between the mean scores (tested by t-test).
There were no statistically significant differences between the mean dUMP suppression 
test scores between NTD-affected or control cells derived from amniotic fluid samples 
(Table 8.1). There were not enough numbers of cells derived from skin, cartilage or 
placental samples to carry out separate analysis of these groups. In order to make a 
comprehensive conclusion with regards to this study more samples are needed.
However, the results shown here suggest there is no difference in the mean dUMP 
suppression test score between amniocytes derived from control and NTD-affected 
fetuses.
8.4 CHAPTER SEVEN
Possible folate-related mechanisms in the causation of NTDs
Work carried out by Rothenberg and collegues (2004) showed the presence of 
autoantibodies against folate receptors in serum of mothers with NTD-affected 
pregnancies. This suggests that impaired maternal cellular folate absorption may be 
associated with NTD-affected pregnancies. This is an interesting discovery but so far is 
an isolated result. Further studies with increased sample numbers are needed to validate 
the hypothesis that maternal autoantibodies to folate receptors may be involved in the 
production of NTDs by limiting folate availability to the embryo.
Mechanisms bv which suppression of methylation may be associated with NTDs 
Results shown in Chapter 4 suggest that changes in cellular methylation processes may 
be responsible for the induced NTD following methionine, ethionine or cycloleucine 
treatment. DNA and protein methylation could potentially be affected. Changes in 
methylation may affect neural tube closure via changes in histone methylation. Histones 
are methylated at arginine and lysine residues and this post-translational modification 
has a regulatory role in gene expression (Martin and Zhang, 2005). Therefore, a possible 
target of disruption of the methylation cycle could be histone methylation, subsequently 
affecting gene expression. Future experiments could investigate this possibility by 
utilising methylation specific histone antibodies (Perez-Burgos et al., 2004).
Folate-related gene polymorphisms
Further work carried out on the cell lines samples from Chapter 6 by Dr. Kit Doudney 
investigated folate gene polymorphisms in cell lines derived from NTD-affected fetuses. 
The genotype analysis for the known polymorphisms in folate-related genes were 
carried out as previously described in the literature and detailed in Table 8.2.
Folate- 
related gene
Polymorphism Detection Method Reference
MTHFR C667T PCR-RFLP with Hinfl. The 
polymorphism creates a Hinfl 
site
(Frosstef a/., 1995)
MTHFR A1298C PCR-RFLP with Mboll. The 
polymorphism abolishes an 
Mboll site.
(Van der Put et al., 
1998)
MTHFRD1 G1958A PCR-RFLP with Hpall. The 
polymorphism abolishes an 
Hpall site.
(Brody et al., 2002)
DHFR 19 bp deletion PCR (Johnson et a l, 
2004)
GCPII C1565T PCR-RFLP with Accl. The 
polymorphism creates an 
Accl site.
(Devlin et al., 2000)
MTR A2756G PCR-RFLP with HaeIII. The 
polymorphism creates a 
Hae III site.
(Leclerc et a l, 1996)
MTRR A66G PCR-RFLP with Ndel. The 
polymorphism abolishes an 
Ndel site.
(Wilson et al., 1999)
Table 8.2 Method of genotype analysis used to generate data in Table 7.1
The methods used to genotype cell samples for known folate-relate gene 
polymorphisms. Abbreviations: DHFR, dihydrofolate reductase; GCPII, glutamate 
carboxypeptidase II; MTHFR, methylene-tetrahydrofolate reductase; MTHFRD1, 
methylenetetrahydrofolate dehydrogenase /methenyltetrahydrofolate cyclohydrolase 
/formyltetrahydrofolate synthetase; MTR, methionine synthase; MTRR methionine 
synthase reductase; PCR-RFLP, polymerase chain reaction-restriction fragment length 
polymorphism.
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